US20080287419A1 - Apoptosis promoters - Google Patents

Apoptosis promoters Download PDF

Info

Publication number
US20080287419A1
US20080287419A1 US12/120,914 US12091408A US2008287419A1 US 20080287419 A1 US20080287419 A1 US 20080287419A1 US 12091408 A US12091408 A US 12091408A US 2008287419 A1 US2008287419 A1 US 2008287419A1
Authority
US
United States
Prior art keywords
cancer
methyl
morpholin
compound
carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US12/120,914
Other versions
US7709467B2 (en
Inventor
Milan Bruncko
Hong Ding
Steven W. Elmore
Aaron R. Kunzer
Christopher L. Lynch
William J. McClellan
Cheol Min Park
Xiahong Song
Xilu Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37695179&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20080287419(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to US12/120,914 priority Critical patent/US7709467B2/en
Publication of US20080287419A1 publication Critical patent/US20080287419A1/en
Priority to US12/630,957 priority patent/US8624027B2/en
Priority to US12/772,951 priority patent/US7906505B2/en
Application granted granted Critical
Publication of US7709467B2 publication Critical patent/US7709467B2/en
Assigned to ABBVIE INC. reassignment ABBVIE INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ABBOTT LABORATORIES
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems

Definitions

  • This invention comprises compounds which inhibit the activity of anti-apoptotic Bcl-2 family protein members, compositions containing the compounds and methods of treating diseases during which are expressed one or more than one of an anti-apoptotic family protein member.
  • Anti-apoptotic Bcl-2 family protein members are associated with a number of diseases and thus are under investigation as potential therapeutic drug targets. These important targets for interventional therapy include, for example, the Bcl-2 family of proteins Bcl-2, Bcl-X 1 and Bcl-W. Recently inhibitors of Bcl-2 family members have been reported in the literature, see, for example, WO 2005/049594, Oltersdorf, et. al. Nature 2005, 435, 677-681, U.S. Pat. No. 6,720,338 and U.S. Pat. No. 7,030,115. While this art teaches inhibitors having high binding to the target protein, this is only one of many parameters that must be considered as a compound is investigated for further or continued drug development.
  • a typical measure of cellular activity is the concentration eliciting 50% cellular effect (EC 50 ).
  • a typical measure of systemic exposure is the area under the curve resulting from graphing the plasma compound concentration after oral administration vs. time (AUC). The ratio between these parameters (AUC/EC 50 ) is well known in the art to constitute a useful pharmacodynamic parameter to predict oral efficacy.
  • FIG. 1 shows comparitive antitumorgenesis of EXAMPLE 1, etoposide and combinations thereof on B-cell lymphoma.
  • FIG. 2 shows comparitive antitumorgenesis of EXAMPLE 1, vincristine and combinations thereof on B-cell lymphoma.
  • FIG. 3 shows comparitive antitumorgenesis of EXAMPLE 1, CHOP and combinations thereof on B-cell lymphoma.
  • FIG. 4 shows comparitive antitumorgenesis of EXAMPLE 1, rituximab and combinations thereof on B-cell lymphoma.
  • FIG. 5 shows comparitive antitumorgenesis of EXAMPLE 1 rapamycin and combinations thereof on B-cell lymphoma.
  • FIG. 6 shows comparitive antitumorgenesis of EXAMPLE 1, R—CHOP and combinations thereof on mantle cell lymphoma.
  • FIG. 7 shows comparitive antitumorgenesis of EXAMPLE 1, bortezomib and combinations thereof on mantle cell lymphoma.
  • One embodiment of this invention comprises compounds having formula (II)
  • X 4 is azepan-1-yl, morpholin-1-yl, 1,4-oxazepan-4-yl, pyrrolidin-1-yl, N(CH 3 ) 2 , N(CH 3 )(CH(CH 3 ) 2 ), 7-azabicyclo[2.2.1]heptan-1-yl or 2-oxa-5-azabicyclo[2.2.1]hept-5-yl, and R 0 is
  • X 5 is CH 2 , C(CH 3 ) 2 or CH 2 CH 2 ;
  • X 6 and X 7 are both hydrogen or are both methyl
  • X 8 is F, Cl, Br or I;
  • X 4 is azepan-1-yl, morpholin-1-yl, pyrrolidin-1-yl, N(CH 3 )(CH(CH 3 ) 2 ) or 7-azabicyclo[2.2.1]heptan-1-yl, and R 0 is
  • X 4 is N(CH 3 ) 2 or morpholin-1-yl, and R 0 is
  • Another embodiment comprises compounds having formula (II), and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof, wherein X 3 is Cl or F;
  • X 4 is azepan-1-yl, morpholin-1-yl, 1,4-oxazepan-4-yl, pyrrolidin-1-yl, N(CH 3 ) 2 , N(CH 3 )(CH(CH 3 ) 2 ), 7-azabicyclo[2.2.1]heptan-1-yl or 2-oxa-5-azabicyclo[2.2.1]hept-5-yl, and R 0 is
  • X 5 is CH 2 , C(CH 3 ) 2 or CH 2 CH 2 ;
  • X 6 and X 7 are both hydrogen or are both methyl
  • X 8 is F, Cl Br or I;
  • X 4 is azepan-1-yl, morpholin-1-yl, pyrrolidin-1-yl, N(CH 3 )(CH(CH 3 ) 2 ) or 7-azabicyclo[2.2.1]heptan-1-yl, and R 0 is
  • X 4 is N(CH 3 ) 2 or morpholin-1-yl, and R 0 is
  • Still another embodiment comprises compounds having formula (II), and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof, wherein X 3 is Cl or F;
  • X 4 is azepan-1-yl, morpholin-1-yl, 1,4-oxazepan-4-yl, pyrrolidin-1-yl, N(CH 3 ) 2 , N(CH 3 )(CH(CH 3 ) 2 ), 7-azabicyclo[2.2.1]heptan-1-yl or 2-oxa-5-azabicyclo[2.2.1]hept-5-yl, and R 0 is
  • X 5 is CH 2 , C(CH 3 ) 2 or CH 2 CH 2 , and X 6 and X 7 are both hydrogen or are both methyl;
  • X 8 is F, Cl, Br or I.
  • Still another embodiment comprises compounds having formula (II), and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof, wherein X 3 is Cl or F;
  • X 4 is azepan-1-yl, morpholin-1-yl, pyrrolidin-1-yl, N(CH 3 )(CH(CH 3 ) 2 ) or 7-azabicyclo[2.2.1]heptan-1-yl;
  • X 6 and X 7 are both hydrogen or are both methyl; and X 8 is F, Cl, Br or I.
  • Still another embodiment comprises compounds having formula (II), and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof,
  • X 3 is Cl or F
  • X 4 is N(CH 3 ) 2 or morpholin-1-yl
  • X 8 is F, Cl, Br or I.
  • Still another embodiment comprises a compound having formula (II), and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof, wherein X 3 is F; X 4 is morpholin-1-yl;
  • X 5 is C(CH 3 ) 2 ; X 6 and X 7 are both methyl; and X 8 is Cl.
  • Still another embodiment comprises compositions for treating diseases during which are expressed one or more than one of antiapoptotic BcI-X L protein, antiapoptotic Bcl-2 protein or antiapoptotic Bcl-w protein, said compositions comprising an excipient and a therapeutically effective amount of the compound having formula (II).
  • Still another embodiment comprises methods of treating diseases in a patient during which are expressed one or more than one of antiapoptotic Bcl-X L protein, antiapoptotic Bcl-2 protein or antiapoptotic Bcl-w protein, said methods comprising administering to the patient a therapeutically effective amount of a compound having formula (II).
  • compositions comprising an excipient and a therapeutically effective amount of the compound having formula (II) for treating diseases of abnormal cell growth and/or dysregulated apoptosis, such as cancer, mesothioloma, bladder cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, ovarian cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, bone cancer, ovarian cancer, cervical cancer, colon cancer, rectal cancer, cancer of the anal region, stomach cancer, gastrointestinal (gastric, colorectal, and duodenal), chronic lymphocytic leukemia, esophageal cancer, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethr
  • Still another embodiment comprises methods of treating mesothioloma, bladder cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, ovarian cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, bone cancer, ovarian cancer, cervical cancer, colon cancer, rectal cancer, cancer of the anal region, stomach cancer, gastrointestinal (gastric, colorectal, and duodenal), chronic lymphocytic leukemia, esophageal cancer, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, testicular cancer, hepatocellular cancer (hepatic and billiary duct), primary or secondary central nervous system tumor, primary or secondary brain tumor
  • Still another embodiment comprises compositions for treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer and spleen cancer, said compositions comprising an excipient and a therapeutically effective amount of the compound having formula (II).
  • Still another embodiment comprises methods of treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer and spleen cancer in a patient, said methods comprising administering to the patient a therapeutically effective amount of a compound having formula (II).
  • Still another embodiment comprises compositions for treating diseases in a patient during which are expressed one or more than one of antiapoptotic BCl-X L protein, antiapoptotic Bcl-2 protein or antiapoptotic Bcl-w protein, said compositions comprising an excipient and a therapeutically effective amount of the compound having formula (II) and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent.
  • Still another embodiment comprises methods of treating diseases in a patient during which is expressed one or more than one of antiapoptotic Bcl-X L protein, antiapoptotic Bcl-2 protein or antiapoptotic Bcl-w protein, said methods comprising administering to the patient a therapeutically effective amount of a compound having formula (II) and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent.
  • Still another embodiment comprises compositions for treating mesothioloma, to bladder cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, ovarian cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, bone cancer, ovarian cancer, cervical cancer, colon cancer, rectal cancer, cancer of the anal region, stomach cancer, gastrointestinal (gastric, colorectal, and duodenal), chronic lymphocytic leukemia, esophageal cancer, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, testicular cancer, hepatocellular cancer (hepatic and billiary duct), primary or secondary central nervous system tumor, primary or secondary
  • Still another embodiment comprises methods of treating mesothioloma, bladder cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, ovarian cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, bone cancer, ovarian cancer, cervical cancer, colon cancer, rectal cancer, cancer of the anal region, stomach cancer, gastrointestinal (gastric, colorectal, and duodenal), chronic lymphocytic leukemia, esophageal cancer, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, testicular cancer, hepatocellular cancer (hepatic and billiary duct), primary or secondary central nervous system tumor, primary or secondary brain tumor
  • Still another embodiment comprises methods of treating mesothioloma, bladder cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, ovarian cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, bone cancer, ovarian cancer, cervical cancer, colon cancer, rectal cancer, cancer of the anal region, stomach cancer, gastrointestinal (gastric, colorectal and duodenal), chronic lymphocytic leukemia, esophageal cancer, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, testicular cancer, hepatocellular cancer (hepatic and billiary duct), primary or secondary central nervous system tumor, primary or secondary brain tumor,
  • Still another embodiment comprises methods of treating B-cell lymphoma in a patient comprising administering thereto a therapeutically acceptable amounts of a compound having formula (II) and etoposide.
  • Still another embodiment comprises methods of treating B-cell lymphoma in a patient comprising administering thereto therapeutically acceptable amounts of a compound having formula (II) and vincristine.
  • Still another embodiment comprises methods of treating B-cell lymphoma in a patient comprising administering thereto therapeutically acceptable amounts of a compound having formula (II) and CHOP.
  • Still another embodiment comprises methods of treating B-cell lymphoma in a patient comprising administering thereto therapeutically acceptable amounts of a compound having formula (II) and rituximab.
  • Still another embodiment comprises methods of treating B-cell lymphoma in a patient comprising administering thereto therapeutically acceptable amounts of a compound having formula (II) and rapamycin.
  • Still another embodiment comprises methods of treating mantle cell lymphoma in a patient comprising administering thereto therapeutically acceptable amounts of a compound having formula (II) and R—CHOP.
  • Still another embodiment comprises methods of treating mantle cell lymphoma in a patient comprising administering thereto therapeutically acceptable amounts of a compound having formula (II) and bortezomib.
  • Variable moieties of compounds herein are represented by identifiers (capital letters with numerical and/or alphabetical superscripts) and may be specifically embodied.
  • variable moiety may be the same or different as another specific embodiment having the same identifier.
  • antiitumorigenesis means reduction of tumor growth.
  • Compounds of this invention may contain asymmetrically substituted carbon atoms in the R or S configuration, wherein the terms “R” and “S” are as defined in Pure Appl. Chem. (1976) 45, 13-10.
  • Compounds having asymmetrically substituted carbon atoms with equal amounts of R and S configurations are racemic at those atoms. Atoms having excess of one configuration over the other are assigned the configuration in excess, preferably an excess of about 85%-90%, more preferably an excess of about 95%-99%, and still more preferably an excess greater than about 99%. Accordingly, this invention is meant to embrace racemic mixtures and relative and absolute diastereoisomers of the compounds thereof.
  • Compounds of this invention may also contain carbon-carbon double bonds or carbon-nitrogen double bonds in the Z or E configuration, in which the term “Z” represents the larger two substituents on the same side of a carbon-carbon or carbon-nitrogen double bond and the term “E” represents the larger two substituents on opposite sides of a carbon-carbon or carbon-nitrogen double bond.
  • the compounds of this invention may also exist as a mixture of “Z” and “E” isomers.
  • Compounds of this invention may also exist as tautomers or equilibrium mixtures thereof wherein a proton of a compound shifts from one atom to another.
  • tautomers include, but are not limited to, keto-enol, phenol-keto, oxime-nitroso, nitro-aci, imine-enamine and the like.
  • Compounds having formula (II) having NH, C(O)OH, OH or SH moieties may have attached thereto prodrug-forming moieties.
  • the prodrug-forming moieties are removed by metabolic processes and release the compounds having the freed NH, C(O)OH, OH or SH in vivo.
  • Prodrugs are useful for adjusting such pharmacokinetic properties of the compounds as solubility and/or hydrophobicity, absorption in the gastrointestinal tract, bioavailability, tissue penetration, and rate of clearance.
  • Metabolites of compounds having formula (II), produced by in vitro or in vivo metabolic processes, may also have utility for treating diseases associated with expression of an anti-apoptotic family protein member such as of BCl-X L , protein, Bcl-2 protein or Bcl-w protein.
  • an anti-apoptotic family protein member such as of BCl-X L , protein, Bcl-2 protein or Bcl-w protein.
  • Compounds having formula (II) may also be radiolabeled with a radioactive isotope such as a radioactive isotope of carbon (i.e. 13 C), hydrogen (i.e. 3 H), nitrogen (i.e. 15 N), phosphorus (i.e. P), sulfur (i.e. 35 S) or iodide (i.e. 125 I).
  • Radioactive isotopes may be incorporated into the compounds having formula (II) by reacting the same and a radioactive derivitizing agent or by incorporating a radiolabeled intermediate into their syntheses.
  • the radiolabeled compounds of formula (II) are useful for both prognostic and diagnostic applications as well as for in vivo and in vitro imaging.
  • Certain precursor compounds which may be metabolized in vitro or in vivo to form compounds having formula (II) may also have utility for treating diseases associated with expression of an anti-apoptotic family protein member such as of BCl-X L protein, Bcl-2 protein or Bcl-w protein.
  • Compounds having formula (II) may exist as acid addition salts, basic addition salts or zwitterions. Salts of compounds having formula (II) are prepared during their isolation or following their purification. Acid addition salts are those derived from the reaction of a compound having formula (II) with acid.
  • salts including the acetate, adipate, alginate, bicarbonate, citrate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, formate, fumarate, glycerophosphate, glutamate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, lactobionate, lactate, maleate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, phosphate, picrate, propionate, succinate, tartrate, thiocyanate, trichloroacetic, trifluoroacetic, para-toluenesulfonate and undecan
  • Compounds having formula (II) may be administered, for example, bucally, ophthalmically, orally, osmotically, parenterally (intramuscularly, intraperitoneally intrasternally, intravenously, subcutaneously), rectally, topically, transdermally, vaginally and intraarterially as well as by intraarticular injection, infusion, and placement in the body, such as, for example, the vasculature by means of, for example, a stent.
  • Therapeutically effective amounts of a compound having formula (II) depend on recipient of treatment, disease treated and severity thereof, composition comprising it, time of administration, route of administration, duration of treatment, potency, rate of clearance and whether or not another drug is co-administered.
  • the amount of a compound having formula (II) used to make a composition to be administered daily to a patient in a single dose or in divided doses is from about 0.03 to about 200 mg/kg body weight.
  • Single dose compositions contain these amounts or a combination of submultiples thereof.
  • Excipients include, but are not limited to, encapsulators and additives such as absorption accelerators, antioxidants, binders, buffers, coating agents, coloring agents, diluents, disintegrating agents, emulsifiers, extenders, fillers, flavoring agents, humectants, lubricants, perfumes, preservatives, propellants, releasing agents, sterilizing agents, sweeteners, solubilizers, wetting agents, mixtures thereof and the like.
  • encapsulators and additives such as absorption accelerators, antioxidants, binders, buffers, coating agents, coloring agents, diluents, disintegrating agents, emulsifiers, extenders, fillers, flavoring agents, humectants, lubricants, perfumes, preservatives, propellants, releasing agents, sterilizing agents, sweeteners, solubilizers, wetting agents, mixtures thereof and the like.
  • Excipients for preparation of compositions comprising a compound having formula (II) to be administered orally include, but are not limited to, agar, alginic acid, aluminum hydroxide, benzyl alcohol, benzyl benzoate, 1,3-butylene glycol, carbomers, castor oil, celluloses cellulose acetate, cocoa butter, corn starch, corn oil, cottonseed oil, cross-povidone, diglycerides, ethanol, ethyl cellulose, ethyl laureate, ethyl oleate, fatty acid esters, gelatin, germ oil, glucose, glycerol, groundnut oil, hydroxypropylmethyl celluose, isopropanol, isotonic saline, lactose, magnesium hydroxide, magnesium stearate, malt, mannitol, monoglycerides, olive oil, peanut oil, potassium phosphate salts, potato starch, povidone, propylene glyco
  • Excipients for preparation of compositions comprising a compound having formula (II) to be administered ophthalmically or orally include, but are not limited to, 1,3-butylene glycol, castor oil, corn oil, cottonseed oil, ethanol, fatty acid esters of sorbitan, germ oil, groundnut oil, glycerol, isopropanol, olive oil, polyethylene glycols, propylene glycol, sesame oil, water, mixtures thereof and the like.
  • Excipients for preparation of compositions comprising a compound having formula (II) to be administered osmotically include, but are not limited to, chlorofluorohydrocarbons, ethanol, water, mixtures thereof and the like.
  • Excipients for preparation of compositions comprising a compound having formula (II) to be administered parenterally include, but are not limited to, 1,3-butanediol, castor oil, corn oil, cottonseed oil, dextrose, germ oil, groundnut oil, liposomes, oleic acid, olive oil, peanut oil, Ringer's solution, safflower oil, sesame oil, soybean oil, U.S.P. or isotonic sodium chloride solution, water, mixtures thereof and the like.
  • Excipients for preparation of compositions comprising a compound having formula (II) to be administered rectally or vaginally include, but are not limited to, cocoa butter, polyethylene glycol, wax, mixtures thereof and the like.
  • This invention also comprises combination therapeutic methods of treating disease conditions involving abnormal cell growth and/or dysregulated apoptosis, such as cancer, in a patient comprising administering thereto a therapeutically effective amount of a pharmaceutical composition comprising a compound having formula (II) and a therapeutically effective amount of one or more than one additional therapeutic agents and/or ionizing radiation.
  • the combination therapeutic methods include administering compositions of a compound having formula (II) and one or more than one additional therapeutic agents or ionizing radiation to a patient using any desired dosing and/or scheduling regimen.
  • Compounds having formula (II) may be administered with one or more than one additional therapeutic agents, wherein the additional therapeutic agents include ionizing radiation or chemotherapeutic agents, wherein chemotherapeutic agents include, but are not limited to, carboplatin, cisplatin, cyclophosphamide, dacarbazine, dexamethasone, docetaxel, doxorubicin, etoposide, fludarabine, irinotecan, CHOP (C: Cytoxan® (cyclophosphamide); H: Adriamycin® (hydroxydoxorubicin); O: Vincristine (Oncovin®); P: prednisone), paclitaxel, rapamycin, Rituxin® (rituximab), vincristine and the like.
  • additional therapeutic agents include ionizing radiation or chemotherapeutic agents
  • chemotherapeutic agents include, but are not limited to, carboplatin, cisplatin, cyclo
  • Compounds having formula (II) are also expected to be useful as chemotherapeutic agents in combination with therapeutic agents that include, but are not limited to, angiogenesis inhibitors, antiproliferative agents, kinase inhibitors, receptor tyrosine kinase inhibitors, aurora kinase inhibitors, polo-like kinase inhibitors, bcr-abl kinase inhibitors, growth factor inhibitors, COX-2 inhibitors, non-steroidal anti-inflammatory drugs (NSAIDS), antimitotic agents, alkylating agents, antimetabolites, intercalating antibiotics, platinum containing agents, growth factor inhibitors, ionizing radiation, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biologic response modifiers, immunologicals, antibodies, hormonal therapies, retinoids/deltoids plant alkaloids, proteasome inhibitors, HSP-90 inhibitors, histone deacetylase inhibitors (HDAC) inhibitors, purine analogs, pyrimidine analogs, MEK inhibitor
  • Angiogenesis inhibitors include, but are not limited to, EGFR inhibitors. PDGFR inhibitors, VEGFR inhibitors, TIE2 inhibitors, IGF1R inhibitors, matrix metalloproteinase 2 (MMP-2) inhibitors, matrix metalloproteinase 9 (MMP-9) inhibitors and thrombospondin analogs.
  • MMP-2 matrix metalloproteinase 2
  • MMP-9 matrix metalloproteinase 9
  • EGFR inhibitors include, but are not limited to, Iressa (gefitinib), Tarceva (erlotirnib or OSI-774), Erbitux (cetuximab), EMD-7200, ABX-EGF, HR3, IgA antibodies, TP-38 (IVAX), EGFR fusion protein, EGF-vaccine, anti-EGFr immunoliposomes and Tykerb (lapatinib).
  • PDGFR inhibitors include, but are not limited to, CP-673,451 and CP-868596.
  • VEGFR inhibitors include, but are not limited to, Avastin (bevacizumab), Sutent (sunitinib, SU 11248), Nexavar (sorafenib, BAY43-9006), CP-547,632, axitinib (AG13736), Zactima (vandetanib, ZD-6474), AEE788, AZD-2171, VEGF trap, Vatalanib (PTK-787, ZK-222584), Macugen, IM862, Pazopanib (GW786034), ABT-869 and angiozyme.
  • thrombospondin analogs include, but are not limited to, TSP-1, ABT-510, ABT-567 and ABT-898.
  • aurora kinase inhibitors include, but are not limited to, VX-680. AZD-1152 and MLN-8054.
  • polo-like kinase inhibitor includes, but is not limited to BI-2536.
  • bcr-abl kinase inhibitors include, but are not limited to, Gleevec (imatinib) and Dasatinib (BMS354825).
  • platinum containing agents includes, but are not limited to, cisplatin, Paraplatin (carboplatin), eptaplatin, lobaplatin, nedaplatin, Eloxatin (oxaliplatin) and satraplatin.
  • mTOR inhibitors includes, but are not limited to, CCI-779, rapamycin, temsirolimus, everolimus, RAD001, and AP-23573.
  • HSP-90 inhibitors includes, but are not limited to, geldanamycin, radicicol, 17-AAG, KOS-953, 17-DMAG, CNF-101, CNF-1010, 17-AAG-nab, NCS-683664, Mycograb, CNF-2024, PU3, PU24FC1, VER49009, IPI-504, SNX-2112 and STA-9090.
  • HDAC histone deacetylase inhibitors
  • SAHA Suberoylanilide hydroxamic acid
  • MS-275 Valproic acid
  • TSA TSA
  • LAQ-824 Trapoxin
  • Depsipeptide Depsipeptide
  • MEK inhibitors include, but are not limited to, PD325901, ARRY-142886, ARRY-438162 and PD98059.
  • CDK inhibitors include, but are not limited to, flavopyridol, MCS-5A, CVT-2584, seliciclib (CYC-202, R-roscovitine), ZK-304709, PHA-690509, BMI-1040, GPC-286199, BMS-387,032, PD0332991 and AZD-5438.
  • COX-2 inhibitors include, but are not limited to, CELEBREXTM (celecoxib), parecoxib, deracoxib, ABT-963, MK-663 (etoricoxib), COX-189 Lumiracoxib), BMS347070, RS 57067, NS-398, Bextra (valdecoxib), paracoxib, Vioxx (rofecoxib), SD-8381, 4-Methyl-2-(3,4-dimethylphenyl)-1-(4-sulfamoyl-phenyl-1H-pyrrole, T-614, JTE-522, S-2474, SVT-2016, CT-3, SC-58125 and Arcoxia (etoricoxib).
  • non-steroidal anti-inflammatory drugs examples include, but are not limited to, Salsalate (Amigesic), Diflunisal (Dolobid), Ibuprofen (Motrin), Ketoprofen (Orudis), Nabumetone (Relafen), Piroxicam (Feldene), Naproxen (Aleve, Naprosyn), Diclofenac (Voltaren), Indomethacin (Indocin), Sulindac (Clinoril), Tolmetin (Tolectin), Etodolac (Lodine), Ketorolac (Toradol) and Oxaprozin (Daypro).
  • Salsalate Amigesic
  • Diflunisal Dolobid
  • Ibuprofen Metrin
  • Ketoprofen Orudis
  • Nabumetone Relafen
  • Piroxicam Piroxicam
  • Naproxen Aleve, Naprosyn
  • Diclofenac Voltaren
  • Indomethacin Indometh
  • ErbB2 receptor inhibitors include, but are not limited to, CP-724-714, CI-1033 (canertinibj, Herceptin (trastuzumab), Omitarg (2C4, petuzumab), TAK-165, GW-572016 (Ionafarnib), GW-282974, EKB-569, PI-166, dHER2 (HER2 Vaccine), APC8024 (HER2 Vaccine), anti-HER/2neu bispecific antibody, B7.her2IgG3, AS HER2 trifunctional bispecific antibodies, mAB AR-209 and mAB 2B-1.
  • alkylating agents include, but are not limited to, nitrogen mustard N-oxide, cyclophosphamide, ifosfamide, trofosfamide, chlorambucil, melphalan, busulfan, mitobronitol, carboquone, thiotepa, ranimustine, nimustine.
  • Cloretazine (VNP 40101M), temozolomide, AMD-473, altretamine, AP-5280, apaziquone, brostallicin, bendamustine, carmustine, estramustine, fotemustine, glufosfamide, KW-2170, mafosfamide, and mitolactol, carmustine (BCNU), lomustine (CCNU), Busulfan, Treosulfan, Decarbazine and Temozolomide.
  • antimetabolites include but are not limited to, methotrexate, 6-mercaptopurine riboside, mercaptopurine, 5-fluorouracil (5-FU) alone or in combination with leucovorin, tegafur, UFT, doxifluridine, carmofur, cytarabine, cytarabine ocfosfate, enocitabine, S-1, Alimta (premetrexed disodium, LY231514, MTA), Gemzar (gemcitabine, Eli Lilly), fludarabine, 5-azacitidine, capecitabine, cladribine, clofarabine, decitabine, eflomithine, ethnylcytidine, cytosine arabinoside, hydroxyurea, TS-1, melphalan, nelarabine, nolatrexed, ocfosate, disodium premetrexed, pentostatin, pelitrex
  • antibiotics include intercalating antibiotics but are not limited to, aclarubicin, actinomycin D, amrubicin, annamycin, adriamycin, bleomycin, daunorubicin, doxorubicin, elsamitrucin, epirbucin, glarbuicin, idarubicin, mitomycin C, nemorubicin, neocarzinostatin, peplomycin, pirarubicin, rebeccamycin, stimalamer, streptozocih, vairubicin, zinostatin and combinations thereof.
  • topoisomerase inhibiting agents include, but are not limited to, one or more agents selected from the group consisting of aclarubicin, amonafide, belotecan, camptothecin, 10-hydroxycamptothecin, 9-aminocamptothecin, Amsacrine, Cardioxane (Dexrazoxine), diflomotecan, irinotecan HCL (Camptosar), edotecarin, epirubicin (Ellence), etoposide, exatecan, Becatecarin, gimatecan, lurtotecan, orathecin (Supergen), BN-80915, mitoxantrone, pirarbucin, pixantrone, rubitecan, sobuzoxane, SN-38, tafluposide and topotecan.
  • antibodies include, but are not limited to, Rittiximab. Cetuximab, Bevacizumab, Trastuzimab, specific CD40 antibodies and specific IGF1R antibodies, chTNT-1/B, Denosumab, Panorex (Edrecolomab), Rencarex (WX G250), Zanolimumab, Lintuzumab, Ticilimumab.
  • hormonal therapies include, but are not limited to, exemestane (Aromasin), leuprolide acetate, Buserelin, Cetrorelix, Deslorelin, Vantas, anastrozole (Arimidex), fosrelin (Zoladex), goserelin, Degarelix, doxercalciferol, fadrozole, formestane, tamoxifen citrate (tamoxifen), Arzoxifene. Casodex.
  • Abarelix Abarelix, Trelstar, finasteride, fulvestrant, toretnifene, raloxifene, Trilostane (Modrastane, Desopan), lasofoxifene, letrozole, flutamide, bicalutamide, megesterol, mifepristone, nilutamide, dexamethasone, predisone and other glucocorticoids.
  • retinoids/deltoids examples include, but are not limited to, seocalcitol (EB 1089, CB 1093), lexacalcitrol (KH 1060), fenretinide, Panretin (aliretinoin), Atragen, Bexarotene and LGD-1550.
  • plant alkaloids examples include, but are not limited to, vincristine, vinblastine, vindesine and vinorelbine.
  • proteasome inhibitors include, but are not limited to bortezomib (Velcade), MG132, NPI-0052 and PR-171.
  • immunologicals include, but are not limited to, interferons and numerous other immune enhancing agents.
  • Interferons include interferon alpha, interferon alpha-2a, interferon alpha-2b, interferon beta, interferon gamma-1a, interferon gamma-1b (Actimmune), or interferon gamma-n1 and combinations thereof.
  • Other agents include Alfaferone (Leukocyte alpha interferon, Cliferon), filgrastim, lentinan, sizofilan, TheraCys, ubenimex, WF-10, aldesleukin, alemtuzumab, BAM-002, decarbazine, daclizumab, denileukin, gemtuzumab ozogamicin, ibritumomab, imiquimod, lenograstim, lentinan, melanoma vaccine (Corixa), molgramostim, OncoVAC-CL, sargaramostim, tasonermin, tecleukin, thymalasin, tositumomab, Virulizin, Z-100, epratuzumab, mitumomab, oregovomab, pemtumomab (Y-muHMFG1), Provenge (Dendreon), CTLA4 (cytotoxic lymphocyte
  • biological response modifiers are agents that modify defense mechanisms of living organisms or biological responses, such as survival, growth, or differentiation of tissue cells to direct them to have anti-tumor activity.
  • agents include Icrestin, lentinan, sizofuran, picibanil PF-3512676 (CpG-8954) and ubenimex.
  • pyrimidine analogs include, but are not limited to, 5-Fluorouracil, Floxuridine, Doxifluridine, Ratitrexed, cytarabine (ara C), Cytosine arabinoside, Fludarabine, triacetyluridine Troxacitabine (Troxatyl) and Gemcitabine.
  • purine analogs include but are not limited to, Mercaptopurine and thioguanine.
  • antimitotic agents include, but are not limited to, N-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide, paclitaxel, docetaxel, epothilone D (KOS-862), PNU100940 (109881), Batabulin, Ixabepilone (BMS 247550), Patupilone, XRP-9881, Vinflunine and ZK-EPO.
  • Radiotherapy examples include but are not limited to, external beam radiotherapy (XBRT), or teletherapy, brachtherapy or sealed source radiotherapy, unsealed source radiotherapy.
  • XBRT external beam radiotherapy
  • teletherapy brachtherapy
  • sealed source radiotherapy unsealed source radiotherapy.
  • compounds having formula (II) may be combined with other antitumor agents selected from the following agents, Genasense, Panitumumab, Zevalin, Bexxar (Corixa), Arglabin, Abarelix, Alimta, EP0906, discodermolide, Neovastat, enzastaurin, Combrestatin A4P; ZD-6126, AVE-8062, DMXAA, Thymitaq, Temodar, Revlimid, Cypat, Histerelin, Plenaizis, Atrasentan, Celeuk (celmoleukin), Satraplatin, thalomide (Thalidomide), theratope, Temilifene, ABI-007, Evista, Atamestane, Xyotax, Targretin, Triazone, Aposyn, Nevastat, Ceplene, Lanreotide, Aredia (pamidronic acid), Orathecin, Virulizin, Gastrimmune, DX-8951
  • BAX and BAD peptides are reported in Zhang, H. C., Nimmer, P., Rosenberg, S. H., Ng, S.C., and Joseph, M. (2002). Development of a High-Throughput Fluorescence Polarization Assay for Bcl-x(L). Analytical Biochemistry 307, 70-75.
  • Binding affinity of compounds having formula (II) to Bcl-X 1 protein is indicia of their inhibition of the activity of this protein.
  • representative examples were diluted in DMSO to concentrations between 100 ⁇ M and 1 pM and added to each well of a 96-well microtiter plate.
  • a mixture comprising 125 ⁇ L per well of assay buffer (20 mM phosphate buffer (pH 7.4), 1 mM EDTA, 50 mM NaCl, 0.05% PF-68), 6 nM of Bcl-X L protein (prepared as described in Science 1997, 275, 983-986), 1 nM fluorescein-labeled BAD peptide (prepared in-house) and the DMSO solution of the compound was shaken for 2 minutes and placed in a LJL Analyst (LJL Bio Systems, CA).
  • a negative control (DMSO, 15 nM BAD peptide, assay buffer) and a positive control (DMSO, 1 nM BAD peptide, 6 nM Bcl-X L , assay buffer) were used to determine the range of the assay.
  • Polarization was measured at room temperature using a continuous Fluorescein lamp (excitation 485 nm, emission 530 nm). Percentage of inhibition was determined by (1-((mP value of well-negative control)/range)) ⁇ 100%. The results are shown in TABLE 1.
  • Binding affinity of compounds having formula (II) to Bcl-2 protein is indicia of their inhibition of the activity of this protein.
  • representative examples were diluted in DMSO to concentrations between 10 ⁇ M and 10 ⁇ M and added to each well of a 96-well microtiter plate.
  • a mixture comprising 125 L per well of assay buffer (20 mM phosphate buffer (pH 7.4), 1 mM EDTA, 50 mM NaCl, 0.05% PF-68), 10 nM of Bcl-2 protein (prepared according to the procedure described in PNAS 2001, 98, 3012-3017), 1 nM fluorescein-labeled BAX peptide (prepared in-house) and the DMSO solution of the representative EXAMPLE was shaken for 2 minutes and placed in a LJL Analyst (LJL Bio Systems, CA. Polarization was measured at room temperature using a continuous Fluorescein lamp (excitation 485 nm, emission 530 nm). The results are also shown in TABLE 1.
  • compounds having formula (II) are expected to have utility in treatment of diseases during which anti-apopotic Bcl-X L protein, anti-apopotic Bcl-2 protein, anti-apopotic Bcl-w protein or a combination thereof, are expressed. Determination of Cellular Efficacy in Human Tumor Cell Line
  • NCl-H146 (ATCC, Manassas, Va.) human small cell lung carcinoma cells were plated 50.000 cells per well in 96-well tissue culture plates in a total volume of 100 ⁇ L tissue culture medium supplemented with 10% human serum (Invitrogen, Carlsbad, Calif.) instead of fetal bovine serum and treated with a 2-fold serial dilution of the compounds of interest from 10 ⁇ M to 0.020 ⁇ M. Each concentration was tested in duplicate at least 3 separate times. The number of viable cells following 48 hours of compound treatment was determined using the CellTiter 96® AQ ueous non-radioactive cell proliferation MTS assay according to manufacturer's recommendations (Promega Corp., Madison, Wis.). The results are also shown in TABLE 1.
  • the compounds were prepared as 2 mg/mL solution in a 10% DMSO in PEG-400 formulation for both oral and intravenous administration.
  • the 1 mL/kg intravenous dose was administered as a slow bolus (about 1-2 minutes) in the jugular vein of a rat under light ether anesthetic.
  • the oral dose was administered by gavage.
  • Serial blood samples were obtained from a tail vein of each rat prior 0.1 (IV only), 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 24 hours after dosing.
  • the heparinized samples were thoroughly mixed and placed in an ice bath. Plasma was separated by centrifugation and stored frozen prior to analysis. The results are also shown in TABLE 1.
  • the compounds of interest were separated from the plasma using protein precipitation with acetonitrile.
  • a plasma (100-200 ⁇ L, sample or spiked standard) aliquot was combined with 50 ⁇ L of internal standard (structurally related analog prepared in acetonitrile) and 1 ml acetonitrile in a 96-well polypropylene deep well plate.
  • the plates were vortexed for 30 seconds followed by centrifugation (3500 rpm ⁇ 15 minutes, 4° C.). In an automated manner, the supernatant was transferred to a clean 96-well plate.
  • the samples were evaporated to near dryness on a Micro-VapTM under a stream of dry nitrogen over low heat ( ⁇ 37° C.).
  • the samples were reconstituted vortexing with 0.2 mL 5% DMSO in acetonitrile.
  • a 0.1-0.2 ml aliquot of acetonitrile: 0.1% trifluoroacetic acid (20:80, by volume) was added to each well, followed by an additional 30 second vortexing.
  • the plates were centrifuged (3500 rpm ⁇ 15 minutes, 4° C.) prior to HPLC-MS/MS analysis. Samples were analyzed simultaneously with spiked plasma standards. All samples from each study were analyzed as a single batch on the LC-MS/MS.
  • the compounds of interest and the internal standard were separated from each other and co-extracted contaminants on a 50 ⁇ 3 mm Keystone Betasil CN 5 ⁇ m column with an acetonitrile: 0.1% trifluoroacetic acid mobile phase (50:50, by volume) at a flow rate of 0.7 ml/min. Analysis was performed on a Sciex API 300 Biomolecular Mass Analyzer using a heated nebulizer interface. Peak areas of the title compounds and internal standards were determined using the Sciex MacQuanTM software. Calibration curves were derived from peak area ratio (parent drug/internal standard) of the spiked rat plasma standards using least squares linear regression of the ratio versus the theoretical concentration.
  • the methods were generally linear over the range of the standard curve (correlation coefficients >0.99) with an estimated quantitation limit of 0.01 ⁇ g/mL.
  • the plasma concentration data for each animal were submitted to multi-exponential curve fitting using WinNonlin.
  • the area under the plasma concentration-time curve from 0 to t hours (time of the last measurable plasma concentration) after dosing (AUC 0.4 ) was calculated using the linear trapezoidal rule for the plasma concentration-time profiles.
  • the residual area extrapolated to infinity determined as the final measured plasma concentration (C i ) divided by the terminal elimination rate constant ( ⁇ ), was added to AUC 0-t to produce the total area under the curve. The results are also shown in TABLE 1.
  • Ki (Bcl-2) Ki (Bcl-X L ) EC 50 AUC 0- ⁇ AUC/EC 50 1 ⁇ 0.001 ⁇ M ⁇ 0.001 ⁇ M 0.0891 ⁇ M 5.01 ⁇ M 56 2 ⁇ 0.001 ⁇ M ⁇ 0.001 ⁇ M 0.0291 ⁇ M 7.01 ⁇ M 241 3 ⁇ 0.001 ⁇ M ⁇ 0.001 ⁇ M 0.0288 ⁇ M 4.13 ⁇ M 144 4 ⁇ 0.001 ⁇ M ⁇ 0.001 ⁇ M 0.0587 ⁇ M 6.34 ⁇ M 108 5 ⁇ 0.001 ⁇ M ⁇ 0.001 ⁇ M 0.0388 ⁇ M 2.22 ⁇ M 57 6 ⁇ 0.001 ⁇ M ⁇ 0.001 ⁇ M 0.0010 ⁇ M 0.91 ⁇ M 91 7 ⁇ 0.001 ⁇ M ⁇ 0.001 ⁇ M 0.0589 ⁇ M 3.87 ⁇ M 66 8 ⁇ 0.001 ⁇ M ⁇ 0.001 ⁇ M 0.0212 ⁇ M 1.10 ⁇
  • the compounds of the present invention were also tested against compounds disclosed in WO 2005/049594, identified herein as EXAMPLES A-L, by determining the ratio of systemic exposure to cellular efficacy. This measure, sometimes reported as AUC/EC 50 , is well known to those skilled in the art of pharmaceutical drug discovery and drug development as a useful pharmacodynamic predictor of oral efficacy.
  • cancer includes, but is not limited to acoustic neuroma, acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia (monocytic, myeloblastic, adenocarcinoma, angiosarcoma, astrocytoma, myelomonocytic and promyelocytic), acute t-cell leukemia, basal cell carcinoma, bile duct carcinoma, bladder cancer, brain cancer, breast cancer, bronchogenic carcinoma, cervical cancer, chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia, chronic lymphocytic leukemia, chronic myelocytic (granulocytic) leukemia, colorectal cancer,
  • autoimmune disorders include, but are not limited to, acquired immunodeficiency disease syndrome, autoimmune lymphoproliferative syndrome, hemolytic anemia, inflammatory diseases, and thrombocytopenia (Current Allergy and Asthma Reports 2003, 3:378-384; Br. J. Haematol. 2000 September; 110(3): 584-90; Blood 2000 Feb. 15; 95(4):1283-92; and New England Journal of Medicine 2004 September; 351(14): 1409-1418).
  • compounds having formula (II) would inhibit the growth of cells derived from a cancer or neoplasm such as breast cancer (including estrogen-receptor positive breast cancer), colorectal cancer, endometrial cancer, lung cancer (including small cell lung cancer), lymphoma (including follicular or Diffuse Large B-cell), lymphoma (including non-Hodgkin's lymphoma), neuroblastoma, ovarian cancer, prostate cancer (including hormone-insensitive prostate cancer), testicular cancer (including germ cell testicular cancer).
  • a cancer or neoplasm such as breast cancer (including estrogen-receptor positive breast cancer), colorectal cancer, endometrial cancer, lung cancer (including small cell lung cancer), lymphoma (including follicular or Diffuse Large B-cell), lymphoma (including non-Hodgkin's lymphoma), neuroblastoma, ovarian cancer, prostate cancer (including hormone-insensitive prostate cancer), testicular cancer (including germ cell testicular cancer).
  • compounds having formula (II) would inhibit the growth of cells derived from a pediatric cancer or neoplasm such as embryonal rhabdomyosarcoma, pediatric acute lymphoblastic leukemia, pediatric acute myelogenous leukemia, pediatric alveolar rhabdomyosarcoma, pediatric anaplastic ependymoma, pediatric an aplastic large cell lymphoma, pediatric anaplastic medulloblastoma, pediatric atypical teratoid/rhabdoid tumor of the central nervous syatem, pediatric biphenotypic acute leukemia, pediatric Burkitts lymphoma, pediatric cancers of Ewing's family of tumors such as primitive neuroectodermal rumors, pediatric diffuse anaplastic Wilm's tumor, pediatric favorable histology Wilm's tumor, pediatric glioblastoma, pediatric medulloblastoma, pediatric neuroblastoma, pediatric neuroblastoma-derived myelocytomato
  • autoimmune disorders include, but are not limited to, acquired immunodeficiency disease syndrome, autoimmune lymphoproliferative syndrome, hemolytic anemia, inflammatory diseases, and thrombocytopenia (Current Allergy and Asthma Reports 2003, 3:378-384; Br. J. Haematol. 2000 September; 110(3): 584-90; Blood 2000 Feb. 15; 95(4):1283-92; and New England Journal of Medicine 2004 September; 351(14): 1409-1418).
  • Protecting groups for C(O)OH moieties include, but are not limited to, acetoxymethyl, allyl, benzoylmethyl, benzyl, benzyloxymethyl, tert-butyl, tert-butyldiphenylsilyl, diphenylmethyl, cyclobutyl, cyclohexyl, cyclopentyl, cyclopropyl, diphenylmethylsilyl, ethyl, para-methoxybenzyl, methoxymethyl, methoxyethoxymethyl, methyl, methylthiomethyl, naphthyl, para-nitrobenzyl, phenyl, n-propyl, 2,2,2-trichloroethyl, triethylsilyl, 2-(trimethylsilyl)ethyl, 2-(trimethylsilyl)ethoxymethyl, triphenylmethyl and the like.
  • Protecting groups for C(O) and C(O)H moieties include, but are not limited to, 1,3-dioxylketal, diethylketal, dimethylketal, 1,3-dithianylketal, O-methyloxime, O-phenyloxime and the like.
  • Protecting groups for NH moieties include, but are not limited to, acetyl, alanyl, benzoyl, benzyl (phenylmethyl), benzylidene, benzyloxycarbonyl (Cbz), tert-butoxycarbonyl (Boc), 3,4-dimethoxybenzyloxycarbonyl, diphenylmethyl, diphenylphosphoryl, formyl, methanesulfonyl, para-methoxybenzyloxycarbonyl, phenylacetyl, phthaloyl, succinyl, trichloroethoxycarbonyl, triethylsilyl, trifluoroacetyl, trimethylsilyl, triphenylmethyl, triphenylsilyl, para-toluenesulfonyl and the like.
  • Protecting groups for OH and SH moieties include, but are not limited to, acetyl, allyl, allyloxycarbonyl, benzyloxycarbonyl (Cbz), benzoyl, benzyl, tert-butyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, 3,4-dimethoxybenzyl, 3,4-dimethoxybenzyloxycarbonyl, 1,1-dimethyl-2-propenyl, diphenylmethyl, formyl, methanesulfonyl, methoxyacetyl, 4-methoxybenzyloxycarbonyl, para-methoxybenzyl, methoxycarbonyl, methyl, para-toluenesulfonyl, 2,2,2-trichloroethoxycarbonyl, 2,2,2-trichloroethyl, triethylsilyl, trifluoroacetyl, 2-
  • ADDP means 1,1′-(azodicarbonyl)dipiperidine
  • AD-mix- ⁇ means a mixture of (DHQD) 2 PHAL, K 3 Fe(CN) 6 , K 2 CO 3 and K 2 SO 4 );
  • AIBN means 2,2′-azobis(2-methylpropionitrile);
  • 9-BBN means 9-borabicyclo[3.3.1]nonane;
  • (DHQD) 2 PHAL means hydroquinidine 1,4-phthalazinediyl diethyl ether;
  • DBU means 1,8-diazabicyclo[5.4.0]undec-7-ene;
  • DIBAL means diisobutylaluminum hydride;
  • DIEA means diisopropylethylamine;
  • DMAP means N,N-dimethylaminopyridine;
  • DME means 1,2-dimethoxyethane;
  • DMF means N,N-dimethylformamide;
  • dmpe means 1,
  • compounds having formula (1) may be converted to compounds having formula (2) by reacting the former, chlorosulfonic acid, and ammonia.
  • Compounds having formula (2) may be converted to compounds having formula (II) by reacting the former and compounds having formula (3) and a coupling agent, with or without a base.
  • a coupling agent include EDCI, CDI, and PyBop.
  • bases include TEA, DIEA, DMAP, and mixtures thereof.
  • Compounds having formula (2) may be converted to compounds having formula (II) by reacting the former and compounds having formula Z 1 -COCl and the base.
  • EXAMPLE 1A (16.5 g), diphenyl disulfide (14.5 g) and tributylphosphine (16.6 mL) in toluene (250 mL) at 80° C. was stirred for 24 hours, cooled and concentrated. The concentrate was chromatographed on silica gel with 1:1 ethyl acetate/hexanes.
  • EXAMPLE 1B (18 g) in 30% HBr in acetic acid (250 mL) at 25° C. was stirred for 24 hours, concentrated, poured into 1M HCl and extracted with diethyl ether. The extract was extracted with 1M HCl, and this extract was cooled to 0° C., adjusted to pH 12 with KOH and extracted with dichloromethane. The extract was washed with brine and dried (Na 2 SO 4 ), filtered and concentrated.
  • EXAMPLE 1C (45.4 g) in THF (500 mL) at 55° C. was treated with 1M BH 3 -THF (650 mL) over 2 hours, stirred for 24 hours, cooled to 0° C., treated with methanol (80 mL), poured into methanol (500 mL) and concentrated.
  • a mixture of the concentrate in methanol (400 mL) was treated with a HCl-saturated methanol (800 mL), refluxed for 24 hours, cooled, concentrated, poured into 2M NaOH and extracted with ethyl acetate. The extract was washed with 1M NaOH and brine and dried (Na 2 SO 4 ), filtered and concentrated.
  • the concentrate was chromatographed on silica gel with ethyl acetate 10% methanol/ethyl acetate and 10% methanol/10% acetonitrile/5% TEA/75% ethyl acetate.
  • Methyl viologen hydrochloride (1.17 g) in DMF (80 mL) at 25° C. was saturated with trifluoromethyl iodide, treated with 2-fluorobenzenethiol (9.7 mL) and TEA (20 ml), stirred for 24 hours, diluted with water (240 mL) and extracted with diethyl ether. The extract was washed with 1M NaOH, saturated ammonium chloride and brine and concentrated.
  • EXAMPLE 1 E (17.346 g) in 1:1:2 carbon tetrachloride/acetonitrile/water (800 mL) at 25° C. was treated with sodium periodate (56.8 g) and ruthenium(III) chloride hydrate (183 mg), stirred for 18 hours, diluted with dichloromethane (100 mL) and filtered through diatomaceous earth (Celite®). The filtrate was washed with saturated sodium bicarbonate and extracted with dichloromethane. The extract was washed with brine and dried (MgSO 4 ), filtered and concentrated. The concentrate was filtered through silica gel.
  • EXAMPLE 1F (37.3 g) in chlorosulfonic acid (32.8 mL) at 120° C. was stirred for 18 hours, cooled to 25° C. and pipetted onto crushed ice. The mixture was extracted with ethyl acetate, and the extract was washed with water and brine and dried (MgSO 4 ), filtered and concentrated.
  • EXAMPLE 1G (23 g) in isopropanol (706 mL) at ⁇ 78° C. was treated with ammonium hydroxide (98 mL) over 1 hour, stirred for 1 hour, quenched with 6M HCl (353 mL), warmed to 25° C. and concentrated. The concentrate was mixed with water and extracted with ethyl acetate. The extract was dried (MgSO 4 ), filtered and concentrated. The concentrate was recrystallized from ethyl acetate/hexane.
  • EXAMPLE 1H 13.48 g
  • EXAMPLE 1D 11.56 g
  • THF 218 mL
  • DIEA 15.1 mL
  • the extract was dried (MgSO 4 ), filtered and concentrated.
  • the concentrate was recrystallized from hexanes/ethyl acetate.
  • EXAMPLE 1J (1.7 g) and 4-piperazin-1-ylbenzoic acid ethyl ester (1.9 g) in methanol (30 mL) was treated with sodium cyanoborohydride (0.6 g), adjusted to pH 5 with acetic acid, stirred for 18 hours and filtered through diatomaceous earth (Celite®). The filtrate was concentrated, and the concentrate was chromatographed on silica gel on silica gel with 10-30% ethyl acetate/hexanes.
  • EXAMPLE 1K (1.1 g), 4-chlorophenylboronic acid (0.6 g), 2M Na 2 CO 3 (2 mL) and PdCl 2 (PPh 3 ) 2 (0.1 g) in 7:3:2 DME/water/ethanol (20 mL) was stirred at 85° C. for 18 hours, filtered through diatomaceous earth (Celite®) and concentrated. The concentrate was chromatographed on silica gel with 10-30% ethyl acetate/hexanes.
  • EXAMPLE 1M (31.5 g), EXAMPLE 1I (39.93 g), EDAC-HCl (20.60 g) and DMAP (13.15 g) in dichloromethane (500 mL) at 25° C. was stirred for 18 hours, diluted with dichloromethane, washed with saturated ammonium chloride and brine and dried (MgSO 4 ), filtered and concentrated. The concentrate was chromatographed on silica gel with 0-10% methanol/ammonia-saturated dichloromethane.
  • EXAMPLE 2A (46 g) in 1:1:2 CCl 4 /CH 3 CN/water (1.2 L) at 25° C. was treated with NalO 4 (165.6 g) and RuCl 3 .xH 2 O (534 mg), stirred for 18 hours, diluted with dichloromethane and filtered through diatomaceous earth (Celite®). The filtrate was washed with saturated NaHCO 3 and dried (Na 2 SO 4 ), filtered and concentrated. The concentrate was filtered through silica gel.
  • EXAMPLE 2D (22 g) in isopropanol (700 mL) at ⁇ 78° C. was treated with aqueous ammonia (90 mL) over 1 hour, stirred for another hour, quenched with 6M HCl (300 mL), warmed to 25° C. and concentrated. The concentrate was mixed with water and extracted with ethyl acetate. The extract was dried (MgSO 4 ), filtered and concentrated. The concentrate was recrystallized from hexanes/ethyl acetate.
  • EXAMPLE 2E (2.89 g) and EXAMPLE 1 D (2.39 g) in THF (20 mL) was treated with diisopropylethylamine (3.2 mL), stirred at 60° C. for 18 hours, cooled, treated with saturated sodium bicarbonate and extracted with ethyl acetate. The extract was dried (MgSO 4 ), filtered and concentrated. The concentrate was chromatographed on silica gel with 1.5-5% 7M ammonia in methanol/dichloromethane.
  • EXAMPLE 2G (86 g), 4-chlorophenylboronic acid (50 g), CsF (104 g) and tetrakis(triphenylphosphine)palladium(0) (2.5 g) in 2:1 DME/methanol (600 mL) at 70° C. was stirred for 18 hours and concentrated. The concentrate was dissolved in diethyl ether, and the solution was dried (MgSO 4 ), filtered and concentrated. The concentrate was filtered through silica gel with 20% ethyl acetate/hexanes.
  • Lithium borohydride (18 g) was treated with EXAMPLE 2H (76 g) in diethyl ether (400 mL) and methanol (23 mL), stirred at reflux for 4 hours, cooled, quenched with 1M HCl, diluted with water and extracted with diethyl ether. The extract was dried (MgSO 4 ), filtered and concentrated. The concentrate was chromatographed on silica gel with 0-30% ethyl acetate/hexanes.
  • EXAMPLE 2I (17.5 g) in dichloromethane (100 mL) at 0° C. was treated simultaneously with methanesulfonyl chloride (5.6 mL) and TEA (21 mL), stirred for 5 minutes, treated with 4-piperazin-1-ylbenzoic acid ethyl ester (17 g), stirred at 25° C. for 18 hours, washed with ammonium chloride and dried (Na 2 SO 4 ), filtered and concentrated. The concentrate was chromatographed on silica gel with 10% ethyl acetate/hexanes.
  • EXAMPLE 4B (7.5 g) and bis(cyclopentadienyl)zirconium(IV) chloride hydride (10.31 g) in THF (100 mL) at 25° C. was stirred for 20 minutes and concentrated. The concentrate was chromatographed on silica gel with 50% ethyl acetate in hexane.
  • EXAMPLE 4C (2.87 g) and N-isopropylmethylamine (1.92 g) in 1,2-dichloroethane (50 mL) at 25° C. was treated with sodium triacetoxyborohydride (3 g), stirred for 2 hours, diluted with ethyl acetate, washed with 2M NaOH, water and brine and dried (Na 2 SO 4 ), filtered and concentrated. The concentrate was chromatographed on silica gel with 1% methanol/dichloromethane.
  • This example was prepared by substituting 4-(4-(2-(4-chlorophenyl)cyclo 1-enylmethyl)piperazin-1-yl)benzoic acid, prepared as described in commonly-owned U.S. patent application Ser. No. 10/988,338, and EXAMPLE 4F for EXAMPLE 1M and EXAMPLE 1I, respectively, in EXAMPLE 1N.
  • EXAMPLE 6A (6.13 g) in THF (200 mL) at 25° C. was treated with di-tert-butyldicarbonate (7 g), stirred for 4 hours and concentrated. The concentrate was dissolved into ethyl acetate (500 mL), washed with 1M NaOH, water and brine and dried (Na 2 SO 4 ), filtered and concentrated. The concentrate in THF (200 mL) at 25° C. to was treated with 1M NaOH (200 mL), stirred for 5 hours and isolated. The water layer was extracted with ethyl acetate, and the THF and ethyl acetate extracts were combined, washed with water and brine and dried (Na 2 SO 4 ), filtered and concentrated.
  • EXAMPLE 6D (7.86 g) in dichloromethane (200 mL) at 25° C. was treated with 2M HCl in diethyl ether (200 mL), stirred for 18 hours and concentrated.
  • This example was prepared by substituting 4-(4-(2-(4-chlorophenyl)cyclohept-1-enylmethyl)piperazin-1-yl)benzoic acid, prepared as described in commonly-owned U.S. patent application Ser. No. 10/988,338, and EXAMPLE 9A for EXAMPLE 1M and EXAMPLE 1I, respectively, in EXAMPLE 1N.
  • This example was prepared by substituting 4-(4-(2-(4-chlorophenyl)cyclohept-1-enylmethyl)piperazin-1-yl)benzoic acid, prepared as described in commonly-owned U.S. patent application Ser. No. 10/988,338, and EXAMPLE 6F for EXAMPLE 1M and EXAMPLE 1I, respectively, in EXAMPLE 1N.
  • This example was prepared by substituting EXAMPLE 6C and 1,4-oxazepane for EXAMPLE 4C and N-isopropyl-N-methylamine in EXAMPLE 4D.
  • This example was prepared by substituting azepane for N-isopropyl-N-methylamine in EXAMPLE 4D.
  • This example was prepared by substituting 4-(4-(2-(4-chlorophenyl)cyclohept-1-enylmethyl)piperazin-1-yl)benzoic acid, prepared as described in commonly-owned U.S. patent application Ser. No. 10/988,338, and EXAMPLE 17B for EXAMPLE 1M and EXAMPLE 1I respectively, in EXAMPLE 1N.
  • This example was prepared by substituting pyrrolidine for N-isopropylethylamine in EXAMPLE 4D.
  • This example was prepared by substituting 4-(4-(2-(4-chlorophenyl)cyclo-1-enylmethyl)piperazin-1-yl)benzoic acid, prepared as described in commonly-owned U.S. patent application Ser. No. 10/988,338, and EXAMPLE 27C for EXAMPLE 1M and EXAMPLE 1I, respectively, in EXAMPLE 1N.
  • This example was prepared by substituting 4-(4-(2-(4-chlorophenyl)cyclohept 1-enylmethyl)piperazin-1-yl)benzoic acid, prepared as described in commonly-owned U.S. patent application Ser. No. 10/988,338, and EXAMPLE 30A for EXAMPLE 1M and EXAMPLE 1I, respectively, in EXAMPLE 1N.
  • This example was prepared by substituting 4-(4-(1,1′-biphenyl-2-ylmethyl)-1-piperazinyl)benzoic acid, prepared as described in commonly-owned U.S. patent application Ser. No. 10/988,338, for EXAMPLE 1M and EXAMPLE 17B for EXAMPLE 1I, respectively, in EXAMPLE 1N.

Abstract

Compounds which inhibit the activity of anti-apoptotic family protein members, compositions containing the compounds and methods of treating diseases during which occur expression one or more than one of an anti-apoptotic family protein member are disclosed.

Description

    CROSS REFERENCE SECTION
  • This application is a divisional of U.S. patent application. Ser. No. 11/432,937, filed May 12, 2006, which claims priority to U.S. Provisional Application Ser. No. 60/718,618, filed Sep. 20, 2005 and U.S. Application Ser. No. 60/680,107, May 12, 2005.
    • FIELD OF THE INVENTION
  • This invention comprises compounds which inhibit the activity of anti-apoptotic Bcl-2 family protein members, compositions containing the compounds and methods of treating diseases during which are expressed one or more than one of an anti-apoptotic family protein member.
    • BACKGROUND OF THE INVENTION
  • Anti-apoptotic Bcl-2 family protein members are associated with a number of diseases and thus are under investigation as potential therapeutic drug targets. These important targets for interventional therapy include, for example, the Bcl-2 family of proteins Bcl-2, Bcl-X1 and Bcl-W. Recently inhibitors of Bcl-2 family members have been reported in the literature, see, for example, WO 2005/049594, Oltersdorf, et. al. Nature 2005, 435, 677-681, U.S. Pat. No. 6,720,338 and U.S. Pat. No. 7,030,115. While this art teaches inhibitors having high binding to the target protein, this is only one of many parameters that must be considered as a compound is investigated for further or continued drug development. As part of this development, it is highly desirable to produce compounds that are efficacious in animal models of cancer after oral administration. To achieve this oral efficacy, it is well known in the art that a compound must not only display potent activity against a tumor type or cell line under investigation, but must also achieve acceptable levels of systemic exposure after oral administration. A typical measure of cellular activity is the concentration eliciting 50% cellular effect (EC50). A typical measure of systemic exposure is the area under the curve resulting from graphing the plasma compound concentration after oral administration vs. time (AUC). The ratio between these parameters (AUC/EC50) is well known in the art to constitute a useful pharmacodynamic parameter to predict oral efficacy.
  • The inventors have discovered that while compounds taught in the art may have either potent cellular efficacies or high systemic exposures after oral administration to animals, they do not possess both properties. This results in a low AUC/EC50 ratio and renders these compounds not orally efficacious. This invention is directed to a series of haloalkylsulonylaryl analogs that demonstrate enhanced and unexpected properties with respect to cellular efficacy and systemic exposure after oral administration in animals. Specifically, compounds of this invention maintain potent cellular efficacy while exhibiting suitable systemic exposure after oral administration to animals. This results in AUC/EC50 ratios significantly higher than that of the compounds taught in the art.
    • BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1 shows comparitive antitumorgenesis of EXAMPLE 1, etoposide and combinations thereof on B-cell lymphoma.
  • FIG. 2 shows comparitive antitumorgenesis of EXAMPLE 1, vincristine and combinations thereof on B-cell lymphoma.
  • FIG. 3 shows comparitive antitumorgenesis of EXAMPLE 1, CHOP and combinations thereof on B-cell lymphoma.
  • FIG. 4 shows comparitive antitumorgenesis of EXAMPLE 1, rituximab and combinations thereof on B-cell lymphoma.
  • FIG. 5 shows comparitive antitumorgenesis of EXAMPLE 1 rapamycin and combinations thereof on B-cell lymphoma.
  • FIG. 6 shows comparitive antitumorgenesis of EXAMPLE 1, R—CHOP and combinations thereof on mantle cell lymphoma.
  • FIG. 7 shows comparitive antitumorgenesis of EXAMPLE 1, bortezomib and combinations thereof on mantle cell lymphoma.
    •  SUMMARY OF THE INVENTION
  • One embodiment of this invention comprises compounds having formula (II)
  • Figure US20080287419A1-20081120-C00001
  • and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof, wherein X3 is Cl or F;
  • X4 is azepan-1-yl, morpholin-1-yl, 1,4-oxazepan-4-yl, pyrrolidin-1-yl, N(CH3)2, N(CH3)(CH(CH3)2), 7-azabicyclo[2.2.1]heptan-1-yl or 2-oxa-5-azabicyclo[2.2.1]hept-5-yl, and R0 is
  • Figure US20080287419A1-20081120-C00002
  • wherein
    • X5 is CH2, C(CH3)2 or CH2CH2;
  • X6 and X7 are both hydrogen or are both methyl; and
    • X8 is F, Cl, Br or I; or
  • X4 is azepan-1-yl, morpholin-1-yl, pyrrolidin-1-yl, N(CH3)(CH(CH3)2) or 7-azabicyclo[2.2.1]heptan-1-yl, and R0 is
  • Figure US20080287419A1-20081120-C00003
  • X4 is N(CH3)2 or morpholin-1-yl, and R0 is
  • Figure US20080287419A1-20081120-C00004
  • Another embodiment comprises compounds having formula (II), and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof, wherein X3 is Cl or F;
  • X4 is azepan-1-yl, morpholin-1-yl, 1,4-oxazepan-4-yl, pyrrolidin-1-yl, N(CH3)2, N(CH3)(CH(CH3)2), 7-azabicyclo[2.2.1]heptan-1-yl or 2-oxa-5-azabicyclo[2.2.1]hept-5-yl, and R0 is
  • Figure US20080287419A1-20081120-C00005
  • wherein
    • X5 is CH2, C(CH3)2 or CH2CH2;
  • X6 and X7 are both hydrogen or are both methyl; and
    • X8 is F, Cl Br or I; or
  • X4 is azepan-1-yl, morpholin-1-yl, pyrrolidin-1-yl, N(CH3)(CH(CH3)2) or 7-azabicyclo[2.2.1]heptan-1-yl, and R0 is
  • Figure US20080287419A1-20081120-C00006
  • X4 is N(CH3)2 or morpholin-1-yl, and R0 is
  • Figure US20080287419A1-20081120-C00007
  • Still another embodiment comprises compounds having formula (II), and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof, wherein X3 is Cl or F;
  • X4 is azepan-1-yl, morpholin-1-yl, 1,4-oxazepan-4-yl, pyrrolidin-1-yl, N(CH3)2, N(CH3)(CH(CH3)2), 7-azabicyclo[2.2.1]heptan-1-yl or 2-oxa-5-azabicyclo[2.2.1]hept-5-yl, and R0 is
  • Figure US20080287419A1-20081120-C00008
  • wherein X5 is CH2, C(CH3)2 or CH2CH2, and X6 and X7 are both hydrogen or are both methyl; and
    • X8 is F, Cl, Br or I.
  • Still another embodiment comprises compounds having formula (II), and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof, wherein X3 is Cl or F;
  • X4 is azepan-1-yl, morpholin-1-yl, pyrrolidin-1-yl, N(CH3)(CH(CH3)2) or 7-azabicyclo[2.2.1]heptan-1-yl;
    • R0 is
  • Figure US20080287419A1-20081120-C00009
  • wherein X6 and X7 are both hydrogen or are both methyl; and X8 is F, Cl, Br or I.
  • Still another embodiment comprises compounds having formula (II), and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof,
  • wherein X3 is Cl or F;
  • X4 is N(CH3)2 or morpholin-1-yl;
    • Ro is
  • Figure US20080287419A1-20081120-C00010
    • X8 is F, Cl, Br or I.
  • Still another embodiment comprises a compound having formula (II), and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof, wherein X3 is F; X4 is morpholin-1-yl;
    • R0 is
  • Figure US20080287419A1-20081120-C00011
  • wherein X5 is C(CH3)2; X6 and X7 are both methyl; and X8 is Cl.
  • Still another embodiment comprises
    • N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide.
    • 3-((chloro(difluoro)methyl)sulfonyl)-N-(4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)benzenesulfonamide,
    • 3-((chloro(difluoro)methyl)sulfonyl)-N-(4-(4-((2-(4-chlorophenyl)-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)benzenesulfonamide,
    • N-(4-(4-((2-4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(isopropyl(methyl)amino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide,
    • N-(4-(4-((2-(4-chlorophenyl)-1-cyclohepten-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(isopropyl(methyl)amino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide,
    • 3-((chloro(difluoro)methyl)sulfonyl)-N-(4-(4-((2-(4-chlorophenyl)cyclohexen-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl)-1-((phenylsulfanyl)methyl)propyl)amino)benzenesulfonamide,
    • N-(4-(4-((2-(4-chlorophenyl)cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide,
    • 4-(((1R)-3-(7-azabicyclo[2.2.1]hept-7-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-((2-(4-chlorophenyl)cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide,
    • N-(4-(4-((2-(4-chlorophenyl)cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(2-oxa-5-azabicyclo[2.2.1]hept-5-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide,
    • N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(2-oxa-5-azabicyclo[2.2.1]hept-5-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide,
    • 3-((chloro(difluoro)methyl)sulfonyl)-N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(2-oxa-5-azabicyclo[2.2.1]hept-5-yl)-1-((phenylsulfanyl)methyl)propyl)amino)benzenesulfonamide,
    • N-(4-(4-((2-(4-chlorophenyl)cyclohept-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(2-oxa-5-azabicyclo[2.2.1]hept-5-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide,
    • 3-((chloro(difluoro)methyl)sulfonyl)-N-(4-(4-((2-(4-chlorophenyl)cyclohept-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(2-oxa-5-azabicyclo[2.2.1]hept-5-yl)-1-((phenylsulfanyl)methyl)propyl)amino)benzenesulfonamide,
    • N-(4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(isopropyl(methyl)amino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide,
    • N-(4-(4-((2-(4-chlorophenyl)cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(1,4-oxazepan-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide,
    • 4-(((1R)-3-(azepan-1-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-((2-(4-chlorophenyl)-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide,
    • N-4-(4-((2-(4-chlorophenyl)cyclohept-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide,
    • 3-((chloro(difluoro)methyl)sulfonyl)-N-(4-(4-((2-(4-chlorophenyl)cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)benzenesulfonamide,
    • 3-((chloro(difluoro)methyl)sulfonyl)-N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)benzenesulfonamide,
    • N-4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide,
    • N-(4-(4-((4-(4-chlorophenyl)-5,6-dihydro-2H-pyran-3-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide,
    • 3-((chloro(difluoro)methyl)sulfonyl)-N-(4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(isopropyl(methyl)amino)-1-((phenylsulfanyl)methyl)propyl)amino)benzenesulfonamide.
    • 3-((chloro(difluoro)methyl)sulfonyl)-N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(isopropyl(methyl)amino)-1-((phenylsulfanyl)methyl)propyl)amino)benzenesulfonamide,
    • N-(4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide,
    • 3-((chloro(difluoro)methyl)sulfonyl)-N-(4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl)-1-((phenylsulfanyl)methyl)propyl)amino)benzenesulfonamide,
    • N-(4-(4-((2-(4-chlorophenyl)cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide,
    • N-(4-(4-((2-(4-chlorophenyl)cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-1-((phenylsulfanyl)methyl)-3-(pyrrolidin-1-yl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide,
    • 3-((chloro(difluoro)methyl)sulfonyl)-N-(4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)benzenesulfonamide,
    • N-(4-(4-((2-(4-chlorophenyl)cyclohept-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-1-((phenylsulfanyl)methyl)-3-(pyrrolidin-1-yl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide,
    • 3-((chloro(difluoro)methyl)sulfonyl)-N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-1-((phenylsulfanyl)methyl)-3-(pyrrolidin-1-yl)propyl)amino)benzenesulfonamide,
    • 3-((chloro(difluoro)methyl)sulfonyl)-N-(4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-1-((phenylsulfanyl)methyl)-3-(pyrrolidin-1-yl)propyl)amino)benzenesulfonamide,
    • 3-((chloro(difluoro)methyl)sulfonyl)-N-(4-(4-((2-(4-chlorophenyl)cyclohept-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-1-((phenylsulfanyl)methyl)-3-(pyrrolidin-1-yl)propyl)amino)benzenesulfonamide,
    • N-(4-(4-((2-(4-chlorophenyl)cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(isopropyl(methyl)amino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide,
    • N-(4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-1-((phenylsulfanyl)methyl)-3-(pyrrolidin-1-yl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide,
    • 3-((chloro(difluoro)methyl)sulfonyl)-N-(4-(4-((2-(4-chlorophenyl)cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-1-((phenylsulfanyl)methyl)-3-(pyrrolidin-1-yl)propyl)amino)benzenesulfonamide,
    • N-(4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide,
    • N-(4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide
    • N-(4-(4-((4′-chloro(1,1′-biphenyl)-2-yl)methyl)-1-piperazinyl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide and
    • N-(4-(4-((4′-chloro(1,1′-biphenyl)-2-yl)methyl)-1-piperazinyl)benzoyl)-4-(((1R)-3-(4-morpholinyl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide.
      and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof.
  • Still another embodiment comprises compositions for treating diseases during which are expressed one or more than one of antiapoptotic BcI-XL protein, antiapoptotic Bcl-2 protein or antiapoptotic Bcl-w protein, said compositions comprising an excipient and a therapeutically effective amount of the compound having formula (II).
  • Still another embodiment comprises methods of treating diseases in a patient during which are expressed one or more than one of antiapoptotic Bcl-XL protein, antiapoptotic Bcl-2 protein or antiapoptotic Bcl-w protein, said methods comprising administering to the patient a therapeutically effective amount of a compound having formula (II).
  • Still another embodiment comprises compositions comprising an excipient and a therapeutically effective amount of the compound having formula (II) for treating diseases of abnormal cell growth and/or dysregulated apoptosis, such as cancer, mesothioloma, bladder cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, ovarian cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, bone cancer, ovarian cancer, cervical cancer, colon cancer, rectal cancer, cancer of the anal region, stomach cancer, gastrointestinal (gastric, colorectal, and duodenal), chronic lymphocytic leukemia, esophageal cancer, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, testicular cancer, hepatocellular cancer (hepatic and billiary duct), primary or secondary central nervous system tumor, primary or secondary brain tumor, Hodgkin's disease, chronic or acute leukemia, chronic myeloid leukemia, lymphocytic lymphomas, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, multiple myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer, cancer of the kidney and ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system, primary central nervous system lymphoma, non Hodgkin's lymphoma, spinal axis tumors, brains stem glioma, pituitary adenoma, adrenocortical cancer, gall bladder cancer, cancer of the spleen, cholangiocarcinoma, fibrosarcoma, neuroblastoma, retinoblasitoma, or a combination thereof.
  • Still another embodiment comprises methods of treating mesothioloma, bladder cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, ovarian cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, bone cancer, ovarian cancer, cervical cancer, colon cancer, rectal cancer, cancer of the anal region, stomach cancer, gastrointestinal (gastric, colorectal, and duodenal), chronic lymphocytic leukemia, esophageal cancer, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, testicular cancer, hepatocellular cancer (hepatic and billiary duct), primary or secondary central nervous system tumor, primary or secondary brain tumor, Hodgkin's disease, chronic or acute leukemia, chronic myeloid leukemia, lymphocytic lymphomas, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, multiple myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer, cancer of the kidney and ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system, primary central nervous system lymphoma, non Hodgkin's lymphoma, spinal axis tumors, brains-stem glioma, pituitary adenoma, adrenocortical cancer, gall bladder cancer, cancer of the spleen, cholangiocarcinoma, fibrosarcoma, neuroblastoma, retinoblasitoma, or a combination of one or more of the above cancers in a patient, said methods comprising administering thereto a therapeutically effective amount of a compound having formula (II).
  • Still another embodiment comprises compositions for treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer and spleen cancer, said compositions comprising an excipient and a therapeutically effective amount of the compound having formula (II).
  • Still another embodiment comprises methods of treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer and spleen cancer in a patient, said methods comprising administering to the patient a therapeutically effective amount of a compound having formula (II).
  • Still another embodiment comprises compositions for treating diseases in a patient during which are expressed one or more than one of antiapoptotic BCl-XL protein, antiapoptotic Bcl-2 protein or antiapoptotic Bcl-w protein, said compositions comprising an excipient and a therapeutically effective amount of the compound having formula (II) and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent.
  • Still another embodiment comprises methods of treating diseases in a patient during which is expressed one or more than one of antiapoptotic Bcl-XL protein, antiapoptotic Bcl-2 protein or antiapoptotic Bcl-w protein, said methods comprising administering to the patient a therapeutically effective amount of a compound having formula (II) and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent.
  • Still another embodiment comprises compositions for treating mesothioloma, to bladder cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, ovarian cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, bone cancer, ovarian cancer, cervical cancer, colon cancer, rectal cancer, cancer of the anal region, stomach cancer, gastrointestinal (gastric, colorectal, and duodenal), chronic lymphocytic leukemia, esophageal cancer, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, testicular cancer, hepatocellular cancer (hepatic and billiary duct), primary or secondary central nervous system tumor, primary or secondary brain tumor, Hodgkin's disease, chronic or acute leukemia, chronic myeloid leukemia, lymphocytic lymphomas, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, multiple myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer, cancer of the kidney and ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system, primary central nervous system lymphoma, non Hodgkin's lymphoma, spinal axis tumors, brains stem glioma, pituitary adenoma, adrenocortical cancer, gall bladder cancer, cancer of the spleen, cholangiocarcinoma, fibrosarcoma, neuroblastoma, retinoblasitoma, or a combination of one or more of the above cancers, said compositions comprising an excipient and therapeutically effective amount of a compound having formula (II) and one additional therapeutic agent or more than one additional therapeutic agent.
  • Still another embodiment comprises methods of treating mesothioloma, bladder cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, ovarian cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, bone cancer, ovarian cancer, cervical cancer, colon cancer, rectal cancer, cancer of the anal region, stomach cancer, gastrointestinal (gastric, colorectal, and duodenal), chronic lymphocytic leukemia, esophageal cancer, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, testicular cancer, hepatocellular cancer (hepatic and billiary duct), primary or secondary central nervous system tumor, primary or secondary brain tumor, Hodgkin's disease, chronic or acute leukemia, chronic myeloid leukemia, lymphocytic lymphomas, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, multiple myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer, cancer of the kidney and ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system, primary central nervous system lymphoma, non Hodgkin's lymphoma, spinal axis tumors, brains stem glioma, pituitary adenoma, adrenocortical cancer, gall bladder cancer, cancer of the spleen, cholangiocarcinoma, fibrosarcoma, neuroblastoma, retinoblasitoma, or a combination of one or more of the above cancers in a patient, said methods comprising administering thereto therapeutically effective amounts of a compound having formula (II) and one additional therapeutic agent or more than one additional therapeutic agent.
  • Still another embodiment comprises methods of treating mesothioloma, bladder cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, ovarian cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, bone cancer, ovarian cancer, cervical cancer, colon cancer, rectal cancer, cancer of the anal region, stomach cancer, gastrointestinal (gastric, colorectal and duodenal), chronic lymphocytic leukemia, esophageal cancer, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, testicular cancer, hepatocellular cancer (hepatic and billiary duct), primary or secondary central nervous system tumor, primary or secondary brain tumor, Hodgkin's disease, chronic or acute leukemia, chronic myeloid leukemia, lymphocytic lymphomas, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, multiple myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer, cancer of the kidney and ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system, primary central nervous system lymphoma, non Hodgkin's lymphoma, spinal axis tumors, brains stem glioma, pituitary adenoma, adrenocortical cancer, gall bladder cancer, cancer of the spleen, cholangiocarcinoma, fibrosarcoma, neuroblastoma, retinoblasitoma, or a combination of one or more of the above cancers in a patient, said methods comprising administering thereto therapeutically effective amounts of a compound having formula (II) and one or more than one of etoposide vincristine CHOP, rituximab, rapamycin, R—CHOP or bortezomib.
  • Still another embodiment comprises methods of treating B-cell lymphoma in a patient comprising administering thereto a therapeutically acceptable amounts of a compound having formula (II) and etoposide.
  • Still another embodiment comprises methods of treating B-cell lymphoma in a patient comprising administering thereto therapeutically acceptable amounts of a compound having formula (II) and vincristine.
  • Still another embodiment comprises methods of treating B-cell lymphoma in a patient comprising administering thereto therapeutically acceptable amounts of a compound having formula (II) and CHOP.
  • Still another embodiment comprises methods of treating B-cell lymphoma in a patient comprising administering thereto therapeutically acceptable amounts of a compound having formula (II) and rituximab.
  • Still another embodiment comprises methods of treating B-cell lymphoma in a patient comprising administering thereto therapeutically acceptable amounts of a compound having formula (II) and rapamycin.
  • Still another embodiment comprises methods of treating mantle cell lymphoma in a patient comprising administering thereto therapeutically acceptable amounts of a compound having formula (II) and R—CHOP.
  • Still another embodiment comprises methods of treating mantle cell lymphoma in a patient comprising administering thereto therapeutically acceptable amounts of a compound having formula (II) and bortezomib.
    • DETAILED DESCRIPTION OF THE INVENTION
  • Variable moieties of compounds herein are represented by identifiers (capital letters with numerical and/or alphabetical superscripts) and may be specifically embodied.
  • It is meant to be understood that proper valences are maintained for all moieties and combinations thereof and that monovalent moieties having more than one atom are attached through their left ends.
  • It is also meant to be understood that a specific embodiment of a variable moiety may be the same or different as another specific embodiment having the same identifier.
  • The term “antitumorigenesis,” as used herein, means reduction of tumor growth.
  • Compounds of this invention may contain asymmetrically substituted carbon atoms in the R or S configuration, wherein the terms “R” and “S” are as defined in Pure Appl. Chem. (1976) 45, 13-10. Compounds having asymmetrically substituted carbon atoms with equal amounts of R and S configurations are racemic at those atoms. Atoms having excess of one configuration over the other are assigned the configuration in excess, preferably an excess of about 85%-90%, more preferably an excess of about 95%-99%, and still more preferably an excess greater than about 99%. Accordingly, this invention is meant to embrace racemic mixtures and relative and absolute diastereoisomers of the compounds thereof.
  • Compounds of this invention may also contain carbon-carbon double bonds or carbon-nitrogen double bonds in the Z or E configuration, in which the term “Z” represents the larger two substituents on the same side of a carbon-carbon or carbon-nitrogen double bond and the term “E” represents the larger two substituents on opposite sides of a carbon-carbon or carbon-nitrogen double bond. The compounds of this invention may also exist as a mixture of “Z” and “E” isomers.
  • Compounds of this invention may also exist as tautomers or equilibrium mixtures thereof wherein a proton of a compound shifts from one atom to another. Examples of tautomers include, but are not limited to, keto-enol, phenol-keto, oxime-nitroso, nitro-aci, imine-enamine and the like.
  • Compounds having formula (II) having NH, C(O)OH, OH or SH moieties may have attached thereto prodrug-forming moieties. The prodrug-forming moieties are removed by metabolic processes and release the compounds having the freed NH, C(O)OH, OH or SH in vivo. Prodrugs are useful for adjusting such pharmacokinetic properties of the compounds as solubility and/or hydrophobicity, absorption in the gastrointestinal tract, bioavailability, tissue penetration, and rate of clearance.
  • Metabolites of compounds having formula (II), produced by in vitro or in vivo metabolic processes, may also have utility for treating diseases associated with expression of an anti-apoptotic family protein member such as of BCl-XL, protein, Bcl-2 protein or Bcl-w protein.
  • Compounds having formula (II) may also be radiolabeled with a radioactive isotope such as a radioactive isotope of carbon (i.e. 13C), hydrogen (i.e. 3H), nitrogen (i.e. 15N), phosphorus (i.e. P), sulfur (i.e. 35S) or iodide (i.e. 125I). Radioactive isotopes may be incorporated into the compounds having formula (II) by reacting the same and a radioactive derivitizing agent or by incorporating a radiolabeled intermediate into their syntheses. The radiolabeled compounds of formula (II) are useful for both prognostic and diagnostic applications as well as for in vivo and in vitro imaging.
  • Certain precursor compounds which may be metabolized in vitro or in vivo to form compounds having formula (II) may also have utility for treating diseases associated with expression of an anti-apoptotic family protein member such as of BCl-XL protein, Bcl-2 protein or Bcl-w protein.
  • Compounds having formula (II) may exist as acid addition salts, basic addition salts or zwitterions. Salts of compounds having formula (II) are prepared during their isolation or following their purification. Acid addition salts are those derived from the reaction of a compound having formula (II) with acid. Accordingly, salts including the acetate, adipate, alginate, bicarbonate, citrate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, formate, fumarate, glycerophosphate, glutamate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, lactobionate, lactate, maleate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, phosphate, picrate, propionate, succinate, tartrate, thiocyanate, trichloroacetic, trifluoroacetic, para-toluenesulfonate and undecanoate salts of the compounds having formula (II) are meant to be embraced by this invention. Basic addition salts of compounds are those derived from the reaction of the compounds having formula (II) with the bicarbonate, carbonate, hydroxide or phosphate of cations such as lithium, sodium, potassium, calcium and magnesium.
  • Compounds having formula (II) may be administered, for example, bucally, ophthalmically, orally, osmotically, parenterally (intramuscularly, intraperitoneally intrasternally, intravenously, subcutaneously), rectally, topically, transdermally, vaginally and intraarterially as well as by intraarticular injection, infusion, and placement in the body, such as, for example, the vasculature by means of, for example, a stent.
  • Therapeutically effective amounts of a compound having formula (II) depend on recipient of treatment, disease treated and severity thereof, composition comprising it, time of administration, route of administration, duration of treatment, potency, rate of clearance and whether or not another drug is co-administered. The amount of a compound having formula (II) used to make a composition to be administered daily to a patient in a single dose or in divided doses is from about 0.03 to about 200 mg/kg body weight. Single dose compositions contain these amounts or a combination of submultiples thereof.
  • Compounds having formula (II) may be administered with or without an excipient. Excipients include, but are not limited to, encapsulators and additives such as absorption accelerators, antioxidants, binders, buffers, coating agents, coloring agents, diluents, disintegrating agents, emulsifiers, extenders, fillers, flavoring agents, humectants, lubricants, perfumes, preservatives, propellants, releasing agents, sterilizing agents, sweeteners, solubilizers, wetting agents, mixtures thereof and the like.
  • Excipients for preparation of compositions comprising a compound having formula (II) to be administered orally include, but are not limited to, agar, alginic acid, aluminum hydroxide, benzyl alcohol, benzyl benzoate, 1,3-butylene glycol, carbomers, castor oil, celluloses cellulose acetate, cocoa butter, corn starch, corn oil, cottonseed oil, cross-povidone, diglycerides, ethanol, ethyl cellulose, ethyl laureate, ethyl oleate, fatty acid esters, gelatin, germ oil, glucose, glycerol, groundnut oil, hydroxypropylmethyl celluose, isopropanol, isotonic saline, lactose, magnesium hydroxide, magnesium stearate, malt, mannitol, monoglycerides, olive oil, peanut oil, potassium phosphate salts, potato starch, povidone, propylene glycol, Ringer's solution, safflower oil, sesame oil, sodium carboxymethyl cellulose, sodium phosphate salts, sodium lauryl sulfate, sodium sorbitol, soybean oil, stearic acids, stearyl fumarate, sucrose, surfactants, talc, tragacanth, tetrahydrofurfuryl alcohol, triglycerides, water, mixtures thereof and the like. Excipients for preparation of compositions comprising a compound having formula (II) to be administered ophthalmically or orally include, but are not limited to, 1,3-butylene glycol, castor oil, corn oil, cottonseed oil, ethanol, fatty acid esters of sorbitan, germ oil, groundnut oil, glycerol, isopropanol, olive oil, polyethylene glycols, propylene glycol, sesame oil, water, mixtures thereof and the like. Excipients for preparation of compositions comprising a compound having formula (II) to be administered osmotically include, but are not limited to, chlorofluorohydrocarbons, ethanol, water, mixtures thereof and the like. Excipients for preparation of compositions comprising a compound having formula (II) to be administered parenterally include, but are not limited to, 1,3-butanediol, castor oil, corn oil, cottonseed oil, dextrose, germ oil, groundnut oil, liposomes, oleic acid, olive oil, peanut oil, Ringer's solution, safflower oil, sesame oil, soybean oil, U.S.P. or isotonic sodium chloride solution, water, mixtures thereof and the like. Excipients for preparation of compositions comprising a compound having formula (II) to be administered rectally or vaginally include, but are not limited to, cocoa butter, polyethylene glycol, wax, mixtures thereof and the like.
  • This invention also comprises combination therapeutic methods of treating disease conditions involving abnormal cell growth and/or dysregulated apoptosis, such as cancer, in a patient comprising administering thereto a therapeutically effective amount of a pharmaceutical composition comprising a compound having formula (II) and a therapeutically effective amount of one or more than one additional therapeutic agents and/or ionizing radiation.
  • The combination therapeutic methods include administering compositions of a compound having formula (II) and one or more than one additional therapeutic agents or ionizing radiation to a patient using any desired dosing and/or scheduling regimen.
  • Compounds having formula (II) may be administered with one or more than one additional therapeutic agents, wherein the additional therapeutic agents include ionizing radiation or chemotherapeutic agents, wherein chemotherapeutic agents include, but are not limited to, carboplatin, cisplatin, cyclophosphamide, dacarbazine, dexamethasone, docetaxel, doxorubicin, etoposide, fludarabine, irinotecan, CHOP (C: Cytoxan® (cyclophosphamide); H: Adriamycin® (hydroxydoxorubicin); O: Vincristine (Oncovin®); P: prednisone), paclitaxel, rapamycin, Rituxin® (rituximab), vincristine and the like.
  • Compounds having formula (II) are also expected to be useful as chemotherapeutic agents in combination with therapeutic agents that include, but are not limited to, angiogenesis inhibitors, antiproliferative agents, kinase inhibitors, receptor tyrosine kinase inhibitors, aurora kinase inhibitors, polo-like kinase inhibitors, bcr-abl kinase inhibitors, growth factor inhibitors, COX-2 inhibitors, non-steroidal anti-inflammatory drugs (NSAIDS), antimitotic agents, alkylating agents, antimetabolites, intercalating antibiotics, platinum containing agents, growth factor inhibitors, ionizing radiation, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biologic response modifiers, immunologicals, antibodies, hormonal therapies, retinoids/deltoids plant alkaloids, proteasome inhibitors, HSP-90 inhibitors, histone deacetylase inhibitors (HDAC) inhibitors, purine analogs, pyrimidine analogs, MEK inhibitors, CDK inhibitors, ErbB2 receptor inhibitors, mTOR inhibitors as well as other antitumor agents.
  • Angiogenesis inhibitors include, but are not limited to, EGFR inhibitors. PDGFR inhibitors, VEGFR inhibitors, TIE2 inhibitors, IGF1R inhibitors, matrix metalloproteinase 2 (MMP-2) inhibitors, matrix metalloproteinase 9 (MMP-9) inhibitors and thrombospondin analogs.
  • Examples of EGFR inhibitors include, but are not limited to, Iressa (gefitinib), Tarceva (erlotirnib or OSI-774), Erbitux (cetuximab), EMD-7200, ABX-EGF, HR3, IgA antibodies, TP-38 (IVAX), EGFR fusion protein, EGF-vaccine, anti-EGFr immunoliposomes and Tykerb (lapatinib).
  • Examples of PDGFR inhibitors include, but are not limited to, CP-673,451 and CP-868596.
  • Examples of VEGFR inhibitors include, but are not limited to, Avastin (bevacizumab), Sutent (sunitinib, SU 11248), Nexavar (sorafenib, BAY43-9006), CP-547,632, axitinib (AG13736), Zactima (vandetanib, ZD-6474), AEE788, AZD-2171, VEGF trap, Vatalanib (PTK-787, ZK-222584), Macugen, IM862, Pazopanib (GW786034), ABT-869 and angiozyme.
  • Examples of thrombospondin analogs include, but are not limited to, TSP-1, ABT-510, ABT-567 and ABT-898.
  • Examples of aurora kinase inhibitors include, but are not limited to, VX-680. AZD-1152 and MLN-8054.
  • An example of a polo-like kinase inhibitor includes, but is not limited to BI-2536.
  • Examples of bcr-abl kinase inhibitors include, but are not limited to, Gleevec (imatinib) and Dasatinib (BMS354825).
  • Examples of platinum containing agents includes, but are not limited to, cisplatin, Paraplatin (carboplatin), eptaplatin, lobaplatin, nedaplatin, Eloxatin (oxaliplatin) and satraplatin.
  • Examples of mTOR inhibitors includes, but are not limited to, CCI-779, rapamycin, temsirolimus, everolimus, RAD001, and AP-23573.
  • Examples of HSP-90 inhibitors includes, but are not limited to, geldanamycin, radicicol, 17-AAG, KOS-953, 17-DMAG, CNF-101, CNF-1010, 17-AAG-nab, NCS-683664, Mycograb, CNF-2024, PU3, PU24FC1, VER49009, IPI-504, SNX-2112 and STA-9090.
  • Examples of histone deacetylase inhibitors (HDAC) includes, but are not limited to, Suberoylanilide hydroxamic acid (SAHA), MS-275. Valproic acid, TSA, LAQ-824, Trapoxin, and Depsipeptide.
  • Examples of MEK inhibitors include, but are not limited to, PD325901, ARRY-142886, ARRY-438162 and PD98059.
  • Examples of CDK inhibitors include, but are not limited to, flavopyridol, MCS-5A, CVT-2584, seliciclib (CYC-202, R-roscovitine), ZK-304709, PHA-690509, BMI-1040, GPC-286199, BMS-387,032, PD0332991 and AZD-5438.
  • Examples of useful COX-2 inhibitors include, but are not limited to, CELEBREX™ (celecoxib), parecoxib, deracoxib, ABT-963, MK-663 (etoricoxib), COX-189 Lumiracoxib), BMS347070, RS 57067, NS-398, Bextra (valdecoxib), paracoxib, Vioxx (rofecoxib), SD-8381, 4-Methyl-2-(3,4-dimethylphenyl)-1-(4-sulfamoyl-phenyl-1H-pyrrole, T-614, JTE-522, S-2474, SVT-2016, CT-3, SC-58125 and Arcoxia (etoricoxib).
  • Examples of non-steroidal anti-inflammatory drugs (NSAIDs) include, but are not limited to, Salsalate (Amigesic), Diflunisal (Dolobid), Ibuprofen (Motrin), Ketoprofen (Orudis), Nabumetone (Relafen), Piroxicam (Feldene), Naproxen (Aleve, Naprosyn), Diclofenac (Voltaren), Indomethacin (Indocin), Sulindac (Clinoril), Tolmetin (Tolectin), Etodolac (Lodine), Ketorolac (Toradol) and Oxaprozin (Daypro).
  • Examples of ErbB2 receptor inhibitors include, but are not limited to, CP-724-714, CI-1033 (canertinibj, Herceptin (trastuzumab), Omitarg (2C4, petuzumab), TAK-165, GW-572016 (Ionafarnib), GW-282974, EKB-569, PI-166, dHER2 (HER2 Vaccine), APC8024 (HER2 Vaccine), anti-HER/2neu bispecific antibody, B7.her2IgG3, AS HER2 trifunctional bispecific antibodies, mAB AR-209 and mAB 2B-1.
  • Examples of alkylating agents include, but are not limited to, nitrogen mustard N-oxide, cyclophosphamide, ifosfamide, trofosfamide, chlorambucil, melphalan, busulfan, mitobronitol, carboquone, thiotepa, ranimustine, nimustine. Cloretazine (VNP 40101M), temozolomide, AMD-473, altretamine, AP-5280, apaziquone, brostallicin, bendamustine, carmustine, estramustine, fotemustine, glufosfamide, KW-2170, mafosfamide, and mitolactol, carmustine (BCNU), lomustine (CCNU), Busulfan, Treosulfan, Decarbazine and Temozolomide.
  • Examples of antimetabolites include but are not limited to, methotrexate, 6-mercaptopurine riboside, mercaptopurine, 5-fluorouracil (5-FU) alone or in combination with leucovorin, tegafur, UFT, doxifluridine, carmofur, cytarabine, cytarabine ocfosfate, enocitabine, S-1, Alimta (premetrexed disodium, LY231514, MTA), Gemzar (gemcitabine, Eli Lilly), fludarabine, 5-azacitidine, capecitabine, cladribine, clofarabine, decitabine, eflomithine, ethnylcytidine, cytosine arabinoside, hydroxyurea, TS-1, melphalan, nelarabine, nolatrexed, ocfosate, disodium premetrexed, pentostatin, pelitrexol, raltitrexed, triapine, trimetrexate, vidarabine, mycophenolic acid, tiazofurin, Ribavirin, EICAR, hydroxyurea and deferoxamine.
  • Examples of antibiotics include intercalating antibiotics but are not limited to, aclarubicin, actinomycin D, amrubicin, annamycin, adriamycin, bleomycin, daunorubicin, doxorubicin, elsamitrucin, epirbucin, glarbuicin, idarubicin, mitomycin C, nemorubicin, neocarzinostatin, peplomycin, pirarubicin, rebeccamycin, stimalamer, streptozocih, vairubicin, zinostatin and combinations thereof.
  • Examples of topoisomerase inhibiting agents include, but are not limited to, one or more agents selected from the group consisting of aclarubicin, amonafide, belotecan, camptothecin, 10-hydroxycamptothecin, 9-aminocamptothecin, Amsacrine, Cardioxane (Dexrazoxine), diflomotecan, irinotecan HCL (Camptosar), edotecarin, epirubicin (Ellence), etoposide, exatecan, Becatecarin, gimatecan, lurtotecan, orathecin (Supergen), BN-80915, mitoxantrone, pirarbucin, pixantrone, rubitecan, sobuzoxane, SN-38, tafluposide and topotecan.
  • Examples of antibodies include, but are not limited to, Rittiximab. Cetuximab, Bevacizumab, Trastuzimab, specific CD40 antibodies and specific IGF1R antibodies, chTNT-1/B, Denosumab, Panorex (Edrecolomab), Rencarex (WX G250), Zanolimumab, Lintuzumab, Ticilimumab.
  • Examples of hormonal therapies include, but are not limited to, exemestane (Aromasin), leuprolide acetate, Buserelin, Cetrorelix, Deslorelin, Vantas, anastrozole (Arimidex), fosrelin (Zoladex), goserelin, Degarelix, doxercalciferol, fadrozole, formestane, tamoxifen citrate (tamoxifen), Arzoxifene. Casodex. Abarelix, Trelstar, finasteride, fulvestrant, toretnifene, raloxifene, Trilostane (Modrastane, Desopan), lasofoxifene, letrozole, flutamide, bicalutamide, megesterol, mifepristone, nilutamide, dexamethasone, predisone and other glucocorticoids.
  • Examples of retinoids/deltoids include, but are not limited to, seocalcitol (EB 1089, CB 1093), lexacalcitrol (KH 1060), fenretinide, Panretin (aliretinoin), Atragen, Bexarotene and LGD-1550.
  • Examples of plant alkaloids include, but are not limited to, vincristine, vinblastine, vindesine and vinorelbine.
  • Examples of proteasome inhibitors include, but are not limited to bortezomib (Velcade), MG132, NPI-0052 and PR-171.
  • Examples of immunologicals include, but are not limited to, interferons and numerous other immune enhancing agents. Interferons include interferon alpha, interferon alpha-2a, interferon alpha-2b, interferon beta, interferon gamma-1a, interferon gamma-1b (Actimmune), or interferon gamma-n1 and combinations thereof. Other agents include Alfaferone (Leukocyte alpha interferon, Cliferon), filgrastim, lentinan, sizofilan, TheraCys, ubenimex, WF-10, aldesleukin, alemtuzumab, BAM-002, decarbazine, daclizumab, denileukin, gemtuzumab ozogamicin, ibritumomab, imiquimod, lenograstim, lentinan, melanoma vaccine (Corixa), molgramostim, OncoVAC-CL, sargaramostim, tasonermin, tecleukin, thymalasin, tositumomab, Virulizin, Z-100, epratuzumab, mitumomab, oregovomab, pemtumomab (Y-muHMFG1), Provenge (Dendreon), CTLA4 (cytotoxic lymphocyte antigen 4) antibodies and agents capable of blocking CTLA4 such as MDX-010.
  • Examples of biological response modifiers are agents that modify defense mechanisms of living organisms or biological responses, such as survival, growth, or differentiation of tissue cells to direct them to have anti-tumor activity. Such agents include Icrestin, lentinan, sizofuran, picibanil PF-3512676 (CpG-8954) and ubenimex.
  • Examples of pyrimidine analogs include, but are not limited to, 5-Fluorouracil, Floxuridine, Doxifluridine, Ratitrexed, cytarabine (ara C), Cytosine arabinoside, Fludarabine, triacetyluridine Troxacitabine (Troxatyl) and Gemcitabine.
  • Examples of purine analogs include but are not limited to, Mercaptopurine and thioguanine.
  • Examples of antimitotic agents include, but are not limited to, N-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide, paclitaxel, docetaxel, epothilone D (KOS-862), PNU100940 (109881), Batabulin, Ixabepilone (BMS 247550), Patupilone, XRP-9881, Vinflunine and ZK-EPO.
  • Compounds of the present invention are also intended to be used as a radiosensitizer that enhances the efficacy of radiotherapy. Examples of radiotherapy include but are not limited to, external beam radiotherapy (XBRT), or teletherapy, brachtherapy or sealed source radiotherapy, unsealed source radiotherapy.
  • Additionally, compounds having formula (II) may be combined with other antitumor agents selected from the following agents, Genasense, Panitumumab, Zevalin, Bexxar (Corixa), Arglabin, Abarelix, Alimta, EP0906, discodermolide, Neovastat, enzastaurin, Combrestatin A4P; ZD-6126, AVE-8062, DMXAA, Thymitaq, Temodar, Revlimid, Cypat, Histerelin, Plenaizis, Atrasentan, Celeuk (celmoleukin), Satraplatin, thalomide (Thalidomide), theratope, Temilifene, ABI-007, Evista, Atamestane, Xyotax, Targretin, Triazone, Aposyn, Nevastat, Ceplene, Lanreotide, Aredia (pamidronic acid), Orathecin, Virulizin, Gastrimmune, DX-8951f, Mepact (Liposome muramyl tripeptide phophatidylethanolamine, Junovan), Dimericine (Liposome T4 endonuclase V), Onconase, BEC2, Xcytrin, CeaVac, NewTrexin, OvaRex, Osidem, Advexin, RSR13 (efaproxiral, Cotara, NBI-3001 (IL-4), Canvaxin, GMK vaccine, PEG Interferon A, Taxoprexin, gene therapy agents such as TNFerade (GeneVac) or GVAX, Interferon-alpha, Interferon-gamma, Gardasil, Eniluracil (GW 776C85), Lonafarnib, ABT-100, Tumor necrosis factor, Lovastatin, staurosporine, dactinomycin, zorubicin, Bosentan, OncbVAX, Cervarix, Cintredekin besudotox (IL-13-PE38, IL-13-PE38QQR, Interleukin 13-pseudomonas exotoxin), Oncophage (HSPPC 96), Phenoxodiol (NV 06), IGN 101, PANVAC (CEA, MUC-1 vaccinia), ampligen, ibandronic acid, miltefosine, L-asparaginase, procarbazine, Trabectedin (ET-743, Ecteinascidin 743, Yondelis), 5,10-methylenetetrahydrofolate, hydroxycarbamide, pegaspargase, pentostatin, tazarotne, TransMID 107R (KSB 311), Trisenox, Telcyta, tretinoin, acitretin, Zometa (zolendronic acid), Pandimex (Aglycon protopanaxadiol, PBD-2131), Talabostat (PT100), Tesmilifene, Tetrandrine, halofuginone, rebimastat, removab, squalamine, ukrain, paditaxel, Zinecard and Vitaxin.
  • BAX and BAD peptides are reported in Zhang, H. C., Nimmer, P., Rosenberg, S. H., Ng, S.C., and Joseph, M. (2002). Development of a High-Throughput Fluorescence Polarization Assay for Bcl-x(L). Analytical Biochemistry 307, 70-75.
  • Binding affinity of compounds having formula (II) to Bcl-X1 protein is indicia of their inhibition of the activity of this protein. To determine the binding affinity of compounds having formula (II) to Bcl-XL protein, representative examples were diluted in DMSO to concentrations between 100 μM and 1 pM and added to each well of a 96-well microtiter plate. A mixture comprising 125 μL per well of assay buffer (20 mM phosphate buffer (pH 7.4), 1 mM EDTA, 50 mM NaCl, 0.05% PF-68), 6 nM of Bcl-XL protein (prepared as described in Science 1997, 275, 983-986), 1 nM fluorescein-labeled BAD peptide (prepared in-house) and the DMSO solution of the compound was shaken for 2 minutes and placed in a LJL Analyst (LJL Bio Systems, CA). A negative control (DMSO, 15 nM BAD peptide, assay buffer) and a positive control (DMSO, 1 nM BAD peptide, 6 nM Bcl-XL, assay buffer) were used to determine the range of the assay. Polarization was measured at room temperature using a continuous Fluorescein lamp (excitation 485 nm, emission 530 nm). Percentage of inhibition was determined by (1-((mP value of well-negative control)/range))×100%. The results are shown in TABLE 1.
  • Binding affinity of compounds having formula (II) to Bcl-2 protein is indicia of their inhibition of the activity of this protein. To determine the binding affinity of compounds having formula (II) to Bcl-2, representative examples were diluted in DMSO to concentrations between 10 μM and 10 μM and added to each well of a 96-well microtiter plate. A mixture comprising 125 L per well of assay buffer (20 mM phosphate buffer (pH 7.4), 1 mM EDTA, 50 mM NaCl, 0.05% PF-68), 10 nM of Bcl-2 protein (prepared according to the procedure described in PNAS 2001, 98, 3012-3017), 1 nM fluorescein-labeled BAX peptide (prepared in-house) and the DMSO solution of the representative EXAMPLE was shaken for 2 minutes and placed in a LJL Analyst (LJL Bio Systems, CA. Polarization was measured at room temperature using a continuous Fluorescein lamp (excitation 485 nm, emission 530 nm). The results are also shown in TABLE 1.
  • These data demonstrate the utility of compounds having formula (II) as binders to and inhibitors of anti-apopotic BCl-XL protein and anti-apopotic Bcl-2.
  • It is expected that, because compounds having formula (II) bind to and inhibit the activity of BCl-XL and Bcl-2, they would also have utility as inhibitors of anti-apopotic family protein members having close structural homology to BCl-XL and Bcl-2 such as, for example, anti-apopotic Bcl-w protein.
  • Accordingly, compounds having formula (II) are expected to have utility in treatment of diseases during which anti-apopotic Bcl-XL protein, anti-apopotic Bcl-2 protein, anti-apopotic Bcl-w protein or a combination thereof, are expressed. Determination of Cellular Efficacy in Human Tumor Cell Line
  • NCl-H146 (ATCC, Manassas, Va.) human small cell lung carcinoma cells were plated 50.000 cells per well in 96-well tissue culture plates in a total volume of 100 μL tissue culture medium supplemented with 10% human serum (Invitrogen, Carlsbad, Calif.) instead of fetal bovine serum and treated with a 2-fold serial dilution of the compounds of interest from 10 μM to 0.020 μM. Each concentration was tested in duplicate at least 3 separate times. The number of viable cells following 48 hours of compound treatment was determined using the CellTiter 96® AQueous non-radioactive cell proliferation MTS assay according to manufacturer's recommendations (Promega Corp., Madison, Wis.). The results are also shown in TABLE 1.
    • Pharmacokinetic Evaluation of Selected Compounds in Rat
  • The pharmacokinetic behavior of compounds of this invention was determined following a single 2 mg/kg intravenous or 5 mg/kg oral dose in male Sprague-Dawley derived rats (n=3 per group). The compounds were prepared as 2 mg/mL solution in a 10% DMSO in PEG-400 formulation for both oral and intravenous administration. The 1 mL/kg intravenous dose was administered as a slow bolus (about 1-2 minutes) in the jugular vein of a rat under light ether anesthetic. The oral dose was administered by gavage. Serial blood samples were obtained from a tail vein of each rat prior 0.1 (IV only), 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 24 hours after dosing. The heparinized samples were thoroughly mixed and placed in an ice bath. Plasma was separated by centrifugation and stored frozen prior to analysis. The results are also shown in TABLE 1.
  • The compounds of interest were separated from the plasma using protein precipitation with acetonitrile. A plasma (100-200 μL, sample or spiked standard) aliquot was combined with 50 μL of internal standard (structurally related analog prepared in acetonitrile) and 1 ml acetonitrile in a 96-well polypropylene deep well plate. The plates were vortexed for 30 seconds followed by centrifugation (3500 rpm×15 minutes, 4° C.). In an automated manner, the supernatant was transferred to a clean 96-well plate. The samples were evaporated to near dryness on a Micro-Vap™ under a stream of dry nitrogen over low heat (−37° C.). The samples were reconstituted vortexing with 0.2 mL 5% DMSO in acetonitrile. A 0.1-0.2 ml aliquot of acetonitrile: 0.1% trifluoroacetic acid (20:80, by volume) was added to each well, followed by an additional 30 second vortexing. The plates were centrifuged (3500 rpm×15 minutes, 4° C.) prior to HPLC-MS/MS analysis. Samples were analyzed simultaneously with spiked plasma standards. All samples from each study were analyzed as a single batch on the LC-MS/MS.
  • The compounds of interest and the internal standard were separated from each other and co-extracted contaminants on a 50×3 mm Keystone Betasil CN 5 μm column with an acetonitrile: 0.1% trifluoroacetic acid mobile phase (50:50, by volume) at a flow rate of 0.7 ml/min. Analysis was performed on a Sciex API 300 Biomolecular Mass Analyzer using a heated nebulizer interface. Peak areas of the title compounds and internal standards were determined using the Sciex MacQuan™ software. Calibration curves were derived from peak area ratio (parent drug/internal standard) of the spiked rat plasma standards using least squares linear regression of the ratio versus the theoretical concentration. The methods were generally linear over the range of the standard curve (correlation coefficients >0.99) with an estimated quantitation limit of 0.01 μg/mL. The plasma concentration data for each animal were submitted to multi-exponential curve fitting using WinNonlin. The area under the plasma concentration-time curve from 0 to t hours (time of the last measurable plasma concentration) after dosing (AUC0.4) was calculated using the linear trapezoidal rule for the plasma concentration-time profiles. The residual area extrapolated to infinity, determined as the final measured plasma concentration (Ci) divided by the terminal elimination rate constant (β), was added to AUC0-t to produce the total area under the curve. The results are also shown in TABLE 1.
  • TABLE 1
    Ex. Ki (Bcl-2) Ki (Bcl-XL) EC50 AUC0-∞ AUC/EC50
    1 ≦0.001 μM ≦0.001 μM 0.0891 μM 5.01 μM 56
    2 ≦0.001 μM ≦0.001 μM 0.0291 μM 7.01 μM 241
    3 ≦0.001 μM ≦0.001 μM 0.0288 μM 4.13 μM 144
    4 ≦0.001 μM ≦0.001 μM 0.0587 μM 6.34 μM 108
    5 ≦0.001 μM ≦0.001 μM 0.0388 μM 2.22 μM 57
    6 ≦0.001 μM ≦0.001 μM 0.0010 μM 0.91 μM 91
    7 ≦0.001 μM ≦0.001 μM 0.0589 μM 3.87 μM 66
    8 ≦0.001 μM ≦0.001 μM 0.0212 μM 1.10 μM 52
    9 ≦0.001 μM ≦0.001 μM 0.0137 μM 1.88 μM 137
    10 ≦0.001 μM ≦0.001 μM 0.0342 μM 2.48 μM 73
    11 ≦0.002 μM ≦0.003 μM 0.0206 μM 2.40 μM 117
    12 ≦0.001 μM ≦0.001 μM 0.0271 μM 2.07 μM 76
    13 ≦0.001 μM ≦0.001 μM 0.0190 μM 2.06 μM 108
    14 ≦0.001 μM ≦0.001 μM 0.0309 μM 3.42 μM 111
    15 ≦0.001 μM ≦0.001 μM 0.0099 μM 1.25 μM 126
    16 ≦0.002 μM ≦0.002 μM 0.0374 μM 2.37 μM 63
    17 ≦0.001 μM ≦0.001 μM 0.0287 μM 0.88 μM 31
    18 ≦0.001 μM ≦0.001 μM 0.0154 μM 0.61 μM 40
    19 ≦0.001 μM ≦0.001 μM 0.0158 μM 7.12 μM 451
    20 ≦0.001 μM ≦0.001 μM 0.0277 μM 3.11 μM 112
    21 ≦0.001 μM ≦0.001 μM 0.0643 μM 1.81 μM 28
    22 ≦0.001 μM ≦0.001 μM 0.0388 μM 4.08 μM 105
    23 ≦0.001 μM ≦0.001 μM 0.0528 μM 3.54 μM 67
    24 ≦0.001 μM ≦0.001 μM 0.0443 μM 8.04 μM 181
    25 ≦0.001 μM ≦0.001 μM 0.0164 μM 1.67 μM 102
    26 ≦0.001 μM ≦0.001 μM 0.0243 μM 0.80 μM 33
    27 ≦0.001 μM ≦0.001 μM 0.0185 μM 2.08 μM 112
    28 ≦0.001 μM ≦0.001 μM 0.0242 μM 6.30 μM 260
    29 ≦0.001 μM ≦0.001 μM 0.0298 μM 1.74 μM 58
    30 ≦0.001 μM ≦0.001 μM 0.0317 μM 3.39 μM 107
    31 ≦0.001 μM ≦0.001 μM 0.0130 μM 5.10 μM 392
    32 ≦0.001 μM ≦0.001 μM 0.0187 μM 1.38 μM 73.9
    33 ≦0.001 μM ≦0.001 μM 0.0378 μM 3.01 μM 79.8
    34 ≦0.001 μM ≦0.001 μM 0.0200 μM 11.0 μM 554
    35 ≦0.001 μM ≦0.001 μM 0.0076 μM 1.26 μM 166
    36 ≦0.001 μM ≦0.001 μM 0.0242 μM 4.22 μM 174
    37 ≦0.001 μM ≦0.001 μM 0.0175 μM 7.30 μM 417
    38 ≦0.001 μM ≦0.001 μM 0.0394 μM 0.67 μM 17
    39 ≦0.001 μM ≦0.001 μM 0.0827 μM 1.66 μM 20
  • The compounds of the present invention were also tested against compounds disclosed in WO 2005/049594, identified herein as EXAMPLES A-L, by determining the ratio of systemic exposure to cellular efficacy. This measure, sometimes reported as AUC/EC50, is well known to those skilled in the art of pharmaceutical drug discovery and drug development as a useful pharmacodynamic predictor of oral efficacy.
  • The examples of the present invention and compounds disclosed in WO 2005/049594 were both tested H146 cellular assay and evaluated for oral pharmacokinetic properties in rat, both as previously described herein. The results are shown in TABLES 2 and 3. As can be seen with reference to the data, the compounds of the present invention have a more preferred pharmacodynamic profile as compared to the compounds known in the art. From these results a number of observations can be drawn. It can be observed that the compounds having a NO2 moiety at position W tend to have good to excellent cellular potency. However when the pharmacokinetic properties of these same compounds are determined, it can be seen that the systemic exposure after oral administration is poor, resulting in AUC/EC50 ratios of from 0.5 to 19.7. On the other hand, when compounds having a CF3 or CN moiety at position WI are tested in the cellular assay, the results demonstrate that these derivatives have relatively poor cellular efficacy while at the same time having suitable systemic exposure after oral administration. Again, this combination provides overall AUC/EC50 ratios from about 2.8 to about <7.4. Surprisingly, compounds of the present invention demonstrate cellular efficacy on par with compounds having an NO2 moiety while maintaining suitable systemic exposure after oral administration. The resulting AUC/EC50 ratios for the compounds of the invention are from about 20 to about 554.
  • TABLE 2
    Figure US20080287419A1-20081120-C00012
    H146, Cmax, AUC,
    EXAMPLE W1 W2 W3 EC50, (μM) (μM) (μM) AUC/EC50
    38 SO2CF3 N(CH3)2 H 0.039 0.072 0.665 16.9
    A CF3 N(CH3)2 H 1.599 0.371 4.412 2.8
    B NO2 N(CH3)2 H 0.063 0.039 0.283 4.5
    C CN N(CH3)2 H 1.807 0.315 1.917 1.1
    D CF3 N(CH3)2 F 7.329 0.386 3.827 0.5
    39 SO2CF3
    Figure US20080287419A1-20081120-C00013
         		H 0.083 0.290 1.657 20.0
    E NO2
    Figure US20080287419A1-20081120-C00014
         		H 0.974 0.195 1.157 1.2
    F CF3
    Figure US20080287419A1-20081120-C00015
         		H >1.00 0.592 7.365 <7.4
  • TABLE 3
    Figure US20080287419A1-20081120-C00016
    H146
    EX- EC50, Cmax, AUC, AUC/
    AMPLE W1 W2 (μM) (μM) (μM) EC50
    18 SO2CF2Cl N(CH3)2 0.015 0.059 0.609 39.5
    26 SO2CF3 N(CH3)2 0.024 0.097 0.803 33.0
    G NO2 N(CH3)2 0.026 0.057 0.507 19.7
    H CF3 N(CH3)2 0.410 0.215 1.973 4.8
     3 SO2CF2Cl
    Figure US20080287419A1-20081120-C00017
         		0.029 0.385 4.131 143.6
     7 SO2CF3
    Figure US20080287419A1-20081120-C00018
         		0.059 0.518 3.867 65.6
    I NO2
    Figure US20080287419A1-20081120-C00019
         		0.094 0.267 1.977 21.0
     6 SO2CF2Cl
    Figure US20080287419A1-20081120-C00020
         		0.010 0.113 0.913 91.6
     9 SO2CF3
    Figure US20080287419A1-20081120-C00021
         		0.014 0.156 1.878 137.5
    J NO2
    Figure US20080287419A1-20081120-C00022
         		0.028 0.047 0.402 14.3
     8 SO2CF3
    Figure US20080287419A1-20081120-C00023
         		0.021 0.071 1.098 51.7
    K NO2
    Figure US20080287419A1-20081120-C00024
         		0.049 0.077 0.368 7.5
    33 SO2CF3 N(i-Pr)CH3 0.038 0.129 3.013 79.8
    L NO2 N(i-Pr)CH3 0.034 0.0367 0.615 18.2
    i-Pr means iso-propyl
  • As shown in FIGS. 1-7, studies pertaining to the oral efficacy of EXAMPLE 1 in combination with etoposide, vincristine, CHOP, rituximab, rituximab with CHOP, rapamycin, and velcade demonstrated that EXAMPLE 1 synergistically enhanced efficacy of these cytotoxic agents during combination therapy when administered orally.
  • Further, combinations comprising EXAMPLE 1 and vincristine resulted in 10% complete tumor regression.
  • Still further, combinations comprising EXAMPLE 1 and rituximab resulted in 70% complete tumor regression whereas no tumor regressions were observed for rituximab alone.
  • Still further, combinations comprising EXAMPLE 1 and rapamycin resulted in 70% complete tumor regression whereas 10% tumor regressions were observed for rapamycin alone.
  • Still further, combinations comprising EXAMPLE 1 and rituximab with CHOP resulted in 90% complete tumor regression whereas 10% tumor regressions were observed for rituximab with CHOP only.
  • Still further, combinations comprising EXAMPLE 1 and bortexomib resulted in 10% complete tumor regression whereas no tumor regressions were observed for bortexomib alone.
  • Diseases during which anti-apopotic Bcl-XL protein, anti-apopotic Bcl-2 protein, anti-apopotic Bcl-w protein or a combination thereof, are expressed include, but are not limited to, cancer and autoimmune disorders, wherein cancer includes, but is not limited to acoustic neuroma, acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia (monocytic, myeloblastic, adenocarcinoma, angiosarcoma, astrocytoma, myelomonocytic and promyelocytic), acute t-cell leukemia, basal cell carcinoma, bile duct carcinoma, bladder cancer, brain cancer, breast cancer, bronchogenic carcinoma, cervical cancer, chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia, chronic lymphocytic leukemia, chronic myelocytic (granulocytic) leukemia, colorectal cancer, craniopharyngioma, cystadenocarcinoma, diffuse large B-cell lymphoma, dysproliferative changes (dysplasias and metaplasias), embryonal carcinoma, endometrial cancer, endotheliosarcoma, ependymoma, epithelial carcinoma, erythroleukemia, esophageal cancer, estrogen-receptor positive breast cancer, essential thrombocythemia, Ewing's tumor, fibrosarcoma, follicular lymphoma, germ cell testicular cancer, glioma, heavy chain disease, hemangioblastoma, hepatoma, hepatocellular cancer, hormone insensitive prostate cancer, leiomyosarcoma, liposarcoma, lung carcinoma, lymphagioendotheliosarcoma, lymphangiosarcoma, lymphoblastic leukemia, lymphoma (Hodgkin's and non-Hodgkin's), malignancies and hyperproliferative disorders of the bladder, breast, colon, lung, ovaries, pancreas, prostate, skin and uterus, lymphoid malignancies of T-cell or B-cell origin, leukemia, lymphoma, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, multiple myeloma, myelogenous leukemia, myeloma, myxosarcoma, neuroblastoma, non-small cell lung cancer, oligodendroglioma, oral cancer, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinomas, papillary carcinoma, pinealoma, polycythemia vera, prostate cancer, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, sebaceous gland carcinoma, seminoma, small cell lung carcinoma, solid tumors (carcinomas and sarcomas), small cell lung cancer squamous cell carcinoma, synovioma, sweat gland carcinoma, Waldenstrom's macroglobulinemia, testicular tumors, uterine cancer and Wilms' tumor, (Cancer Res., 2000, 60, 6101-10 and Medicine, 2d Ed., J.B. Lippincott Co., Philadelphia (1985)); autoimmune disorders include, but are not limited to, acquired immunodeficiency disease syndrome, autoimmune lymphoproliferative syndrome, hemolytic anemia, inflammatory diseases, and thrombocytopenia (Current Allergy and Asthma Reports 2003, 3:378-384; Br. J. Haematol. 2000 September; 110(3): 584-90; Blood 2000 Feb. 15; 95(4):1283-92; and New England Journal of Medicine 2004 September; 351(14): 1409-1418).
  • It is also expected that compounds having formula (II) would inhibit the growth of cells derived from a cancer or neoplasm such as breast cancer (including estrogen-receptor positive breast cancer), colorectal cancer, endometrial cancer, lung cancer (including small cell lung cancer), lymphoma (including follicular or Diffuse Large B-cell), lymphoma (including non-Hodgkin's lymphoma), neuroblastoma, ovarian cancer, prostate cancer (including hormone-insensitive prostate cancer), testicular cancer (including germ cell testicular cancer).
  • It is also expected that compounds having formula (II) would inhibit the growth of cells derived from a pediatric cancer or neoplasm such as embryonal rhabdomyosarcoma, pediatric acute lymphoblastic leukemia, pediatric acute myelogenous leukemia, pediatric alveolar rhabdomyosarcoma, pediatric anaplastic ependymoma, pediatric an aplastic large cell lymphoma, pediatric anaplastic medulloblastoma, pediatric atypical teratoid/rhabdoid tumor of the central nervous syatem, pediatric biphenotypic acute leukemia, pediatric Burkitts lymphoma, pediatric cancers of Ewing's family of tumors such as primitive neuroectodermal rumors, pediatric diffuse anaplastic Wilm's tumor, pediatric favorable histology Wilm's tumor, pediatric glioblastoma, pediatric medulloblastoma, pediatric neuroblastoma, pediatric neuroblastoma-derived myelocytomatosis, pediatric pre-B-cell cancers (such as leukemia), pediatric psteosarcoma, pediatric rhabdoid kidney tumor, pediatric rhabdomyosarcoma, and pediatric T-cell cancers such as lymphoma and skin cancer (commonly-owned U.S. application Ser No. 10/988,338), Cancer Res., 2000, 60, 6101-10); autoimmune disorders include, but are not limited to, acquired immunodeficiency disease syndrome, autoimmune lymphoproliferative syndrome, hemolytic anemia, inflammatory diseases, and thrombocytopenia (Current Allergy and Asthma Reports 2003, 3:378-384; Br. J. Haematol. 2000 September; 110(3): 584-90; Blood 2000 Feb. 15; 95(4):1283-92; and New England Journal of Medicine 2004 September; 351(14): 1409-1418).
  • Compounds having formula (II) may be made by synthetic chemical processes, examples of which are shown hereinbelow. It is meant to be understood that the order of the steps in the processes may be varied, that reagents, solvents and reaction conditions may be substituted for those specifically mentioned, and that vulnerable moieties may be protected and deprotected, as necessary.
  • Protecting groups for C(O)OH moieties include, but are not limited to, acetoxymethyl, allyl, benzoylmethyl, benzyl, benzyloxymethyl, tert-butyl, tert-butyldiphenylsilyl, diphenylmethyl, cyclobutyl, cyclohexyl, cyclopentyl, cyclopropyl, diphenylmethylsilyl, ethyl, para-methoxybenzyl, methoxymethyl, methoxyethoxymethyl, methyl, methylthiomethyl, naphthyl, para-nitrobenzyl, phenyl, n-propyl, 2,2,2-trichloroethyl, triethylsilyl, 2-(trimethylsilyl)ethyl, 2-(trimethylsilyl)ethoxymethyl, triphenylmethyl and the like.
  • Protecting groups for C(O) and C(O)H moieties include, but are not limited to, 1,3-dioxylketal, diethylketal, dimethylketal, 1,3-dithianylketal, O-methyloxime, O-phenyloxime and the like.
  • Protecting groups for NH moieties include, but are not limited to, acetyl, alanyl, benzoyl, benzyl (phenylmethyl), benzylidene, benzyloxycarbonyl (Cbz), tert-butoxycarbonyl (Boc), 3,4-dimethoxybenzyloxycarbonyl, diphenylmethyl, diphenylphosphoryl, formyl, methanesulfonyl, para-methoxybenzyloxycarbonyl, phenylacetyl, phthaloyl, succinyl, trichloroethoxycarbonyl, triethylsilyl, trifluoroacetyl, trimethylsilyl, triphenylmethyl, triphenylsilyl, para-toluenesulfonyl and the like.
  • Protecting groups for OH and SH moieties include, but are not limited to, acetyl, allyl, allyloxycarbonyl, benzyloxycarbonyl (Cbz), benzoyl, benzyl, tert-butyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, 3,4-dimethoxybenzyl, 3,4-dimethoxybenzyloxycarbonyl, 1,1-dimethyl-2-propenyl, diphenylmethyl, formyl, methanesulfonyl, methoxyacetyl, 4-methoxybenzyloxycarbonyl, para-methoxybenzyl, methoxycarbonyl, methyl, para-toluenesulfonyl, 2,2,2-trichloroethoxycarbonyl, 2,2,2-trichloroethyl, triethylsilyl, trifluoroacetyl, 2-(trimethylsilyl)ethoxycarbonyl, 2-trimethylsilylethyl, triphenylmethyl, 2-(triphenylphosphonio)ethoxycarbonyl and the like.
  • The following abbreviations have the meanings indicated. ADDP means 1,1′-(azodicarbonyl)dipiperidine; AD-mix-β means a mixture of (DHQD)2PHAL, K3Fe(CN)6, K2CO3 and K2SO4); AIBN means 2,2′-azobis(2-methylpropionitrile); 9-BBN means 9-borabicyclo[3.3.1]nonane; (DHQD)2PHAL means hydroquinidine 1,4-phthalazinediyl diethyl ether; DBU means 1,8-diazabicyclo[5.4.0]undec-7-ene; DIBAL means diisobutylaluminum hydride; DIEA means diisopropylethylamine; DMAP means N,N-dimethylaminopyridine; DME means 1,2-dimethoxyethane; DMF means N,N-dimethylformamide; dmpe means 1,2-bis(dimethylphosphino)ethane; DMSO means dimethylsulfoxide; dppb means 1,4-bis(diphenylphosphino)butane; dppe means 1,2-bis(diphenylphosphino)ethane; dppf means 1,1′-bis(diphenylphosphino)ferrocene; dppm means 1,1-bis(diphenylphosphino)methane; EDAC means 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide; Fmoc means fluorenylmethoxycarbonyl; HATU means O-(7-azabenzotriazol-1-yl)-N,N′,N′N′-tetramethyl uronium hexafluorophosphate; HMPA means hexamethylphosphoramide; IPA means-isopropyl alcohol; LDA means lithium diisopropylamide; LHMDS means lithium bis(hexamethyldisilylamide); MP-BH3 means macroporus triethylammonium methylpolystyrene cyanoborohydride; LAH means lithium aluminum hydride; NCS means N-chlorosuccinimide; PyBOP means benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate; TDA-1 means tris(2-(2-methoxyethoxy)ethyl)amine; TEA means triethylamine; TFA means trifluoroacetic acid; THF means tetrahydrofuran; NCS means N-chlorosuccinimide; NMM means N-methylmorpholine; NMP means N-methylpyrrolidine; PPh3 means triphenylphosphine.
  • Figure US20080287419A1-20081120-C00025
  • As shown in SCHEME 1, compounds having formula (1) may be converted to compounds having formula (2) by reacting the former, chlorosulfonic acid, and ammonia.
  • Figure US20080287419A1-20081120-C00026
  • Compounds having formula (2) may be converted to compounds having formula (II) by reacting the former and compounds having formula (3) and a coupling agent, with or without a base. Examples of coupling agents include EDCI, CDI, and PyBop. Examples of bases include TEA, DIEA, DMAP, and mixtures thereof.
  • Compounds having formula (2) may be converted to compounds having formula (II) by reacting the former and compounds having formula Z1-COCl and the base.
  • The following examples are presented to provide what is believed to be the most useful and readily understood description of procedures and conceptual aspects of this invention.
    • EXAMPLE 1A
  • 3-(R)-((Carbobenzyloxy)amino)-γ-butyrolactone, prepared as described in J. Am. Chem. Soc. 1986, 108, 4943-4952; (62 g) and morpholine (46 mL) in dioxane (700 mL) at 65° C. was stirred for 24 hours, cooled and concentrated. The concentrate was chromatographed on silica gel with 10% methanol/ethyl acetate.
    • EXAMPLE 1B
  • EXAMPLE 1A (16.5 g), diphenyl disulfide (14.5 g) and tributylphosphine (16.6 mL) in toluene (250 mL) at 80° C. was stirred for 24 hours, cooled and concentrated. The concentrate was chromatographed on silica gel with 1:1 ethyl acetate/hexanes.
    • EXAMPLE 1C
  • EXAMPLE 1B (18 g) in 30% HBr in acetic acid (250 mL) at 25° C. was stirred for 24 hours, concentrated, poured into 1M HCl and extracted with diethyl ether. The extract was extracted with 1M HCl, and this extract was cooled to 0° C., adjusted to pH 12 with KOH and extracted with dichloromethane. The extract was washed with brine and dried (Na2SO4), filtered and concentrated.
    • EXAMPLE 1D
  • EXAMPLE 1C (45.4 g) in THF (500 mL) at 55° C. was treated with 1M BH3-THF (650 mL) over 2 hours, stirred for 24 hours, cooled to 0° C., treated with methanol (80 mL), poured into methanol (500 mL) and concentrated. A mixture of the concentrate in methanol (400 mL) was treated with a HCl-saturated methanol (800 mL), refluxed for 24 hours, cooled, concentrated, poured into 2M NaOH and extracted with ethyl acetate. The extract was washed with 1M NaOH and brine and dried (Na2SO4), filtered and concentrated. The concentrate was chromatographed on silica gel with ethyl acetate 10% methanol/ethyl acetate and 10% methanol/10% acetonitrile/5% TEA/75% ethyl acetate.
    • EXAMPLE 1E
  • Methyl viologen hydrochloride (1.17 g) in DMF (80 mL) at 25° C. was saturated with trifluoromethyl iodide, treated with 2-fluorobenzenethiol (9.7 mL) and TEA (20 ml), stirred for 24 hours, diluted with water (240 mL) and extracted with diethyl ether. The extract was washed with 1M NaOH, saturated ammonium chloride and brine and concentrated.
    • EXAMPLE 1F
  • EXAMPLE 1 E (17.346 g) in 1:1:2 carbon tetrachloride/acetonitrile/water (800 mL) at 25° C. was treated with sodium periodate (56.8 g) and ruthenium(III) chloride hydrate (183 mg), stirred for 18 hours, diluted with dichloromethane (100 mL) and filtered through diatomaceous earth (Celite®). The filtrate was washed with saturated sodium bicarbonate and extracted with dichloromethane. The extract was washed with brine and dried (MgSO4), filtered and concentrated. The concentrate was filtered through silica gel.
    • EXAMPLE 1G
  • EXAMPLE 1F (37.3 g) in chlorosulfonic acid (32.8 mL) at 120° C. was stirred for 18 hours, cooled to 25° C. and pipetted onto crushed ice. The mixture was extracted with ethyl acetate, and the extract was washed with water and brine and dried (MgSO4), filtered and concentrated.
    • EXAMPLE 1H
  • EXAMPLE 1G (23 g) in isopropanol (706 mL) at −78° C. was treated with ammonium hydroxide (98 mL) over 1 hour, stirred for 1 hour, quenched with 6M HCl (353 mL), warmed to 25° C. and concentrated. The concentrate was mixed with water and extracted with ethyl acetate. The extract was dried (MgSO4), filtered and concentrated. The concentrate was recrystallized from ethyl acetate/hexane.
    • EXAMPLE 1I
  • EXAMPLE 1H (13.48 g) and EXAMPLE 1D (11.56 g) in THF (218 mL) was treated with DIEA (15.1 mL), stirred at 50° C. for 4 hours, cooled, treated with saturated sodium bicarbonate and extracted with ethyl acelate. The extract was dried (MgSO4), filtered and concentrated. The concentrate was recrystallized from hexanes/ethyl acetate.
    • EXAMPLE 1J
  • DMF (10 mL) and chloroform (80 mL) at 3° C. was treated with PBr3 (12 mL), stirred for 20 minutes at 25° C., treated with 4,4-dimethylcyclohexanone (7.15 g) in chloroform (50 mL), stirred for 18 hours, poured onto ice, neutralized with solid sodium bicarbonate and extracted with diethyl ether. The extract was washed with brine and dried (MgSO4), filtered and concentrated. The concentrate was chromatographed on silica gel with 0-10% ethyl acetate/hexanes.
    • EXAMPLE 1K
  • EXAMPLE 1J (1.7 g) and 4-piperazin-1-ylbenzoic acid ethyl ester (1.9 g) in methanol (30 mL) was treated with sodium cyanoborohydride (0.6 g), adjusted to pH 5 with acetic acid, stirred for 18 hours and filtered through diatomaceous earth (Celite®). The filtrate was concentrated, and the concentrate was chromatographed on silica gel on silica gel with 10-30% ethyl acetate/hexanes.
    • EXAMPLE 1L
  • EXAMPLE 1K (1.1 g), 4-chlorophenylboronic acid (0.6 g), 2M Na2CO3 (2 mL) and PdCl2(PPh3)2 (0.1 g) in 7:3:2 DME/water/ethanol (20 mL) was stirred at 85° C. for 18 hours, filtered through diatomaceous earth (Celite®) and concentrated. The concentrate was chromatographed on silica gel with 10-30% ethyl acetate/hexanes.
    • EXAMPLE 1M
  • EXAMPLE 1L (4.59 g) and LiOH (1.25 g) in dioxane (75 mL) and water (10 mL) was stirred at 100° C. for 18 hours, cooled to 25° C. and concentrated. The concentrate was dissolved in water, heated to reflux, neutralized with 1M HCl (28.5 mL), cooled to 25° C., filtered and concentrated.
    • EXAMPLE 1N
  • EXAMPLE 1M (31.5 g), EXAMPLE 1I (39.93 g), EDAC-HCl (20.60 g) and DMAP (13.15 g) in dichloromethane (500 mL) at 25° C. was stirred for 18 hours, diluted with dichloromethane, washed with saturated ammonium chloride and brine and dried (MgSO4), filtered and concentrated. The concentrate was chromatographed on silica gel with 0-10% methanol/ammonia-saturated dichloromethane. 1H NMR (300 MHz, DMSO-d6) δ 8.12 (d, 1H), 7.94 (dd, 1H), 7.71 (d, 2H), 7.38 (d, 2H), 7.30 (m, 4H), 7.18 (m, 1H), 7.12 (d, 2H), 6.98 (d, 1H), 6.85 (d, 3H), 4.07 (m, 1H), 3.53 (br, 4H), 3.28 (m, 12H), 2.44 (m, 8H), 1.99 (m, 3H), 1.80 (m, 1H), 1.44 (t, 2H), 0.97 (s, 6H).
    • EXAMPLE 2A
  • Powdered NaOH (31.2 g), TDA-1 (5 mL) and 2-fluorobenzene thiol (33.6 mL) in benzene (400 mL) was saturated with chlorodifluoromethane, stirred at 80° C. for 30 minutes and filtered through diatomaceotis earth (Celite®). The filtrate was washed with saturated NaHCO3 and the water layer was extracted with diethyl ether. The extracts were combined and dried (MgSO4), filtered and concentrated.
    • EXAMPLE 2B
  • EXAMPLE 2A (46 g) in 1:1:2 CCl4/CH3CN/water (1.2 L) at 25° C. was treated with NalO4 (165.6 g) and RuCl3.xH2O (534 mg), stirred for 18 hours, diluted with dichloromethane and filtered through diatomaceous earth (Celite®). The filtrate was washed with saturated NaHCO3 and dried (Na2SO4), filtered and concentrated. The concentrate was filtered through silica gel.
    • EXAMPLE 2C
  • EXAMPLE 2B (25 g) and NCS (17.55 g) in THF (700 mL) at −78° C. was treated with LHMDS (178.5 mL) over 1 hour, stirred for 1 hour and quenched with ammonium chloride. The mixture was extracted with ethyl acetate, and the extract was washed with brine and dried (MgSO4), filtered and concentrated. The concentrate was chromatographed on silica gel with 0-5% ethyl acetate/hexanes.
    • EXAMPLE 2D
  • EXAMPLE 2C (44 g) in chlorosulfonic acid (36.7 mL) at 120° C. was stirred for 18 hours, cooled to 25° C., pipetted onto crushed ice and extracted with ethyl acetate. The extract was washed with water and brine and dried (MgSO4), filtered and concentrated.
    • EXAMPLE 2E
  • EXAMPLE 2D (22 g) in isopropanol (700 mL) at −78° C. was treated with aqueous ammonia (90 mL) over 1 hour, stirred for another hour, quenched with 6M HCl (300 mL), warmed to 25° C. and concentrated. The concentrate was mixed with water and extracted with ethyl acetate. The extract was dried (MgSO4), filtered and concentrated. The concentrate was recrystallized from hexanes/ethyl acetate.
    • EXAMPLE 2F
  • EXAMPLE 2E (2.89 g) and EXAMPLE 1 D (2.39 g) in THF (20 mL) was treated with diisopropylethylamine (3.2 mL), stirred at 60° C. for 18 hours, cooled, treated with saturated sodium bicarbonate and extracted with ethyl acetate. The extract was dried (MgSO4), filtered and concentrated. The concentrate was chromatographed on silica gel with 1.5-5% 7M ammonia in methanol/dichloromethane.
    • EXAMPLE 2G
  • Hexane-washed 60% oily NaH (17 g) in dichloromethane (300 mL) at −5° C. was treated with 4,4-dimethyl-2-oxo-cyclohexanecarboxylic acid methyl ester, prepared as described in Tetrahedron (1992), 48 (21), 4459-64, (53.89 g), stirred for 30 minutes, cooled to −78° C., treated with trifluoromethanesulfonic anhydride, warmed to 25° C., stirred for 18 hours, washed with brine and dried (MgSO4), filtered and concentrated.
    • EXAMPLE 2H
  • EXAMPLE 2G (86 g), 4-chlorophenylboronic acid (50 g), CsF (104 g) and tetrakis(triphenylphosphine)palladium(0) (2.5 g) in 2:1 DME/methanol (600 mL) at 70° C. was stirred for 18 hours and concentrated. The concentrate was dissolved in diethyl ether, and the solution was dried (MgSO4), filtered and concentrated. The concentrate was filtered through silica gel with 20% ethyl acetate/hexanes.
    • EXAMPLE 2I
  • Lithium borohydride (18 g) was treated with EXAMPLE 2H (76 g) in diethyl ether (400 mL) and methanol (23 mL), stirred at reflux for 4 hours, cooled, quenched with 1M HCl, diluted with water and extracted with diethyl ether. The extract was dried (MgSO4), filtered and concentrated. The concentrate was chromatographed on silica gel with 0-30% ethyl acetate/hexanes.
    • EXAMPLE 2J
  • EXAMPLE 2I (17.5 g) in dichloromethane (100 mL) at 0° C. was treated simultaneously with methanesulfonyl chloride (5.6 mL) and TEA (21 mL), stirred for 5 minutes, treated with 4-piperazin-1-ylbenzoic acid ethyl ester (17 g), stirred at 25° C. for 18 hours, washed with ammonium chloride and dried (Na2SO4), filtered and concentrated. The concentrate was chromatographed on silica gel with 10% ethyl acetate/hexanes.
    • EXAMPLE 2K
  • This example was prepared by substituting EXAMPLE 2J for EXAMPLE 1L in EXAMPLE 1M.
    • EXAMPLE 2L
  • EXAMPLE 2K (16.9 g) and EXAMPLE 2F (22 g) in dichloromethane (200 mL) at 25° C. was treated with EDAC-HCl (11.06 g) and DMAP (7.06 g), stirred for 18 hours, diluted with dichloromethane (400 mL), washed with saturated ammonium chloride and brine and dried (MgSO4), filtered and concentrated. The concentrate was chromatographed on silica gel with 0-10% methanol/ammonia-saturated dichloromethane. 1H NMR (400 MHz, DMSO-d6) δ 8.07 (d, 1H), 7.90 (dd, 1H), 7.71 (d, 2H), 7.36 (m, 4H), 7.29 (m, 2H), 7.20 (m, 1H), 7.09 (d, 2H), 6.86 (d, 1H), 6.80 (d, 2H), 6.76 (d, 1H), 4.02 (m, 1H), 3.50 (m, 4H), 3.33 (m, 2H), 3.16 (m, 4H), 2.81 (s, 2H), 2.29 (m, 12H), 1.99 (s, 2H), 1.94 (m, 1H), 1.71 (m, 1H), 1.42 (t, 2H), 0.96 (s, 6H).
    • EXAMPLE 3A
  • This example was prepared by substituting 2-bromo-cyclohex-1-enecarbaldehyde, prepared as described in Collect. Czech. Chem. Commun., 1961, 26, 3059.) for EXAMPLE 1J in EXAMPLE 1K.
    • EXAMPLE 3B
  • This example was prepared by substituting EXAMPLE 3A for EXAMPLE 1 K in EXAMPLE 1L.
    • EXAMPLE 3C
  • This example was prepared by substituting EXAMPLE 3B for EXAMPLE 1L in EXAMPLE 1M.
    • EXAMPLE 3D
  • This example was prepared by substituting EXAMPLE 3C and EXAMPLE 2F for EXAMPLE 1M and EXAMPLE 1I, respectively, in EXAMPLE 1N. 1H NMR (400 MHz, DMSO-d6) δ 8.11 (d, 1H), 7.92 (dd, 1H), 7.71 (d, 2H), 7.37 (d, 2H), 7.34 (m, 2H), 7.27 (t, 2H), 7.18 (t, 1H), 7.12 (d, 2H), 6.94 (d, 1H), 6.84 (m, 3H), 4.04 (m, 1H), 3.51 (br, 4H), 3.27 (br, 10H), 2.84 (br, 2H), 2.33 (br, 6H), 2.18 (br, 4H), 1.97 (m, 1H), 1.76 (m, 1H), 1.66 (s, 4H).
    • EXAMPLE 4A
  • A solution of 3-(R)-((carbobenzyloxy)amino)-γ-butyrolactone (prepared according to the procedure described in J. Am. Chem. Soc. 1986, 108, 4943-4952, 7.72 g, 32.8 mmol) in THF (100 mL) was saturated with gaseous dimethylamine, stirred at room temperature for 16 hours, and concentrated. The residue was filtered through a plug of silica gel eluting with 50% acetone in hexanes to give the desired product.
    • EXAMPLE 4B
  • A solution of EXAMPLE 4A (8.45 g, 30.14 mmol) in toluene (15 mL) was treated with tributylphosphine (9.76 mL, 39.20 mmol) and diphenyldisulfide (7.30 g, 39.20 mmol) and heated to 80° C. for 16 hours. The reaction mixture was concentrated and purified by column chromatography on silica gel eluting with a gradient of 0-50% ethyl acetate in hexanes to give the desired product.
    • EXAMPLE 4C
  • EXAMPLE 4B (7.5 g) and bis(cyclopentadienyl)zirconium(IV) chloride hydride (10.31 g) in THF (100 mL) at 25° C. was stirred for 20 minutes and concentrated. The concentrate was chromatographed on silica gel with 50% ethyl acetate in hexane.
    • EXAMPLE 4D
  • EXAMPLE 4C (2.87 g) and N-isopropylmethylamine (1.92 g) in 1,2-dichloroethane (50 mL) at 25° C. was treated with sodium triacetoxyborohydride (3 g), stirred for 2 hours, diluted with ethyl acetate, washed with 2M NaOH, water and brine and dried (Na2SO4), filtered and concentrated. The concentrate was chromatographed on silica gel with 1% methanol/dichloromethane.
    • EXAMPLE 4E
  • This example was prepared by substituting EXAMPLE 4D for EXAMPLE 1B in EXAMPLE 1C.
    • EXAMPLE 4F
  • This example was prepared by substituting EXAMPLE 4E for EXAMPLE 1D in EXAMPLE 1I.
    • EXAMPLE 4G
  • This example was prepared by substituting EXAMPLE 4F for EXAMPLE 1I in EXAMPLE 1N. 1H NMR (400 MHz, DMSO-d6) δ 8.08 (s, 1H), 7.98 (d, 1H), 7.71 (d, 2H), 7.37 (m, 4H), 7.28 (t, 2H), 7.20 (t, 1H), 7.12 (d, 2H), 6.89 (d, 1H), 6.78 (d, 2H), 6.70 (d, 1H), 4.01 (m, 1H), 3.13 (m, 6H), 2.75 (m, 2H), 2.28 (m, 6H), 2.04 (m, 4H), 1.99 (m, 2H), 1.43 (m, 2H), 1.12 (m, 10H), 0.97 (s, 6H).
    • EXAMPLE 5
  • This example was prepared by substituting 4-(4-(2-(4-chlorophenyl)cyclo 1-enylmethyl)piperazin-1-yl)benzoic acid, prepared as described in commonly-owned U.S. patent application Ser. No. 10/988,338, and EXAMPLE 4F for EXAMPLE 1M and EXAMPLE 1I, respectively, in EXAMPLE 1N. 1H NMR (400 MHz, DMSO-d6) δ 9.00 (m, 1H), 8.09 (s, 1H), 7.98 (d, 1H), 7.71 (d, 2H), 7.36 (m, 4H), 7.30 (t, 2H), 7.20 (t, 1H), 7.09 (d, 2H), 6.90 (d, 1H), 6.78 (d, 2H), 6.65 (d, 1H), 4.00 (m, 2H), 3.13 (m, 4H), 2.78 (m, 2H), 2.55 (m, 2H), 2.40 (m, 4H), 2.31 (m, 4H), 2.00 (m, 3H), 1.79 (m, 4H), 1.58 (m, 4H), 1.51 (m, 2H), 1.12 (m, 6H).
    • EXAMPLE 6A
  • This example was prepared by substituting EXAMPLE 4B for EXAMPLE 1B in EXAMPLE 1C.
    • EXAMPLE 6B
  • EXAMPLE 6A (6.13 g) in THF (200 mL) at 25° C. was treated with di-tert-butyldicarbonate (7 g), stirred for 4 hours and concentrated. The concentrate was dissolved into ethyl acetate (500 mL), washed with 1M NaOH, water and brine and dried (Na2SO4), filtered and concentrated. The concentrate in THF (200 mL) at 25° C. to was treated with 1M NaOH (200 mL), stirred for 5 hours and isolated. The water layer was extracted with ethyl acetate, and the THF and ethyl acetate extracts were combined, washed with water and brine and dried (Na2SO4), filtered and concentrated.
    • EXAMPLE 6C
  • This example was prepared by substituting EXAMPLE 6B for EXAMPLE 5B in EXAMPLE 4C.
    • EXAMPLE 6D
  • This example was prepared by substituting EXAMPLE 6C and 2-oxa-5-aza-bicyclo[2.2.1]heptane, prepared as described in commonly-owned U.S. patent application Ser. No. 10/988,338, for EXAMPLE 4C and N-isopropylmethyl amine in EXAMPLE 4D.
    • EXAMPLE 6E
  • EXAMPLE 6D (7.86 g) in dichloromethane (200 mL) at 25° C. was treated with 2M HCl in diethyl ether (200 mL), stirred for 18 hours and concentrated.
    • EXAMPLE 6F
  • This example was prepared by substituting EXAMPLE 6E for EXAMPLE 1D in EXAMPLE 2F.
    • EXAMPLE 6G
  • This example was prepared by substituting EXAMPLE 6F and EXAMPLE 3C for EXAMPLE 1I and EXAMPLE 1M in EXAMPLE 1N. 1H NMR (300 MHz, DMSO-d6) δ 8.07 (s, 1H), 7.92 (d, 1H), 7.70 (d, 2H), 7.37 (m, 4H), 7.30 (t, 2H), 7.21 (t, 1H), 7.12 (d, 2H), 6.84 (d, 1H), 6.79 (d, 2H), 4.21 (m, 1H), 4.09 (m, 1H), 4.01 (m, 2H), 3.82 (m, 2H), 3.46 (m, 1H), 3.18 (m, 6H), 2.86 (m, 4H), 2.75 (m, 4H), 2.28 (m, 2H), 2.18 (m, 4H), 1.88 (m, 4H), 1.66 (m, 4H).
    • EXAMPLE 7
  • This example was prepared by substituting EXAMPLE 3C for EXAMPLE 1M in EXAMPLE 1N. 1H NMR (300 MHz, DMSO-d6) δ 8.09 (d, 1H), 7.92 (dd, 1H), 7.71 (d, 2H), 7.31 (m, 7H), 7.18 (tt, 1H), 7.12 (dt, 2H), 6.92 (d, 1H), 6.82 (m, 3H), 4.04 (m, 1H), 3.51 (m, 4H), 3.26 (m, 10H), 2.82 (m, 2H), 2.30 (m, 10H), 1.94 (m, 1H), 1.72 (m, 5H).
    • EXAMPLE 8A
  • A solution of 3-(9H-fluoren-9-ylmethoxycarbonylamino)-4-phenylsulfanylbutyric acid, prepared as described in commonly-owned U.S. patent application Ser. No. 10/988,338 and HATU in DMF was treated with 7-aza-bicyclo[2.2.1]heptane (prepared as described in Org. Lett., 2001, 3, 1371-1374; and N-methylmorpholine, stirred at ambient temperature for 30 min, diluted with ethyl acatate, washed with 1.5% HCl, NaHCO3(aq), H2O and brine, dried (Na2SO4), filtered and concentrated to give the desired product.
    • EXAMPLE 8B
  • A solution of EXAMPLE 8A in THF was treated with diethyl amine, stirred at ambient temperature for 2 hours and concentrated. The residue was purified by silica gel chromatography eluting with CH2Cl2 (saturated with NH3), followed by ethyl acetate to give the desired product.
    • EXAMPLE 8C
  • This example was prepared by substituting EXAMPLE 8B for EXAMPLE 1C in EXAMPLE 1D.
    • EXAMPLE 8D
  • This example was prepared by substituting EXAMPLE 8C for EXAMPLE 1D in EXAMPLE 1I.
    • EXAMPLE 8E
  • This example was prepared by substituting EXAMPLE 8D and EXAMPLE 3C for EXAMPLE 1I and EXAMPLE 1M, respectively, in EXAMPLE 1N. 1H NMR (300 MHz. DMSO-d6) δ 9.19 (m, 1H), 8.07 (d, 1H), 7.97 (d, 1H), 7.71 (d, 2H), 7.31 (m 6H), 7.20 (tt, 1H), 7.12 (dt, 2H), 6.89 (d, 1H), 6.76 (d, 2H), 6.65 (d, 1H), 4.03 (m, 2H), 3.31 (m, 4H), 3.12 (m, 4H), 2.90 (br, 2H), 2.76 (m, 2H), 1.96 (m, 21H).
    • EXAMPLE 9A
  • This example was prepared by substituting EXAMPLE 6E for EXAMPLE 1 D in EXAMPLE 1I.
    • EXAMPLE 9B
  • This example was prepared by substituting EXAMPLE 9A and EXAMPLE 3C for EXAMPLE 1I and EXAMPLE 1M, respectively, in EXAMPLE 1N. 1H NMR (300 MHz, DMSO-d6) δ 8.08 (d, 1H), 7.94 (d, 1H), 7.71 (d, 2H), 7.32 (m 7H), 7.20 (tt, 1H), 7.12 (dt, 2H), 6.87 (d, 1H), 6.78 (d, 3H), 4.40 (m, 1H), 4.03 (m, 2H), 3.83 (m, 2H), 3.54 (m, 2H), 3.26 (m, 2H), 3.14 (m, 4H), 2.80 (br, 2H), 2.78 (m, 4H), 1.97 (m, 14H).
    • EXAMPLE 10
  • This example was prepared by substituting EXAMPLE 9A for EXAMPLE 1I in EXAMPLE 1N. 1H NMR (300 MHz, DMSO-d6) δ 8.09 (d, 1H), 7.95 (d, 1H), 7.71 (d, 2H), 7.33 (m, 7H), 7.20 (tt, 1H), 7.12 (dt, 2H), 6.90 (d, 1H), 6.79 (d, 3H), 4.44 (m, 1H), 4.03 (m, 1H), 3.84 (m, 1H), 3.57 (m, 1H), 3.02 (m, 13H), 2.25 (m, 6H), 1.99 (m, 6H), 1.43 (t, 2H), 0.97 (s, 6H).
    • EXAMPLE 11
  • This example was prepared by substituting EXAMPLE 6F for EXAMPLE 1I in EXAMPLE 1N. 1H NMR (300 MHz, DMSO-d6) δ 8.07 (d, 1H), 7.93 (d, 1H), 7.70 (d, 2H), 7.33 (m, 7H), 7.20 (tt, 1H), 7.12 (dt, 2H), 6.81 (m, 4H), 4.41 (m, 1H), 4.06 (m, 1H), 3.83 (m, 1H), 3.47 (m, 1H), 3.02 (m, 13H), 2.25 (m, 6H), 1.99 (m, 6H), 1.43 (t, 2H), 0.97 (s, 6H).
    • EXAMPLE 12
  • This example was prepared by substituting 4-(4-(2-(4-chlorophenyl)cyclohept-1-enylmethyl)piperazin-1-yl)benzoic acid, prepared as described in commonly-owned U.S. patent application Ser. No. 10/988,338, and EXAMPLE 9A for EXAMPLE 1M and EXAMPLE 1I, respectively, in EXAMPLE 1N. 1H NMR (300 MHz, DMSO-d6) δ 8.09 (d, 1H), 7.95 (dd, 1H), 7.71 (d, 2H), 7.32 (m, 7H), 7.19 (tt, 1H), 7.09 (dt, 2H), 6.90 (d, 1H), 6.79 (d, 3H), 4.45 (m, 1H), 4.03 (m, 2H), 3.85 (m, 2H), 3.55 (m, 2H), 3.04 (m, 8H), 2.34 (m, 8H), 1.85 (m, 7H), 1.54 (m, 5H).
    • EXAMPLE 13
  • This example was prepared by substituting 4-(4-(2-(4-chlorophenyl)cyclohept-1-enylmethyl)piperazin-1-yl)benzoic acid, prepared as described in commonly-owned U.S. patent application Ser. No. 10/988,338, and EXAMPLE 6F for EXAMPLE 1M and EXAMPLE 1I, respectively, in EXAMPLE 1N. 1H NMR (300 MHz, DMSO-d6) δ 8.07 (d, 1H), 7.93 (dd, 1H), 7.71 (d, 2H), 7.32 (m, 7H), 7.20 (tt, 1H), 7.09 (dt, 2H), 6.87 (d, 1H), 6.79 (d, 3H), 4.45 (m, 1H), 4.02 (m, 2H), 3.84 (m, 2H), 3.56 (m, 2H), 3.07 (m, 8H), 2.33 (m, 8H), 1.85 (m, 7H), 1.54 (m, 5H).
    • EXAMPLE 14
  • This example was prepared by substituting EXAMPLE 2K and EXAMPLE 4F for EXAMPLE 1M and EXAMPLE 1I, respectively, in EXAMPLE 1N. 1H NMR (300 MHz, DMSO-d6) δ 8.07 (d, 1H), 7.96 (dd, 1H), 7.71 (d, 2H), 7.33 (m, 7H), 7.20 (tt, 1H), 7.09 (dt, 2H), 6.87 (d, 1H) 6.77 (d, 2H), 6.72 (d, 1H), 4.00 (m, 1H), 3.28 (m, 4H), 3.12 (m, 4H), 2.79 (m, 2H), 2.48 (m, 2H), 2.23 (m, 8H), 2.02 (m, 4H), 1.42 (t, 2H), 1.08 (m, 6H), 0.96 (s, 6H).
    • EXAMPLE 15A
  • This example was prepared by substituting EXAMPLE 6C and 1,4-oxazepane for EXAMPLE 4C and N-isopropyl-N-methylamine in EXAMPLE 4D.
    • EXAMPLE 15B
  • This example was prepared by substituting EXAMPLE 15A for EXAMPLE 6D in EXAMPLE 6E.
    • EXAMPLE 15C
  • This example was prepared by substituting EXAMPLE 15B for EXAMPLE 1D in EXAMPLE 1I.
    • EXAMPLE 15D
  • This example was prepared by substituting EXAMPLE 15C and EXAMPLE 3C for EXAMPLE 1I and EXAMPLE 1M, respectively, in EXAMPLE 1N. 1H NMR (400 MHz, CDCl3) δ 8.32 (s, 1H), 8.01 (br, 1H), 7.67 (d, 2H), 7.34 (t, 4H), 7.24 (m, 3H), 6.99 (m, 3H), 6.67 (br, 3H), 3.97 (br, 1H), 3.88 (s, 2H), 3.79 (s, 2H), 3.73-3.23 (br m, 12H), 3.14 (m, 6H), 2.29 (s, 6H), 2.08 (m, 2H), 1.74 (s, 4H).
    • EXAMPLE 16A
  • This example was prepared by substituting azepane for N-isopropyl-N-methylamine in EXAMPLE 4D.
    • EXAMPLE 16B
  • This example was prepared by substituting EXAMPLE 16A for EXAMPLE 4D in EXAMPLE 4E.
    • EXAMPLE 16C
  • This example was prepared by substituting EXAMPLE 16A for EXAMPLE 1D in EXAMPLE 1I.
    • EXAMPLE 16D
  • This example was prepared by substituting EXAMPLE 16C and EXAMPLE 3C for EXAMPLE 1I and EXAMPLE 1M, respectively, in EXAMPLE 1N. 1H NMR (400 MHz, CDCl3) δ 8.33 (s, 1H), 8.01 (d, 1H), 7.67 (d, 2H), 7.34 (t, 4H), 7.23 (m, 3H), 6.98 (m, 3H), 6.67 (m, 3H), 3.99 (m, 1H), 3.82-3.19 (br m, 10H), 3.12 (s, 4H), 2.86 (m, 2H), 2.55 (br, 2H), 2.29 (s, 4H), 2.06 (m, 1H), 1.93 (m, 3H), 1.74 (s, 8H), 1.60 (m, 2H).
    • EXAMPLE 17A
  • This example was prepared by substituting EXAMPLE 6A for EXAMPLE 1C in EXAMPLE 1D.
    • EXAMPLE 17B
  • This example was prepared by substituting EXAMPLE 17B for EXAMPLE 1D in EXAMPLE 1I.
    • EXAMPLE 17C
  • This example was prepared by substituting 4-(4-(2-(4-chlorophenyl)cyclohept-1-enylmethyl)piperazin-1-yl)benzoic acid, prepared as described in commonly-owned U.S. patent application Ser. No. 10/988,338, and EXAMPLE 17B for EXAMPLE 1M and EXAMPLE 1I respectively, in EXAMPLE 1N. 1H NMR (400 MHz, DMSO-d6) δ 9.58 (brs, 1H), 9.46 (brs, 1H), 8.18 (d, 1H), 8.00 (dd, 1H), 7.77 (d, 2H), 7.41 (d, 2H), 7.29 (d, 2H), 7.24 (m, 2H), 7.13 (m, 4H), 6.96 (m, 3H), 4.12 (m, 1H), 3.87 (m, 1H), 3.63 (m, 1H), 3.38 (m, 4H), 3.15 (m, 4H), 3.02 (m, 2H), 2.74 (s, 6H), 2.46 (m, 4H), 2.09 (m, 2H), 1.81 (m, 2H), 1.57 (m, 4H).
    • EXAMPLE 18A
  • This example, was prepared by substituting EXAMPLE 2E and EXAMPLE 17B for EXAMPLE 1H and EXAMPLE 1D in EXAMPLE 1I.
    • EXAMPLE 18B
  • This example was prepared by substituting EXAMPLE 18A and EXAMPLE 3C for EXAMPLE 1I and EXAMPLE 1M, respectively, in EXAMPLE 1N. 1H NMR (400 MHz, DMSO-d6) δ 9.60 (brs, 1H), 9.47 (brs, 1H), 8.18 (d, 1H), 7.99 (dd, 1H), 7.77 (d, 2H), 7.41 (d, 2H), 7.30 (d, 2H), 7.24 (m, 2H), 7.15 (m, 3H), 7.12 (d, 1H), 6.96 (m, 3H), 6.92 (d, 1H), 4.10 (m, 1H), 3.91 (m, 2H), 3.60 (m, 2H), 3.37 (m, 4H), 3.15 (m, 2H), 3.02 (m, 1H), 2.74 (s, 6H), 2.25 (d, 4H), 2.08 (m, 2H), 1.71 (m, 4H).
    • EXAMPLE 19
  • This example was prepared by substituting EXAMPLE 2F for EXAMPLE 1I in EXAMPLE 1N. 1H NMR (400 MHz, DMSO-d6) δ 8.11 (d, 1H), 7.93 (dd, 1H), 7.71 (d, 2H), 7.36 (m, 4H), 7.27 (m, 2H), 7.18 (m, 1H), 7.12 (d, 2H), 6.97 (d, 1H), 6.85 (m, 3H), 4.05 (m, 1H), 3.53 (m, 4H), 3.23 (m, 1H), 2.83 (m, 1H), 2.34 (m, 8H), 2.22 (m, 2H), 1.99 (m, 2H), 1.96 (m, 1H), 1.77 (m, 1H), 1.44 (t, 2H), 0.97 (s, 6H).
    • EXAMPLE 20
  • This example was prepared by substituting EXAMPLE 17B for EXAMPLE 1I in EXAMPLE 1N. 1H NMR (500 MHz, DMSO-d6) δ 9.46 (brs, 1H), 8.18 (d, 1H), 7.99 (dd, 1H), 7.76 (d, 2H), 7.40 (d, 2H), 7.29 (d, 2H), 7.23 (t, 2H), 7.14 (s, 4H), 6.95 (m, 3H), 4.11 (m, 1H), 3.88 (m, 2H), 3.58 (m, 4H), 3.08 (m, 4H), 2.73 (s, 6H), 2.27 (m, 2H), 2.08 (m, 2H), 2.02 (s, 2H), 1.47 (t, 2H), 1.00 (s, 6H).
    • EXAMPLE 21
  • This example was prepared by substituting 4-(4-(4-(4-chlorophenyl)-5,6-dihydro-2H-pyran-3-ylmethyl)piperazin-1-yl)benzoic acid, prepared as described in commonly-owned U.S. patent application Ser. No. 10/988,338, for EXAMPLE 1M in EXAMPLE 1N. 1H NMR (400 MHz, DMSO-d6) δ 8.27 (d, 1H), 8.11 (d, 1H), 7.89 (d, 2H), 7.59 (d, 2H), 7.48 (m, 4H), 7.37 (m, 3H), 7.13 (m, 1H), 7.01 (m, 3H), 4.35 (s, 2H), 4.24 (m, 1H), 3.97 (m, 2H), 3.68 (m, 4H), 3.36 (m, 6H), 3.07 (m, 3H), 2.68 (s, 2H), 2.59 (m, 4H), 2.14 (m, 2H), 1.93 (m, 2H).
    • EXAMPLE 22A
  • This example was prepared by substituting EXAMPLE 4E for EXAMPLE 2E in EXAMPLE 2F.
    • EXAMPLE 22
  • This example was prepared by substituting EXAMPLE 2K and EXAMPLE 22A for EXAMPLE 1M and EXAMPLE 1I, respectively, in EXAMPLE 1N. 1H NMR (400 MHz, DMSO-d6) δ 9.21 (brs, 1H), 8.17 (m, 1H), 8.00 (dd, 1H), 7.77 (d, 2H), 7.42 (m, 2H), 7.31 (m, 2H), 7.24 (m, 2H), 7.14 (m, 4H), 6.97 (m, 3H), 4.11 (m, 1H), 3.90 (m, 1H), 3.12 (m, 6H), 2.84 (m, 3H), 2.63 (m, 3H), 2.25 (m, 2H), 2.07 (m, 4H), 1.49 (t, 2H), 1.16 (m, 6H), 0.97 (s, 6H).
    • EXAMPLE 23
  • This example was prepared by substituting EXAMPLE 22A for EXAMPLE 1I in EXAMPLE 1N. 1H NMR (400 MHz, DMSO-d6) δ 9.21 (brs, 1H), 8.18 (m, 1H), 7.99 (dd, 1H), 7.78 (d, 2H), 7.40 (d, 2H), 7.30 (d, 2H), 7.24 (m, 2H), 7.15 (m, 4H), 6.97 (m, 3H), 4.11 (m, 1H), 3.89 (m, 1H), 3.13 (m, 6H), 2.84 (m, 2H), 2.63 (m, 3H), 2.28 (m, 2H), 2.07 (m, 4H), 1.48 (t, 2H), 1.17 (m, 6H), 1.00 (s, 6H).
    • EXAMPLE 24
  • This example was prepared by substituting EXAMPLE 2K for EXAMPLE 1M in EXAMPLE 1N. 1H NMR (500 MHz, DMSO-d6) δ 12.14 (brs, 1H), 9.89 (brs, 1H), 9.52 (s, 1H), 8.18 (d, 1H), 8.00 (dd, 1H), 7.77 (d, 2H), 7.41 (d, 2H), 7.30 (d, 2H), 7.24 (t, 2H), 7.14 (m, 4H), 6.96 (m, 3H), 4.12 (m, 1H), 3.93 (m, 3H), 3.63 (m, 4H), 2.93 (m, 10H), 2.24 (m, 2H), 2.09 (m, 4H), 1.48 (t, 2H), 0.97 (s, 6H).
    • EXAMPLE 25
  • This example was prepared by substituting EXAMPLE 2K and EXAMPLE 6F for EXAMPLE 1M and EXAMPLE 1I, respectively, in EXAMPLE 1N. 1H NMR (500 MHz, DMSO-d6) δ 9.58 (brs, 1H), 9.39 (brs, 1H), 8.17 (s, 1H), 7.99 (dd, 1H), 7.77 (d, 2H), 7.41 (d, 2H), 7.30 (d, 2H), 7.24 (t, 2H), 7.14 (m, 4H), 6.97 (m, 3H), 4.63 (d, 1H), 4.43 (d, 1H), 4.13 (m, 1H), 3.92 (m, 2H), 3.69 (m, 2H), 3.52 (m, 2H), 3.01 (m, 6H), 2.25 (m, 2H), 2.04 (m, 6H), 1.49 (m, 2H), 0.98 (s, 6H).
    • EXAMPLE 26
  • This example was prepared by substituting EXAMPLE 17B and EXAMPLE 3C for EXAMPLE 1I and EXAMPLE 1M, respectively, in EXAMPLE 1N. 1H NMR (500 MHz, DMSO-d6) δ 9.49 (brs, 1H), 8.08 (d, 1H), 7.95 (dd, 1H), 7.71 (d, 2H), 7.36 (m, 4H), 7.30 (t, 2H), 7.20 (t, 1H), 7.12 (d, 2H), 6.84 (m, 2H), 6.78 (d, 2H), 3.98 (m, 1H), 3.28 (m, 2H), 3.12 (brs, 4H), 2.81 (brs, 1H), 2.77 (s, 1H), 2.46 (s, 6H), 2.28 (s, 4H), 2.19 (m, 4H), 2.00 (m, 1H), 1.90 (m, 1H), 1.65 (m, 4H).
    • EXAMPLE 27A
  • This example was prepared by substituting pyrrolidine for N-isopropylethylamine in EXAMPLE 4D.
    • EXAMPLE 27B
  • This example was prepared by substituting EXAMPLE 27A for EXAMPLE 4D in EXAMPLE 4E.
    • EXAMPLE 27C
  • This example was prepared by substituting EXAMPLE 27B for EXAMPLE 1D in EXAMPLE 1I.
    • EXAMPLE 27D
  • This example was prepared by substituting EXAMPLE 27C and EXAMPLE 3C for EXAMPLE 1I and EXAMPLE 1M, respectively, in EXAMPLE 1N. 1H NMR (400 MHz, DMSO-d6) δ 8.08 (d, 1H), 7.96 (dd, 1H), 7.71 (d, 2H), 7.36 (m, 4H), 7.30 (t, 2H), 7.20 (t, 1H), 7.12 (d, 2H), 6.87 (m, 1H), 6.77 (d, 2H), 6.72 (d, 1H), 4.00 (m, 1H), 3.26 (m, 2H), 3.12 (brs, 4H), 2.97 (m, 6H), 2.76 (s, 1H), 2.28 (brs, 4H), 2.19, (m, 4H), 2.05 (m, 1H), 1.95 (m, 1H), 1.82 (brs, 4H), 1.65 (m, 4H).
    • EXAMPLE 28
  • This example was prepared by substituting EXAMPLE 2K and EXAMPLE 17B for EXAMPLE 1M and EXAMPLE 1I, respectively, in EXAMPLE 1N. 1H NMR (500 MHz, DMSO-d6) δ 9.59 (brs, 1H), 8.08 (d, 1H), 7.94 (dd, 1H), 7.70 (d, 2H), 7.36 (m, 4H), 7.30 (t, 2H), 7.21 (tt, 1H), 7.09 (d, 2H), 6.83 (d, 1H), 6.78 (d, 3H), 3.97 (m, 1H), 3.28 (m, 2H), 3.13 (brs, 4H), 2.90 (brs, 2H), 2.79 (s, 2H), 2.55 (s, 6H), 2.28 (brs, 4H), 2.20 (m, 2H), 1.99 (s, 2H), 1.90 (m, 2H), 1.42 (t, 2H), 0.96 (s, 6H).
    • EXAMPLE 29
  • This example was prepared by substituting 4-(4-(2-(4-chlorophenyl)cyclo-1-enylmethyl)piperazin-1-yl)benzoic acid, prepared as described in commonly-owned U.S. patent application Ser. No. 10/988,338, and EXAMPLE 27C for EXAMPLE 1M and EXAMPLE 1I, respectively, in EXAMPLE 1N. 1H NMR (400 MHz, DMSO-d6) δ 9.60 (brs, 1H), 8.08 (d, 1H), 7.94 (dd, 1H), 7.71 (d, 2H), 7.36 (m, 4H), 7.30 (t, 2H), 7.20 (t, 1H), 7.09 (d, 2H), 6.83 (d, 1H), 6.77 (d, 3H), 3.99 (m, 1H), 3.26 (m, 2H), 3.12 (brs, 4H), 2.80 (m, 5H), 2.76 (s, 2H), 2.40 (m, 4H), 2.31 (brs, 4H), 1.99 (m, 1H), 1.89 (m, 1H), 1.77 (brs, 6H), 1.58 (m, 2H), 1.51 (m, 2H).
    • EXAMPLE 30A
  • This example was prepared by substituting EXAMPLE 2E and EXAMPLE 27B for EXAMPLE 1H and EXAMPLE 1D in EXAMPLE 1I.
    • EXAMPLE 30B
  • This example was prepared by substituting EXAMPLE 30A for EXAMPLE 1I and EXAMPLE 1D in EXAMPLE 1N. 1H NMR (400 MHz, DMSO-d6) δ 9.57 (brs, 1H), 8.07 (d, 1H), 7.93 (dd, 1H), 7.70 (d, 2H), 7.36 (m, 4H), 7.30 (t, 2H), 7.21 (t, 1H), 7.12 (d, 2H), 6.81 (d, 1H), 6.77 (d, 3H), 3.99 (m, 1H), 3.26 (m, 2H), 3.12 (brs, 4H), 2.80 (m, 5H), 2.76 (s, 2H), 2.27 (m, 4H), 2.22 (m, 2H), 1.99 (m, 3H), 1.88 (m, 1H), 1.77 (brs, 4H), 1.43 (t, 2H), 0.97 (s, 6H).
    • EXAMPLE 31
  • This example was prepared by substituting EXAMPLE 2K and EXAMPLE 30A for EXAMPLE 1M and EXAMPLE 1I, respectively, in EXAMPLE 1N. 1H NMR (400 MHz, DMSO-d6) δ 9.52 (brs, 1H), 8.06 (d, 1H), 7.92 (dd, 1H), 7.70 (d, 2H), 7.36 (m, 4H), 7.30 (t, 2H), 7.21 (t, 1H), 7.08 (d, 2H), 6.81 (d, 1H), 6.77 (d, 3H), 3.99 (m, 1H), 3.26 (m, 2H), 3.12 (brs, 4H), 2.76 (s, 2H), 2.75 (m, 5H), 2.26 (m, 4H), 2.20 (m, 2H), 1.99 (m, 3H), 1.86 (m, 1H), 1.76 (brs, 4H), 1.42 (t, 2H), 0.96 (s, 6H).
    • EXAMPLE 32
  • This example was prepared by substituting 4-(4-(2-(4-chlorophenyl)cyclohept 1-enylmethyl)piperazin-1-yl)benzoic acid, prepared as described in commonly-owned U.S. patent application Ser. No. 10/988,338, and EXAMPLE 30A for EXAMPLE 1M and EXAMPLE 1I, respectively, in EXAMPLE 1N. 1H NMR (400 MHz, DMSO-d6) δ 9.50 (brs, 1H), 8.08 (d, 1H), 7.94 (dd, 1H), 7.71 (d, 2H), 7.36 (m, 4H), 7.30 (t, 2H), 7.20 (t, 1H), 7.09 (d, 2H), 6.83 (d, 1H), 6.77 (d, 3H), 3.99 (m, 1H), 3.26 (m, 2H), 3.12 (brs, 4H), 2.80 (m, 5H), 2.76 (s, 2H), 2.40 (m, 4H), 2.31 (brs, 4H), 1.98 (m, 1H), 1.87 (m, 1H), 1:76 (brs, 6H), 1.58 (m, 2H), 1.51 (m, 2H).
    • EXAMPLE 33
  • This example was prepared by substituting EXAMPLE 4F and EXAMPLE 3C for EXAMPLE 1I and EXAMPLE 1M, respectively, in EXAMPLE 1N. 1H NMR (300 MHz, DMSO-d6) δ 9.03 (s, 1H), 8.08 (d, 1H), 7.97 (d, 1H), 7.71 (d, 2H), 7.39-7.34 (m, 4H), 7.30 (t, 2H), 7.20 (tt, 1H), 7.13 (dt, 2H), 6.88 (m, 1H), 6.78 (d, 2H), 6.70 (m, 1H), 3.99 (m, 1H), 3.37-3.26 (m, 4H), 3.12 (s, 4H), 2.76 (s, 2H), 2.68-2.53 (m, 2H), 2.34-2.13 (m, OH), 2.10-1.95 (m, 2H), 1.66 (s, 4H), 1.13 (m, 6H).
    • EXAMPLE 34
  • This example was prepared by substituting EXAMPLE 2K and EXAMPLE 27C for EXAMPLE 1M and EXAMPLE 1I, respectively, in EXAMPLE 1N. 1H NMR (300 MHz, DMSO-d6) δ 9.53 (s, 1H), 8.08 (d, 1H), 7.97 (dd, 1H), 7.71 (d, 2H), 7.40-7.34 (m, 4H), 7.30 (t, 2H), 7.20 (tt, 1H), 7.09 (d, 2H), 6.89 (d, 1H), 6.78 (d, 2H), 6.71 (d, 1H), 4.01 (m, 1H), 3.38-3.27 (m, 4H), 3.20-2.84 (m, 10H), 2.79 (s, 2H), 2.27 (s, 4H), 2.20 (t, 2H), 2.03 (m, 2H), 1.85 (m, 4H), 1.42 (t, 2H), 0.96 (s, 6H).
    • EXAMPLE 35
  • This example was prepared by substituting EXAMPLE 3C and EXAMPLE 30A for EXAMPLE 1M and EXAMPLE 1I, respectively in EXAMPLE 1N. 1H NMR (400 MHz, DMSO-d6) 8 ppm 8.06 (d, 1H), 7.93 (dd, 1H), 7.71 (d, 2H), 7.36 (m, 4H), 7.30 (m, 2H), 7.21 (m, 1H), 7.12 (d, 2H), 6.81 (d, 1H),6.77 (d, 3H), 3.97 (m, 1H), 3.26 (m, 4H), 3.12 (s, 4H), 2.78 (m, 6H), 2.27 (s, 4H), 2.18 (m, 4H), 1.99 (m, 1H), 1.87 (m, 1H), 1.76 (s, 4H), 1.66 (s, 4H).
    • EXAMPLE 36
  • This example was prepared by substituting EXAMPLE 2K and EXAMPLE 9A for EXAMPLE 1M and EXAMPLE 1I, respectively, in EXAMPLE 1N. 1H NMR (400 MHz, DMSO-d6) δ 8.09 (d, 1H), 7.97 (dd, 1H), 7.71 (d, 2H), 7.33 (m, 6H), 7.21 (m, 1H), 7.08 (d, 2H), 6.87 (m, 1H), 6.78 (m, 3H), 3.99 (m, 1H), 3.14 (m, 4H), 2.95 (m, 1H), 2.80 (m, 3H), 2.58 (s, 6H), 2.28 (m, 4H), 2.20 (m, 2H), 1.99 (m, 4H), 1.42 (t, 2H), 0.96 (s, 6H).
    • EXAMPLE 37
  • This example was prepared by substituting EXAMPLE 2K and EXAMPLE 17B for EXAMPLE 1M and EXAMPLE 1I, respectively, in EXAMPLE 1N. 1H NMR (400 MHz, DMSO-d6) δ 8.09 (d, 1H), 7.97 (dd, 1H), 7.71 (d, 2H), 7.33 (m, 6H), 7.21 (m, 1H), 7.08 (d, 2H), 6.87 (m, 1H), 6.78 (m, 3H), 3.99 (m, 1H), 3.14 (m, 4H), 2.95 (m, 1H), 2.80 (m, 3H), 2.58 (s, 6H), 2.28 (m, 4H), 2.20 (m, 2H), 1.99 (m, 4H), 1.42 (t, 2H), 0.96 (s, 6H).
    • EXAMPLE 38
  • This example was prepared by substituting 4-(4-(1,1′-biphenyl-2-ylmethyl)-1-piperazinyl)benzoic acid, prepared as described in commonly-owned U.S. patent application Ser. No. 10/988,338, for EXAMPLE 1M and EXAMPLE 17B for EXAMPLE 1I, respectively, in EXAMPLE 1N. 1H NMR (400 MHz, DMSO-d6) δ 8.19 (d, 1H), 7.99 (dd, 1H), 7.76 (d, 3H), 7.52 (d, 4H), 7.40 (d, 2H), 7.35 (m, 1H), 7.30 (d, 2H), 7.24 (t, 2H), 7.16 (t, 2H), 6.96 (m, 3H), 4.25 (br, 2H), 4.12 (m, 1H), 3.37 (m, 2H), 3.14 (m, 1H), 3.10 (br, 8H), 2.74 (s, 6H), 2.10 (m, 2H).
    • EXAMPLE 39
  • This example was prepared by substituting 4-(4-(1,1′-biphenyl-2-ylmethyl)-1-piperazinyl)benzoic: acid, prepared as described in commonly-owned U.S. patent application Ser. No. 10/988,338, for EXAMPLE 1M in EXAMPLE 1N. 1H NMR (400 MHz, DMSO-d6) δ 8.19 (d, 1H), 8.00 (dd, 1H), 7.76 (d, 2H), 7.52 (m, 5H), 7.14 (m, 8H), 6.96 (m, 3H), 4.29 (m, 2H), 4.14 (m, 2H), 4.02 (m, 1H), 3.10 (m, 8H), 2.13 (m, 2H).
  • The foregoing is meant to illustrate the invention but not to limit it. Variations and changes obvious to one skilled in the art are intended to be within the scope of the invention as defined in the claims.

Claims (11)

1. A compound having formula (II):
Figure US20080287419A1-20081120-C00027
or a therapeutically acceptable salt thereof, wherein X3 is Cl or F;
X4 is azepan-1-yl, morpholin-1-yl, 1,4-oxazepan-4-yl, pyrrolidin-1-yl, N(CH3)2, N(CH3)(CH(CH3)2), 7-azabicyclo[2.2.1]heptan-1-yl or 2-oxa-5-azabicyclo[2.2.1]hept-5-yl, and R0 is
Figure US20080287419A1-20081120-C00028
wherein
X is CH2, C(CH3)2 or CH2CH2;
X6 and X7 are both hydrogen or are both methyl; and
X8 is F, Cl, Br or i; or
X4 is azepan-1-yl, morpholin-1-yl, pyrrolidin-1-yl, N(CH3)(CH(CH3)2) or 7-azabicyclo[2.2.1]heptan-1-yl, and R0 is
Figure US20080287419A1-20081120-C00029
X4 is N(CH3)2 or morpholin-1-yl, and R0 is
Figure US20080287419A1-20081120-C00030
2. A compound of claim 1, or a therapeutically acceptable salt thereof, wherein X3 is Cl or F;
X4 is azepan-1-yl, morpholin-1-yl, 1,4-oxazepan-4-yl, pyrrolidin-1-yl, N(CH3)2, N(CH3)(CH(CH3)2), 7-azabicyclo[2.2.1]heptan-1-yl or 2-oxa-5-azabicyclo[2.2.1]hept-5-yl, and R0 is
Figure US20080287419A1-20081120-C00031
wherein
X5 is CH2, C(CH3)2 or CH2CH2;
X6 and X7 are both hydrogen or are both methyl; and
X8 is F, Cl, Br or l; or
X4 is azepan-1-yl, morpholin-1-yl, pyrrolidin-1-yl, N(CH3)(CH(CH3)2) or 7-azabicyclo[2.2.1]heptan-1-yl, and R0 is
Figure US20080287419A1-20081120-C00032
X4 is N(CH3)2 or morpholin-1-yl, and R0 is
Figure US20080287419A1-20081120-C00033
3. A compound of claim 1, or a therapeutically acceptable salt thereof, wherein X3 is Cl or F;
X4 is azepan-1-yl, morpholin-1-yl, 1,4-oxazepan-4-yl, pyrrolidin-1-yl, N(CH3)2, N(CH3)(CH(CH3)2), 7-azabicyclo[2.2.1]heptan-1-yl or 2-oxa-5-azabicyclo[2.2.1]hept-5-yl, and R0 is
Figure US20080287419A1-20081120-C00034
wherein X5 is CH2, C(CH3)2 or CH2CH2, and X6 and X7 are both hydrogen or are both methyl; and
X8 is F, Cl, Br or I.
4. A compound of claim 1, or a therapeutically acceptable salt thereof, wherein X3 is Cl or F;
X4 is azepan-1-yl, morpholin-1-yl, pyrrolidin-1-yl, N(CH3)(CH(CH3)2) or 7-azabicyclo[2.2.1]heptan-1-yl; R0 is
Figure US20080287419A1-20081120-C00035
wherein X6 and X7 are both hydrogen or are both methyl; and X8 is F, Cl, Br or I.
5. A compound of claim 1, or a therapeutically acceptable salt thereof, wherein X3 is Cl or F;
X4 is N(CH3)2 or morpholin-1-yl; R0 is
Figure US20080287419A1-20081120-C00036
X8 is F, Cl, Br or I.
6. A compound of claim 1, or a therapeutically acceptable salt thereof, wherein X3 is F; X4 is morpholin-1-yl; R0 is
Figure US20080287419A1-20081120-C00037
wherein X5 is C(CH3)2; X6 and X7 are both methyl; and X8 is Cl.
7. A compound of claim 1, or a therapeutically acceptable salt thereof, wherein X3 is Cl or F;
X4 is azepan-1-yl, morpholin-1-yl, pyrrolidin-1-yl, N(CH3)(CH(CH3)2) or 7-azabicyclo[2.2.1]heptan-1-yl; R0 is
Figure US20080287419A1-20081120-C00038
wherein X6 and X7 are both hydrogen or are both methyl; and X8 is F, Cl, Br or I.
8. A compound of claim 1, or a therapeutically acceptable salt thereof, wherein X3 is Cl or F;
X4 is N(CH3)2 or morpholin-1-yl; R0 is
Figure US20080287419A1-20081120-C00039
X8 is F, Cl, Br or I.
9. A compound of claim 1, or a therapeutically acceptable salt thereof, wherein X3 is Cl or F; X4 is morpholin-1-yl; R0 is
Figure US20080287419A1-20081120-C00040
wherein X5 is C(CH3)2; X6 and X7 are both methyl; and X8 is Cl.
10. A composition comprising an excipient and a therapeutically effective amount of a compound of claim 1.
11. A method of treating mesothioloma, bladder cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, ovarian cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, bone cancer, ovarian cancer, cervical cancer, colon cancer, rectal cancer, cancer of the anal region, stomach cancer, gastrointestinal (gastric, colorectal, and duodenal), chronic lymphocytic leukemia, esophageal cancer, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, testicular cancer, hepatocellular cancer (hepatic and billiary duct), primary or secondary central nervous system tumor, primary or secondary brain tumor, Hodgkin's disease, chronic or acute leukemia, chronic myeloid leukemia, lymphocytic lymphomas, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, multiple myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer, cancer of the kidney and ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system, primary central nervous system lymphoma, non Hodgkin's lymphoma, spinal axis tumors, brains stem glioma, pituitary adenoma, adrenocortical cancer, gall bladder cancer, cancer of the spleen, cholangiocarcinoma, fibrosarcoma, neuroblastoma, retinoblasitoma, or a combination thereof in a patient, said method comprising administering to the patient a therapeutically effective amount of a compound of claim 1.
US12/120,914 2005-05-12 2008-05-15 Apoptosis promoters Active US7709467B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/120,914 US7709467B2 (en) 2005-05-12 2008-05-15 Apoptosis promoters
US12/630,957 US8624027B2 (en) 2005-05-12 2009-12-04 Combination therapy for treating cancer and diagnostic assays for use therein
US12/772,951 US7906505B2 (en) 2005-05-12 2010-05-03 Apoptosis promoters

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68010705P 2005-05-12 2005-05-12
US71861805P 2005-09-20 2005-09-20
US11/432,937 US7390799B2 (en) 2005-05-12 2006-05-12 Apoptosis promoters
US12/120,914 US7709467B2 (en) 2005-05-12 2008-05-15 Apoptosis promoters

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US11/432,937 Continuation US7390799B2 (en) 2005-05-12 2006-05-12 Apoptosis promoters
US11/432,937 Division US7390799B2 (en) 2005-05-12 2006-05-12 Apoptosis promoters

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/630,957 Continuation-In-Part US8624027B2 (en) 2005-05-12 2009-12-04 Combination therapy for treating cancer and diagnostic assays for use therein
US12/772,951 Continuation US7906505B2 (en) 2005-05-12 2010-05-03 Apoptosis promoters

Publications (2)

Publication Number Publication Date
US20080287419A1 true US20080287419A1 (en) 2008-11-20
US7709467B2 US7709467B2 (en) 2010-05-04

Family

ID=37695179

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/432,937 Active 2026-09-09 US7390799B2 (en) 2005-05-12 2006-05-12 Apoptosis promoters
US12/120,914 Active US7709467B2 (en) 2005-05-12 2008-05-15 Apoptosis promoters
US12/772,951 Active US7906505B2 (en) 2005-05-12 2010-05-03 Apoptosis promoters

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US11/432,937 Active 2026-09-09 US7390799B2 (en) 2005-05-12 2006-05-12 Apoptosis promoters

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/772,951 Active US7906505B2 (en) 2005-05-12 2010-05-03 Apoptosis promoters

Country Status (20)

Country Link
US (3) US7390799B2 (en)
EP (2) EP1888550B1 (en)
JP (1) JP5132550B2 (en)
KR (3) KR101533268B1 (en)
CN (2) CN101175738B (en)
AU (2) AU2006297853B2 (en)
BR (1) BRPI0610108B8 (en)
CA (1) CA2606147C (en)
CY (1) CY1119601T1 (en)
DK (1) DK1888550T3 (en)
ES (1) ES2493466T3 (en)
IL (1) IL186141A (en)
MX (1) MX2007014049A (en)
NZ (2) NZ561609A (en)
PL (2) PL2757099T3 (en)
PT (1) PT1888550E (en)
SI (1) SI1888550T1 (en)
TW (2) TWI337608B (en)
WO (1) WO2007040650A2 (en)
ZA (1) ZA200800279B (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060128706A1 (en) * 2003-11-13 2006-06-15 Milan Bruncko Apoptosis promoters
US20070015787A1 (en) * 2003-11-13 2007-01-18 Milan Bruncko Apoptosis promoters
US20070072860A1 (en) * 2003-11-13 2007-03-29 Milan Bruncko Apoptosis promoters
US20080076779A1 (en) * 2006-09-05 2008-03-27 Elmore Steven W Treatment of myeoproliferative diseases
US20100022773A1 (en) * 2003-11-13 2010-01-28 Milan Bruncko Apoptosis promoters
US20100056517A1 (en) * 2006-11-15 2010-03-04 Genentech, Inc. Arylsulfonamide compounds
US20100087436A1 (en) * 2006-11-16 2010-04-08 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
US20110269728A1 (en) * 2010-03-24 2011-11-03 Deng Pan Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
US10071130B2 (en) 2013-12-12 2018-09-11 The University Of Chicago Methods and compositions related to Hsp90 inhibitors and breast cancer
US10456392B2 (en) 2012-05-25 2019-10-29 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US10898478B2 (en) 2017-03-31 2021-01-26 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat cervical cancer
US11058670B2 (en) 2019-02-22 2021-07-13 Corcept Therapeutics Incorporated Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11285159B2 (en) 2019-11-05 2022-03-29 Abbvie Inc. Dosing regimens for use in treating myelofibrosis and MPN-related disorders with navitoclax
US11389432B2 (en) 2018-12-19 2022-07-19 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11464764B2 (en) 2018-12-19 2022-10-11 Corcept Therapeutics Incorporated Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound

Families Citing this family (193)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
US8580782B2 (en) * 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US8097416B2 (en) 2003-09-11 2012-01-17 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US20120122096A1 (en) * 2003-09-11 2012-05-17 Rangarajan Sampath Compositions for use in identification of bacteria
US20080138808A1 (en) * 2003-09-11 2008-06-12 Hall Thomas A Methods for identification of sepsis-causing bacteria
US8546082B2 (en) * 2003-09-11 2013-10-01 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8624027B2 (en) * 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
TWI337608B (en) * 2005-05-12 2011-02-21 Abbott Lab Apoptosis promoters
US20080233567A1 (en) * 2006-09-05 2008-09-25 Murray William E Companion diagnostic assays for cancer therapy
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
WO2008064116A2 (en) * 2006-11-16 2008-05-29 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
EP2178893A4 (en) * 2007-07-16 2012-09-19 Poniard Pharmaceuticals Inc Oral formulations for picoplatin
US20090098118A1 (en) * 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
RU2526201C2 (en) * 2007-11-16 2014-08-20 Эббви Инк. Method of treating arthritis
US20090149461A1 (en) * 2007-12-06 2009-06-11 Abbott Laboratories Method of treating cancer
WO2009085216A2 (en) 2007-12-20 2009-07-09 Squicor Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease
CN101220008B (en) * 2008-01-21 2011-04-27 中国科学院广州生物医药与健康研究院 Synthesis of compound ABT-263
US20110052580A1 (en) * 2008-02-08 2011-03-03 Poniard Pharmaceuticals, Inc. Use of picoplatin and bevacizumab to treat colorectal cancer
ATE540026T1 (en) * 2008-06-09 2012-01-15 Bristol Myers Squibb Co HYDROXYPHENYL SULPHONIC ACID AMIDES AS ANTIAPOPTOTIC BCL INHIBITORS
US8168784B2 (en) * 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
UA108193C2 (en) * 2008-12-04 2015-04-10 APOPTOZINDUCE FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTO-IMMUNE DISEASES
US8586754B2 (en) * 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
CR20160269A (en) * 2008-12-05 2016-08-16 Abbvie Inc DERIVATIVES OF SULFONAMIDE AS INDUCTIVE AGENTS OF APOPTOSIS WITH SELECTIVITY BY BCL-2 FOR THE TREATMENT OF CANCER AND COMMON DISEASES
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
BRPI0922884A2 (en) 2008-12-08 2018-11-06 Boehringer Ingelheim Int cancer treatment compounds
HUE025527T2 (en) * 2009-01-19 2016-04-28 Abbvie Inc Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
RU2538965C2 (en) 2009-01-19 2015-01-10 Эббви Инк. Apoptosis inducing agents for treating cancer and immune and autoimmune diseases
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
US20100278921A1 (en) 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
US8362013B2 (en) * 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US20100280031A1 (en) * 2009-04-30 2010-11-04 Paul David Lipid formulation of apoptosis promoter
SG10201704742YA (en) * 2009-05-26 2017-07-28 Abbvie Ireland Unlimited Co Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI532484B (en) * 2009-06-08 2016-05-11 艾伯維有限公司 Solid dispersions containing an apoptosis-promoting agent
TWI540132B (en) 2009-06-08 2016-07-01 亞培公司 Pharmaceutical dosage form for oral administration of a bcl-2 family inhibitor
SG176929A1 (en) 2009-06-18 2012-01-30 Abbott Lab Stable nanoparticulate drug suspension
ES2427628T3 (en) * 2009-08-24 2013-10-31 H. Lundbeck A/S New compositions of 1- [2- (2,4-dimethyl-phenylsulfanyl) -phenyl] piperazine
WO2011034934A1 (en) * 2009-09-20 2011-03-24 Abbott Laboratories Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases
MX2012007325A (en) * 2009-12-22 2012-07-20 Abbott Lab Abt-263 capsule.
AU2014202478B2 (en) * 2010-03-25 2016-04-28 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
KR20130040834A (en) * 2010-03-25 2013-04-24 아비에 인코포레이티드 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN101798292A (en) * 2010-03-29 2010-08-11 无锡好芳德药业有限公司 Method for preparing novel Bc1-2 protein inhibitor derived from ABT-263
TWI520960B (en) 2010-05-26 2016-02-11 艾伯維有限公司 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
MX342405B (en) 2010-06-03 2016-09-28 Pharmacyclics Inc The use of inhibitors of bruton's tyrosine kinase (btk).
TWI535712B (en) * 2010-08-06 2016-06-01 阿斯特捷利康公司 Chemical compounds
UA113500C2 (en) 2010-10-29 2017-02-10 MEL EXTRUSION SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT
MX349533B (en) 2010-10-29 2017-08-02 Abbvie Inc Solid dispersions containing an apoptosis-inducing agent.
JP5876067B2 (en) 2010-11-23 2016-03-02 アッヴィ・バハマズ・リミテッド Treatment method using selective BCL-2 inhibitor
CN107266435A (en) 2010-11-23 2017-10-20 Abbvie 公司 The salt and crystalline form of cell death inducer
SG192126A1 (en) 2011-01-25 2013-09-30 Univ Michigan Bcl-2/bcl-xl inhibitors and therapeutic methods using the same
US20130303560A1 (en) * 2011-02-01 2013-11-14 Sunnybrook Research Institute Combination
US20140189897A1 (en) 2011-06-21 2014-07-03 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
US8946445B2 (en) 2011-10-12 2015-02-03 Nanjing Allgen Pharma Co., Ltd. Heterocyclic molecules as apoptosis inducers
CN103127510B (en) * 2011-11-30 2015-03-25 北京天和瑞通科技发展有限公司 Medicine composition containing hepatic cell growth factor receptor inhibitor and Bcl-2 inhibitor and application thereof
EP2790725A4 (en) 2011-12-13 2015-11-04 Buck Inst For Res On Aging Methods for improving medical therapies
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
WO2013158664A2 (en) 2012-04-17 2013-10-24 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
CN110305162A (en) 2013-01-16 2019-10-08 密歇根大学董事会 BCL-2/Bcl-xL inhibitor and the treatment method for using the inhibitor
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20140279528A1 (en) * 2013-03-15 2014-09-18 Motorola Mobility Llc Wearable Authentication Device
PL3027618T3 (en) 2013-07-30 2021-04-19 Kronos Bio, Inc. Polymorph of syk inhibitors
TWI735853B (en) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 Syk inhibitors
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
AU2015211021B2 (en) 2014-01-28 2020-07-02 Buck Institute For Research On Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
WO2015131080A1 (en) 2014-02-28 2015-09-03 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
MA40075A (en) 2014-07-14 2016-01-21 Gilead Sciences Inc Combinations for treating cancers
CN112430250A (en) 2014-08-12 2021-03-02 莫纳什大学 Lymphatic prodrugs
TW201639573A (en) 2015-02-03 2016-11-16 吉李德科學股份有限公司 Combination therapies for treating cancers
WO2016131100A1 (en) * 2015-02-18 2016-08-25 The Walter And Eliza Hall Institute Of Medical Research Methods of treating infectious diseases
ES2930585T3 (en) 2015-02-27 2022-12-19 Nimbus Lakshmi Inc TYK2 inhibitors and uses thereof
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
WO2017021963A1 (en) 2015-08-03 2017-02-09 Biokine Therapeutics Ltd. Cxcr4 binding agents for treatment of diseases
EP4327809A3 (en) 2015-09-02 2024-04-17 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
CN114031658A (en) 2015-09-08 2022-02-11 莫纳什大学 Lymphatic prodrugs
US10683308B2 (en) 2015-09-11 2020-06-16 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
DK3364958T3 (en) 2015-10-23 2023-04-11 Navitor Pharm Inc MODULATORS OF SESTRIN-GATOR2 INTERACTION AND THEIR APPLICATIONS
WO2017106352A1 (en) 2015-12-14 2017-06-22 Raze Therapeutics, Inc. Caffeine inhibitors of mthfd2 and uses thereof
WO2017101851A1 (en) * 2015-12-18 2017-06-22 Unity Biotechnology, Inc. Acylsulfonamide derivatives for treating senescence-associated diseases and disorders
US10570119B2 (en) 2016-01-11 2020-02-25 Merrimack Pharmaceuticals, Inc. Inhibiting ataxia telangiectasia and Rad3-related protein (ATR)
MA43871A (en) * 2016-01-11 2018-11-21 Merrimack Pharmaceuticals Inc INHIBITION OF B-CELL LYMPHOMA 2 (BCL -2) AND RELATED PROTEINS
PL3426244T3 (en) * 2016-03-09 2023-09-25 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
EP3884939B1 (en) 2016-03-09 2023-10-25 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
EA201892075A1 (en) 2016-03-15 2019-04-30 Оризон Дженомикс, С.А. COMBINATION OF LSD1 INHIBITORS FOR USE FOR THE TREATMENT OF SOLID TUMORS
CN109462980B (en) 2016-03-15 2022-02-08 奥莱松基因组股份有限公司 Combination of LSD1 inhibitors for the treatment of hematologic malignancies
EP3436002A4 (en) 2016-03-28 2019-12-04 Presage Biosciences, Inc. Pharmaceutical combinations for the treatment of cancer
CN109153722A (en) 2016-04-08 2019-01-04 X4 制药有限公司 Method for treating cancer
EP3445452A4 (en) 2016-04-21 2019-10-30 BioVentures, LLC Compounds that induce degradation of anti-apoptotic bcl-2 family proteins and the uses thereof
CN116554168A (en) 2016-06-21 2023-08-08 X4 制药有限公司 CXCR4 inhibitors and uses thereof
EP3472129A4 (en) 2016-06-21 2019-12-04 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
JP7084624B2 (en) 2016-06-21 2022-06-15 エックス４ ファーマシューティカルズ， インコーポレイテッド CXCR4 inhibitor and its use
EP3526222B1 (en) 2016-10-14 2022-08-17 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
AU2017345736B2 (en) 2016-10-21 2022-04-07 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
US20180133212A1 (en) 2016-11-03 2018-05-17 Gilead Sciences, Inc. Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer
WO2018089499A1 (en) 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF
WO2018102397A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
WO2018106636A1 (en) 2016-12-05 2018-06-14 Raze Therapeutics, Inc. Shmt inhibitors and uses thereof
WO2018127699A1 (en) 2017-01-06 2018-07-12 Bicyclerd Limited Compounds for treating cancer
JOP20190191A1 (en) 2017-02-22 2019-08-08 Astrazeneca Ab Therapeutic dendrimers
CN110582501B (en) 2017-03-08 2022-09-23 林伯士拉克许米公司 TYK2 inhibitor, use and production method thereof
EP3375778A1 (en) 2017-03-14 2018-09-19 Artax Biopharma Inc. Aryl-piperidine derivatives
EP3375784A1 (en) 2017-03-14 2018-09-19 Artax Biopharma Inc. Aza-dihydro-acridone derivatives
WO2018191146A1 (en) 2017-04-10 2018-10-18 Navitor Pharmaceuticals, Inc. Heteroaryl rheb inhibitors and uses thereof
CN110809467B (en) 2017-04-26 2023-03-10 纳维托制药有限公司 Modulators of SESTRIN-GATOR2 interactions and uses thereof
WO2019023468A1 (en) 2017-07-28 2019-01-31 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
US11384082B2 (en) 2017-08-25 2022-07-12 Kronos Bio, Inc. Hydrates of polymorphs of 6-(1H-indazol-6-YL)-N-(4-morpholinophenyl)-2,3-dihydroimidazo[1,2-A]pyrazin-8-amine bisemsylate as Syk inhibitors
AU2018324037A1 (en) 2017-08-29 2020-04-16 Monash University Lymphatic system-directing lipid prodrugs
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
US11623932B2 (en) 2017-09-22 2023-04-11 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
EP3727362A4 (en) 2017-12-19 2021-10-06 PureTech LYT, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
WO2019133531A1 (en) 2017-12-26 2019-07-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CN111801327B (en) 2018-01-10 2024-02-09 里科瑞尔姆Ip控股有限责任公司 Benzamide compounds
WO2019140387A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
TWI816742B (en) 2018-01-29 2023-10-01 美商維泰克斯製藥公司 Gcn2 inhibitors and uses thereof
SG11202006832YA (en) 2018-01-29 2020-08-28 Merck Patent Gmbh Gcn2 inhibitors and uses thereof
JP7317032B2 (en) 2018-02-27 2023-07-28 アルタックス バイオファーマ インコーポレイテッド Chromene Derivatives as Inhibitors of the TCR-NCK Interaction
WO2019178433A1 (en) 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 in combination with anti-cancer agents for the treatment of pancreatic cancer
CN112218865B (en) 2018-04-24 2024-03-12 沃泰克斯药物股份有限公司 Pteridinone compounds and uses thereof
CN112236428A (en) 2018-04-24 2021-01-15 默克专利股份有限公司 Antiproliferative compounds and uses thereof
CN112437772B (en) 2018-04-29 2023-11-21 百济神州有限公司 Bcl-2 inhibitors
EA202092692A1 (en) 2018-06-15 2021-04-21 Навитор Фармасьютикалз, Инк. ANALOGUES OF RAPAMICIN AND THEIR APPLICATIONS
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
US11491168B2 (en) 2018-07-31 2022-11-08 Ascentage Pharma (Suzhou) Co., Ltd. Combination of Bcl-2/Bcl-xL inhibitors and chemotherapeutic agent and use thereof
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US20220089587A1 (en) 2018-09-07 2022-03-24 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
AU2019343044A1 (en) 2018-09-18 2021-03-18 Signalchem Lifesciences Corporation Combination therapy for treating blood cancer
JP2022502515A (en) 2018-10-15 2022-01-11 ニンバス ラクシュミ， インコーポレイテッド TYK2 inhibitors and their use
US11345654B2 (en) 2018-10-24 2022-05-31 Navitor Pharmaceuticals, Inc. Polymorphic compounds and uses thereof
US11352350B2 (en) 2018-11-30 2022-06-07 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
JP2022509260A (en) 2018-11-30 2022-01-20 ニンバス ラクシュミ， インコーポレイテッド TYK2 inhibitors and their use
EP3670659A1 (en) 2018-12-20 2020-06-24 Abivax Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
CN113348021A (en) 2019-01-23 2021-09-03 林伯士拉克许米公司 TYK2 inhibitors and uses thereof
CN113950479A (en) 2019-02-22 2022-01-18 克洛诺斯生物股份有限公司 Solid forms of condensed pyrazines as SYK inhibitors
CA3135569A1 (en) 2019-04-02 2020-10-08 Bicycletx Limited Bicycle toxin conjugates and uses thereof
CN113939300A (en) 2019-04-05 2022-01-14 凯麦拉医疗公司 STAT degradants and uses thereof
KR20220034739A (en) 2019-05-31 2022-03-18 이케나 온콜로지, 인코포레이티드 TEAD inhibitors and uses thereof
CA3142361A1 (en) 2019-06-12 2020-12-17 Juno Therapeutics, Inc. Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
US11845724B2 (en) 2019-09-11 2023-12-19 Vincere Biosciences, Inc. USP30 inhibitors and uses thereof
BR112022004451A2 (en) 2019-09-13 2022-06-21 Nimbus Saturn Inc hpk1 antagonists and uses thereof
WO2021087432A1 (en) 2019-11-01 2021-05-06 Navitor Pharmaceuticals, Inc. Methods of treatment using an mtorc1 modulator
IL293549A (en) 2019-12-05 2022-08-01 Anakuria Therapeutics Inc Rapamycin analogs and uses thereof
IL293917A (en) 2019-12-17 2022-08-01 Kymera Therapeutics Inc Irak degraders and uses thereof
EP4076524A4 (en) 2019-12-17 2023-11-29 Kymera Therapeutics, Inc. Irak degraders and uses thereof
KR20220151160A (en) 2019-12-23 2022-11-14 카이메라 쎄라퓨틱스 인코포레이티드 SMARCA disintegrant and its uses
US11753403B2 (en) 2020-03-03 2023-09-12 PIC Therapeutics, Inc. EIF4E inhibitors and uses thereof
BR112022018678A2 (en) 2020-03-19 2022-11-01 Kymera Therapeutics Inc MDM2 DEGRADATORS AND THEIR USES
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
WO2021233948A1 (en) 2020-05-19 2021-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to treat a pathogen lung infection
TW202210483A (en) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Crystalline forms of irak degraders
WO2022008464A1 (en) 2020-07-06 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml)
KR20230044480A (en) 2020-07-30 2023-04-04 카이메라 쎄라퓨틱스 인코포레이티드 Methods of treating mutant lymphoma
WO2022038158A1 (en) 2020-08-17 2022-02-24 Bicycletx Limited Bicycle conjugates specific for nectin-4 and uses thereof
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2022120354A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2022133030A1 (en) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Combination therapy of a cell therapy and a bcl2 inhibitor
BR112023015590A2 (en) 2021-02-02 2023-10-17 Liminal Biosciences Ltd GPR84 ANTAGONISTS AND USES THEREOF
KR20230152692A (en) 2021-02-02 2023-11-03 리미널 바이오사이언시스 리미티드 GPR84 antagonists and their uses
CA3207380A1 (en) 2021-02-15 2022-08-18 Haojing RONG Irak4 degraders and uses thereof
JP2024509192A (en) 2021-03-05 2024-02-29 ニンバス サターン， インコーポレイテッド HPK1 antagonists and their uses
JP2024514879A (en) 2021-04-16 2024-04-03 イケナ オンコロジー， インコーポレイテッド MEK inhibitors and their uses
WO2023028238A1 (en) 2021-08-25 2023-03-02 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
US20230150997A1 (en) 2021-08-25 2023-05-18 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
GB202201824D0 (en) 2022-02-11 2022-03-30 Genome Res Ltd Methods of treatment
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023211889A1 (en) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Polymorphic compounds and uses thereof
WO2023215449A1 (en) 2022-05-06 2023-11-09 Treeline Biosciences, Inc. Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
WO2023215471A1 (en) 2022-05-06 2023-11-09 Treeline Biosciences, Inc. Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
US20230390404A1 (en) 2022-05-06 2023-12-07 Treeline Biosciences, Inc. Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
US11878958B2 (en) 2022-05-25 2024-01-23 Ikena Oncology, Inc. MEK inhibitors and uses thereof
WO2024012557A1 (en) * 2022-07-15 2024-01-18 Berrybio (Hong Kong) Limited Anti-apoptotic bcl-2 family protein degraders, pharmaceutical compositions, and therapeutic applications
WO2024028363A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
WO2024028365A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Substituted pyridone gpr84 antagonists and uses thereof
WO2024028364A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Aryl-triazolyl and related gpr84 antagonists and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2413833A (en) * 1943-03-20 1947-01-07 Monsanto Chemicals Substituted 4,4'-diaminodiphenyl sulfones and process of making same
US20030236247A1 (en) * 2002-03-21 2003-12-25 Elmore Steven W. N-sulfonylurea apoptosis promoters
US6720338B2 (en) * 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US20050159427A1 (en) * 2003-11-13 2005-07-21 Milan Bruncko N-acylsulfonamide apoptosis promoters
US20060128706A1 (en) * 2003-11-13 2006-06-15 Milan Bruncko Apoptosis promoters
US20060258657A1 (en) * 2003-11-13 2006-11-16 Milan Bruncko Apoptosis promoters

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
DE3826230A1 (en) 1988-08-02 1990-02-08 Hoechst Ag HETEROCYCLIC N-ACYLSUFONAMIDES, METHOD FOR THE PRODUCTION THEREOF, THE AGENTS THEREOF AND THEIR USE AS HERBICIDES OR GROWTH REGULATORS
ATE255106T1 (en) * 1993-09-10 2003-12-15 Eisai Co Ltd BICYCLIC, HETEROCYCLIC SULFONAMIDES AND SULFONIC ACID ESTERS
US5971983A (en) * 1997-05-09 1999-10-26 The Regents Of The University Of California Tissue ablation device and method of use
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
AR031130A1 (en) * 2000-09-20 2003-09-10 Abbott Lab PROMOTING N-ACILSULFONAMIDS OF APOPTOSIS
WO2002098848A1 (en) 2001-06-06 2002-12-12 Eli Lilly And Company Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents
US20030119894A1 (en) 2001-07-20 2003-06-26 Gemin X Biotechnologies Inc. Methods for treatment of cancer or neoplastic disease and for inhibiting growth of cancer cells and neoplastic cells
UY27450A1 (en) 2001-09-24 2003-04-30 Bayer Corp PREPARATION AND USE OF IMIDAZOL DERIVATIVES FOR THE TREATMENT OF OBESITY
WO2003080586A1 (en) * 2002-03-21 2003-10-02 Abbott Laboratories N-sulfonylurea apoptosis promoters
AR043059A1 (en) 2002-11-12 2005-07-13 Bayer Pharmaceuticals Corp DERIVATIVES OF INDOLIL PIRAZINONA USEFUL FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS
ATE375978T1 (en) 2002-11-22 2007-11-15 Lilly Co Eli BENZOYLSULFONAMIDE AS AN ANTITUMOR AGENT
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
CA2567831C (en) 2004-05-26 2013-01-15 Abbott Laboratories N-sulfonylcarboximidamide apoptosis promoters
TWI337608B (en) * 2005-05-12 2011-02-21 Abbott Lab Apoptosis promoters
WO2008017123A1 (en) 2006-08-11 2008-02-14 The Walter And Eliza Hall Institute Of Medical Research Methods for modulating apoptosis in platelets
WO2008017121A1 (en) 2006-08-11 2008-02-14 The Walter And Eliza Hall Institute Of Medical Research Methods for modulating apoptosis in platelets
CA2662320C (en) 2006-09-05 2014-07-22 Abbott Laboratories Bcl inhibitors treating platelet excess

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2413833A (en) * 1943-03-20 1947-01-07 Monsanto Chemicals Substituted 4,4'-diaminodiphenyl sulfones and process of making same
US6720338B2 (en) * 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US20030236247A1 (en) * 2002-03-21 2003-12-25 Elmore Steven W. N-sulfonylurea apoptosis promoters
US7030115B2 (en) * 2002-03-21 2006-04-18 Abbott Laboratories N-sulfonylurea apoptosis promoters
US20050159427A1 (en) * 2003-11-13 2005-07-21 Milan Bruncko N-acylsulfonamide apoptosis promoters
US20060128706A1 (en) * 2003-11-13 2006-06-15 Milan Bruncko Apoptosis promoters
US20060258657A1 (en) * 2003-11-13 2006-11-16 Milan Bruncko Apoptosis promoters

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9045444B2 (en) 2003-11-13 2015-06-02 Abbvie Inc. Apoptosis promoters
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US20070072860A1 (en) * 2003-11-13 2007-03-29 Milan Bruncko Apoptosis promoters
US20060128706A1 (en) * 2003-11-13 2006-06-15 Milan Bruncko Apoptosis promoters
US20100022773A1 (en) * 2003-11-13 2010-01-28 Milan Bruncko Apoptosis promoters
US20070015787A1 (en) * 2003-11-13 2007-01-18 Milan Bruncko Apoptosis promoters
US8686136B2 (en) 2003-11-13 2014-04-01 Abbvie Inc. Apoptosis promoters
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
US20100240715A1 (en) * 2003-11-13 2010-09-23 Abbott Laboratories Apoptosis promoters
US8354404B2 (en) 2003-11-13 2013-01-15 Abbott Laboratories Apoptosis promoters
US20110144112A9 (en) * 2003-11-13 2011-06-16 Milan Bruncko Apoptosis promoters
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
US8173811B2 (en) 2003-11-13 2012-05-08 Abbott Laboratories Apoptosis promoters
US8084607B2 (en) 2003-11-13 2011-12-27 Abbott Laboratories Apoptosis promoters
US20080076779A1 (en) * 2006-09-05 2008-03-27 Elmore Steven W Treatment of myeoproliferative diseases
US7842681B2 (en) 2006-09-05 2010-11-30 Abbott Laboratories Treatment of myeoproliferative diseases
US8168645B2 (en) 2006-11-15 2012-05-01 Genentech, Inc. Arylsulfonamide compounds
US20100056517A1 (en) * 2006-11-15 2010-03-04 Genentech, Inc. Arylsulfonamide compounds
US20100087436A1 (en) * 2006-11-16 2010-04-08 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
US11883417B2 (en) 2010-03-24 2024-01-30 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
US20110269728A1 (en) * 2010-03-24 2011-11-03 Deng Pan Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
US9623032B2 (en) 2010-03-24 2017-04-18 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
US9149485B2 (en) 2010-03-24 2015-10-06 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
US11234990B2 (en) 2010-03-24 2022-02-01 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
US10441596B2 (en) 2010-03-24 2019-10-15 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
US8710035B2 (en) * 2010-03-24 2014-04-29 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
US10456392B2 (en) 2012-05-25 2019-10-29 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US11648245B2 (en) 2012-05-25 2023-05-16 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US10973813B2 (en) 2012-05-25 2021-04-13 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US11576907B2 (en) 2012-05-25 2023-02-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US10071130B2 (en) 2013-12-12 2018-09-11 The University Of Chicago Methods and compositions related to Hsp90 inhibitors and breast cancer
US10898478B2 (en) 2017-03-31 2021-01-26 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat cervical cancer
US11660295B2 (en) 2017-03-31 2023-05-30 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat cervical cancer
US11389432B2 (en) 2018-12-19 2022-07-19 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11464764B2 (en) 2018-12-19 2022-10-11 Corcept Therapeutics Incorporated Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11925626B2 (en) 2018-12-19 2024-03-12 Corcept Therapeutics Incorporated Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
US11590113B2 (en) 2019-02-22 2023-02-28 Corcept Therapeutics Incorporated Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
US11058670B2 (en) 2019-02-22 2021-07-13 Corcept Therapeutics Incorporated Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
US11684612B2 (en) 2019-02-22 2023-06-27 Corcept Therapeutics Incorporated Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
US11285159B2 (en) 2019-11-05 2022-03-29 Abbvie Inc. Dosing regimens for use in treating myelofibrosis and MPN-related disorders with navitoclax

Also Published As

Publication number Publication date
CN101175738B (en) 2010-10-27
CY1119601T1 (en) 2018-04-04
WO2007040650A2 (en) 2007-04-12
US7906505B2 (en) 2011-03-15
TW200720269A (en) 2007-06-01
KR101509440B1 (en) 2015-04-07
KR20080011695A (en) 2008-02-05
ES2493466T3 (en) 2014-09-11
WO2007040650A3 (en) 2007-05-24
JP2008540577A (en) 2008-11-20
KR20140066798A (en) 2014-06-02
KR20140006086A (en) 2014-01-15
TWI337182B (en) 2011-02-11
PT1888550E (en) 2014-09-03
KR101391263B1 (en) 2014-05-02
MX2007014049A (en) 2008-02-11
CN101928264A (en) 2010-12-29
CN101175738A (en) 2008-05-07
BRPI0610108B1 (en) 2020-11-24
BRPI0610108B8 (en) 2021-05-25
CA2606147C (en) 2011-07-05
AU2010233055B2 (en) 2012-04-26
US7709467B2 (en) 2010-05-04
IL186141A0 (en) 2008-01-20
TWI337608B (en) 2011-02-21
PL1888550T3 (en) 2014-12-31
SI1888550T1 (en) 2014-10-30
JP5132550B2 (en) 2013-01-30
WO2007040650A9 (en) 2007-07-26
NZ583758A (en) 2011-02-25
EP1888550B1 (en) 2014-06-25
AU2006297853A1 (en) 2007-04-12
US20100249133A1 (en) 2010-09-30
IL186141A (en) 2013-08-29
TW201020248A (en) 2010-06-01
EP2757099A1 (en) 2014-07-23
ZA200800279B (en) 2011-10-26
US20070027135A1 (en) 2007-02-01
AU2006297853B2 (en) 2010-08-19
AU2010233055A1 (en) 2010-11-04
BRPI0610108A2 (en) 2010-05-25
EP1888550A2 (en) 2008-02-20
US7390799B2 (en) 2008-06-24
EP2757099B1 (en) 2017-08-23
NZ561609A (en) 2010-03-26
CN101928264B (en) 2012-03-28
CA2606147A1 (en) 2007-04-12
DK1888550T3 (en) 2014-09-29
KR101533268B1 (en) 2015-07-03
PL2757099T3 (en) 2018-02-28

Similar Documents

Publication Publication Date Title
US7709467B2 (en) Apoptosis promoters
US8143284B2 (en) Poly(ADP-ribose)polymerase inhibitors
US8124759B2 (en) Inhibitors of protein kinases
EP2150553B1 (en) Condensed heterocyclic compounds as inhibitors of protein kinases
US20090023743A1 (en) Inhibitors of protein kinases
DK2757099T3 (en) APOPTOSE PROMOTERS
WO2008141140A1 (en) Condensed heterocyclic compounds as inhibitors of protein kinases

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCF Information on status: patent grant

Free format text: PATENTED CASE

AS Assignment

Owner name: ABBVIE INC., ILLINOIS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ABBOTT LABORATORIES;REEL/FRAME:030185/0141

Effective date: 20120801

FPAY Fee payment

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552)

Year of fee payment: 8

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 12